{"idB": "1175680_12_item1_p18_s6", "idA": "1175680_11_item1_p13_s7", "sentA": "The Study design and objectives are available to view at the government s website at www.clinicaltrials.gov, ID NCT01048372.", "sentB": "The Study was completed subsequent to May 31, 2012.", "type": 1, "words": ["<tag1>", "The", "Study", "design", "and", "objectives", "are", "available", "to", "view", "at", "the", "government", "s", "website", "at", "www.clinicaltrials.gov,", "ID", "NCT01048372.", "<tag2>", "The", "Study", "was", "completed", "subsequent", "to", "May", "31,", "2012.", "<tag3>"], "wordsA": ["The", "Study", "design", "and", "objectives", "are", "available", "to", "view", "at", "the", "government", "s", "website", "at", "www.clinicaltrials.gov,", "ID", "NCT01048372."], "wordsB": ["The", "Study", "was", "completed", "subsequent", "to", "May", "31,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p28_s0", "idA": "1175680_11_item1_p17_s15", "sentA": "In all instances, MGH reserves the right to use any invention for research, clinical and educational purposes.", "sentB": "No. 010625192 with an effective registration date of June 11, 2012.", "type": 1, "words": ["<tag1>", "In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes.", "<tag2>", "No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012.", "<tag3>"], "wordsA": ["In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes."], "wordsB": ["No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p30_s2", "idA": "1175680_11_item1_p17_s15", "sentA": "In all instances, MGH reserves the right to use any invention for research, clinical and educational purposes.", "sentB": "This study has now been completed.", "type": 1, "words": ["<tag1>", "In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes.", "<tag2>", "This", "study", "has", "now", "been", "completed.", "<tag3>"], "wordsA": ["In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes."], "wordsB": ["This", "study", "has", "now", "been", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p40_s2", "idA": "1175680_11_item1_p17_s15", "sentA": "In all instances, MGH reserves the right to use any invention for research, clinical and educational purposes.", "sentB": "No. 010625192 with an effective registration date of June 11, 2012.", "type": 1, "words": ["<tag1>", "In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes.", "<tag2>", "No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012.", "<tag3>"], "wordsA": ["In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes."], "wordsB": ["No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p5_s3", "idA": "1175680_11_item1_p17_s15", "sentA": "In all instances, MGH reserves the right to use any invention for research, clinical and educational purposes.", "sentB": "No. 010625192 with an effective registration date of June 11, 2012.", "type": 1, "words": ["<tag1>", "In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes.", "<tag2>", "No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012.", "<tag3>"], "wordsA": ["In", "all", "instances,", "MGH", "reserves", "the", "right", "to", "use", "any", "invention", "for", "research,", "clinical", "and", "educational", "purposes."], "wordsB": ["No.", "010625192", "with", "an", "effective", "registration", "date", "of", "June", "11,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p7_s1", "idA": "1175680_11_item1_p18_s0", "sentA": "The Clinical Trial Agreement also governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "It targets a normal cell molecule called CD11a, part of the heterodimer that makes up the cell adhesion molecule lymphocyte function cell associated antigen ( LFA-1 ).", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "also", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "It", "targets", "a", "normal", "cell", "molecule", "called", "CD11a,", "part", "of", "the", "heterodimer", "that", "makes", "up", "the", "cell", "adhesion", "molecule", "lymphocyte", "function", "cell", "associated", "antigen", "(", "LFA-1", ").", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "also", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["It", "targets", "a", "normal", "cell", "molecule", "called", "CD11a,", "part", "of", "the", "heterodimer", "that", "makes", "up", "the", "cell", "adhesion", "molecule", "lymphocyte", "function", "cell", "associated", "antigen", "(", "LFA-1", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p40_s0", "idA": "1175680_11_item1_p19_s7", "sentA": "These treatment interruptions also can contribute to the generation of resistant viruses.", "sentB": "trademark applications claiming priority to the US application for CYTOFELINE, including Australian App.", "type": 1, "words": ["<tag1>", "These", "treatment", "interruptions", "also", "can", "contribute", "to", "the", "generation", "of", "resistant", "viruses.", "<tag2>", "trademark", "applications", "claiming", "priority", "to", "the", "US", "application", "for", "CYTOFELINE,", "including", "Australian", "App.", "<tag3>"], "wordsA": ["These", "treatment", "interruptions", "also", "can", "contribute", "to", "the", "generation", "of", "resistant", "viruses."], "wordsB": ["trademark", "applications", "claiming", "priority", "to", "the", "US", "application", "for", "CYTOFELINE,", "including", "Australian", "App."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p30_s3", "idA": "1175680_11_item1_p1_s0", "sentA": "We are a development stage biotechnology company (concept company) focused on discovering and developing a class of therapeutic monoclonal antibodies to treat Human Immunodeficiency Virus ( HIV ) infection.", "sentB": "Through the course of this work Dr. Elder was able to identify a panel of anti-human monoclonal antibodies to CD11a that cross react with feline CD11a.", "type": 1, "words": ["<tag1>", "We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection.", "<tag2>", "Through", "the", "course", "of", "this", "work", "Dr.", "Elder", "was", "able", "to", "identify", "a", "panel", "of", "anti-human", "monoclonal", "antibodies", "to", "CD11a", "that", "cross", "react", "with", "feline", "CD11a.", "<tag3>"], "wordsA": ["We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection."], "wordsB": ["Through", "the", "course", "of", "this", "work", "Dr.", "Elder", "was", "able", "to", "identify", "a", "panel", "of", "anti-human", "monoclonal", "antibodies", "to", "CD11a", "that", "cross", "react", "with", "feline", "CD11a."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p7_s2", "idA": "1175680_11_item1_p27_s2", "sentA": "By binding to these cells, Cytolin appears to induce an antiviral activity that can impede infection of new cells and presumably lead to a reduction in viral burden.", "sentB": "Published reports have suggested that blocking or engaging CD11a might somehow limit or prevent HIV infection of CD4 cells and monocytes.", "type": 1, "words": ["<tag1>", "By", "binding", "to", "these", "cells,", "Cytolin", "appears", "to", "induce", "an", "antiviral", "activity", "that", "can", "impede", "infection", "of", "new", "cells", "and", "presumably", "lead", "to", "a", "reduction", "in", "viral", "burden.", "<tag2>", "Published", "reports", "have", "suggested", "that", "blocking", "or", "engaging", "CD11a", "might", "somehow", "limit", "or", "prevent", "HIV", "infection", "of", "CD4", "cells", "and", "monocytes.", "<tag3>"], "wordsA": ["By", "binding", "to", "these", "cells,", "Cytolin", "appears", "to", "induce", "an", "antiviral", "activity", "that", "can", "impede", "infection", "of", "new", "cells", "and", "presumably", "lead", "to", "a", "reduction", "in", "viral", "burden."], "wordsB": ["Published", "reports", "have", "suggested", "that", "blocking", "or", "engaging", "CD11a", "might", "somehow", "limit", "or", "prevent", "HIV", "infection", "of", "CD4", "cells", "and", "monocytes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p30_s4", "idA": "1175680_11_item1_p28_s2", "sentA": "Advances in antibody production technologies, such as high productivity cell culture has enabled manufacturers to produce antibody products more cost-effectively than 20 years ago.", "sentB": "These antibodies limited FIV infection in cell culture.", "type": 1, "words": ["<tag1>", "Advances", "in", "antibody", "production", "technologies,", "such", "as", "high", "productivity", "cell", "culture", "has", "enabled", "manufacturers", "to", "produce", "antibody", "products", "more", "cost-effectively", "than", "20", "years", "ago.", "<tag2>", "These", "antibodies", "limited", "FIV", "infection", "in", "cell", "culture.", "<tag3>"], "wordsA": ["Advances", "in", "antibody", "production", "technologies,", "such", "as", "high", "productivity", "cell", "culture", "has", "enabled", "manufacturers", "to", "produce", "antibody", "products", "more", "cost-effectively", "than", "20", "years", "ago."], "wordsB": ["These", "antibodies", "limited", "FIV", "infection", "in", "cell", "culture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p30_s7", "idA": "1175680_11_item1_p34_s9", "sentA": "We anticipate that we will apply to trademark this product under the name CytoFeline.", "sentB": "While the original six-month period contemplated under the Scripps Agreement has expired, the Company will continue to engage Dr. Elder and Thomas Fitting, Esq., Ph.D., Chief Patent Counsel at Scripps Research, as consultants on an as needed basis through July 12, 2013.", "type": 1, "words": ["<tag1>", "We", "anticipate", "that", "we", "will", "apply", "to", "trademark", "this", "product", "under", "the", "name", "CytoFeline.", "<tag2>", "While", "the", "original", "six-month", "period", "contemplated", "under", "the", "Scripps", "Agreement", "has", "expired,", "the", "Company", "will", "continue", "to", "engage", "Dr.", "Elder", "and", "Thomas", "Fitting,", "Esq.,", "Ph.D.,", "Chief", "Patent", "Counsel", "at", "Scripps", "Research,", "as", "consultants", "on", "an", "as", "needed", "basis", "through", "July", "12,", "2013.", "<tag3>"], "wordsA": ["We", "anticipate", "that", "we", "will", "apply", "to", "trademark", "this", "product", "under", "the", "name", "CytoFeline."], "wordsB": ["While", "the", "original", "six-month", "period", "contemplated", "under", "the", "Scripps", "Agreement", "has", "expired,", "the", "Company", "will", "continue", "to", "engage", "Dr.", "Elder", "and", "Thomas", "Fitting,", "Esq.,", "Ph.D.,", "Chief", "Patent", "Counsel", "at", "Scripps", "Research,", "as", "consultants", "on", "an", "as", "needed", "basis", "through", "July", "12,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p27_s2", "idA": "1175680_11_item1_p3_s0", "sentA": "also acquired the federally registered trademarks, CYTODYN (U.S. Registration No. 2095498) and CYTOLIN (U.S. Registration No. 2095497), and a related trademark symbol.", "sentB": "No. 1247597, and a Chinese App.", "type": 1, "words": ["<tag1>", "also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol.", "<tag2>", "No.", "1247597,", "and", "a", "Chinese", "App.", "<tag3>"], "wordsA": ["also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol."], "wordsB": ["No.", "1247597,", "and", "a", "Chinese", "App."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p40_s1", "idA": "1175680_11_item1_p3_s0", "sentA": "also acquired the federally registered trademarks, CYTODYN (U.S. Registration No. 2095498) and CYTOLIN (U.S. Registration No. 2095497), and a related trademark symbol.", "sentB": "No. 1247597, and a Chinese App.", "type": 1, "words": ["<tag1>", "also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol.", "<tag2>", "No.", "1247597,", "and", "a", "Chinese", "App.", "<tag3>"], "wordsA": ["also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol."], "wordsB": ["No.", "1247597,", "and", "a", "Chinese", "App."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p5_s2", "idA": "1175680_11_item1_p3_s0", "sentA": "also acquired the federally registered trademarks, CYTODYN (U.S. Registration No. 2095498) and CYTOLIN (U.S. Registration No. 2095497), and a related trademark symbol.", "sentB": "No. 1247597, and a Chinese App.", "type": 1, "words": ["<tag1>", "also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol.", "<tag2>", "No.", "1247597,", "and", "a", "Chinese", "App.", "<tag3>"], "wordsA": ["also", "acquired", "the", "federally", "registered", "trademarks,", "CYTODYN", "(U.S.", "Registration", "No.", "2095498)", "and", "CYTOLIN", "(U.S.", "Registration", "No.", "2095497),", "and", "a", "related", "trademark", "symbol."], "wordsB": ["No.", "1247597,", "and", "a", "Chinese", "App."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p33_s0", "idA": "1175680_11_item1_p4_s4", "sentA": "On June 17, 2011 the Company filed for a provisional patent in the United States for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, a retroviral infection in cats.", "sentB": "On June 19, 2012, Dr. VandeWoude and Dr. Richard Trauger, the Company s Managing Director of Science, were awarded a grant of $27,000 by CSU to study the pharmacokinetics of a chimeric version of CytoFeline in uninfected cats.", "type": 1, "words": ["<tag1>", "On", "June", "17,", "2011", "the", "Company", "filed", "for", "a", "provisional", "patent", "in", "the", "United", "States", "for", "the", "use", "of", "these", "antibodies", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV,", "a", "retroviral", "infection", "in", "cats.", "<tag2>", "On", "June", "19,", "2012,", "Dr.", "VandeWoude", "and", "Dr.", "Richard", "Trauger,", "the", "Company", "s", "Managing", "Director", "of", "Science,", "were", "awarded", "a", "grant", "of", "$27,000", "by", "CSU", "to", "study", "the", "pharmacokinetics", "of", "a", "chimeric", "version", "of", "CytoFeline", "in", "uninfected", "cats.", "<tag3>"], "wordsA": ["On", "June", "17,", "2011", "the", "Company", "filed", "for", "a", "provisional", "patent", "in", "the", "United", "States", "for", "the", "use", "of", "these", "antibodies", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV,", "a", "retroviral", "infection", "in", "cats."], "wordsB": ["On", "June", "19,", "2012,", "Dr.", "VandeWoude", "and", "Dr.", "Richard", "Trauger,", "the", "Company", "s", "Managing", "Director", "of", "Science,", "were", "awarded", "a", "grant", "of", "$27,000", "by", "CSU", "to", "study", "the", "pharmacokinetics", "of", "a", "chimeric", "version", "of", "CytoFeline", "in", "uninfected", "cats."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p29_s1", "idA": "1175680_11_item1_p55_s0", "sentA": "Research and Development Costs Our sponsored research and development expenses were $480,765, $328,775, and $2,229,468 in fiscal 2011, 2010 and for the period October 28, 2003 through May 31, 2011, respectively.", "sentB": "No. 1473043 was registered on May 31, 2012.", "type": 1, "words": ["<tag1>", "Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively.", "<tag2>", "No.", "1473043", "was", "registered", "on", "May", "31,", "2012.", "<tag3>"], "wordsA": ["Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively."], "wordsB": ["No.", "1473043", "was", "registered", "on", "May", "31,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p41_s1", "idA": "1175680_11_item1_p55_s0", "sentA": "Research and Development Costs Our sponsored research and development expenses were $480,765, $328,775, and $2,229,468 in fiscal 2011, 2010 and for the period October 28, 2003 through May 31, 2011, respectively.", "sentB": "No. 1473043 was registered on May 31, 2012.", "type": 1, "words": ["<tag1>", "Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively.", "<tag2>", "No.", "1473043", "was", "registered", "on", "May", "31,", "2012.", "<tag3>"], "wordsA": ["Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively."], "wordsB": ["No.", "1473043", "was", "registered", "on", "May", "31,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p6_s1", "idA": "1175680_11_item1_p55_s0", "sentA": "Research and Development Costs Our sponsored research and development expenses were $480,765, $328,775, and $2,229,468 in fiscal 2011, 2010 and for the period October 28, 2003 through May 31, 2011, respectively.", "sentB": "No. 1473043 was registered on May 31, 2012.", "type": 1, "words": ["<tag1>", "Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively.", "<tag2>", "No.", "1473043", "was", "registered", "on", "May", "31,", "2012.", "<tag3>"], "wordsA": ["Research", "and", "Development", "Costs", "Our", "sponsored", "research", "and", "development", "expenses", "were", "$480,765,", "$328,775,", "and", "$2,229,468", "in", "fiscal", "2011,", "2010", "and", "for", "the", "period", "October", "28,", "2003", "through", "May", "31,", "2011,", "respectively."], "wordsB": ["No.", "1473043", "was", "registered", "on", "May", "31,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p30_s6", "idA": "1175680_11_item1_p7_s2", "sentA": "Based on the results of this pilot study, a compassionate use trial was initiated.", "sentB": "The release of this or any data from this study is entirely dependent on Dr. Elder.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "results", "of", "this", "pilot", "study,", "a", "compassionate", "use", "trial", "was", "initiated.", "<tag2>", "The", "release", "of", "this", "or", "any", "data", "from", "this", "study", "is", "entirely", "dependent", "on", "Dr.", "Elder.", "<tag3>"], "wordsA": ["Based", "on", "the", "results", "of", "this", "pilot", "study,", "a", "compassionate", "use", "trial", "was", "initiated."], "wordsB": ["The", "release", "of", "this", "or", "any", "data", "from", "this", "study", "is", "entirely", "dependent", "on", "Dr.", "Elder."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_12_item1_p32_s2", "idA": "1175680_11_item1_p7_s2", "sentA": "Based on the results of this pilot study, a compassionate use trial was initiated.", "sentB": "The release of this or any data from this study is entirely dependent on Dr. VandeWoude.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "results", "of", "this", "pilot", "study,", "a", "compassionate", "use", "trial", "was", "initiated.", "<tag2>", "The", "release", "of", "this", "or", "any", "data", "from", "this", "study", "is", "entirely", "dependent", "on", "Dr.", "VandeWoude.", "<tag3>"], "wordsA": ["Based", "on", "the", "results", "of", "this", "pilot", "study,", "a", "compassionate", "use", "trial", "was", "initiated."], "wordsB": ["The", "release", "of", "this", "or", "any", "data", "from", "this", "study", "is", "entirely", "dependent", "on", "Dr.", "VandeWoude."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p21_s1", "idA": "1175680_12_item1_p10_s3", "sentA": "By contract with Vista Biologicals Corporation, CytoDyn of New Mexico, Inc. had the exclusive right to reference the drug master file, that is, to authorize Vista Biologicals Corporation to manufacture Cytolin in accordance with the terms of the drug master file.", "sentB": "The duration of foreign patents varies in accordance with the provisions of applicable local law, although most countries provide for patent terms of 20 years from the earliest asserted filing date and allow patent extensions similar to those permitted in the U.S. Patents may not enable us to preclude competitors from commercializing drugs in direct competition with our products, and consequently may not provide us with any meaningful competitive advantage.", "type": 1, "words": ["<tag1>", "By", "contract", "with", "Vista", "Biologicals", "Corporation,", "CytoDyn", "of", "New", "Mexico,", "Inc.", "had", "the", "exclusive", "right", "to", "reference", "the", "drug", "master", "file,", "that", "is,", "to", "authorize", "Vista", "Biologicals", "Corporation", "to", "manufacture", "Cytolin", "in", "accordance", "with", "the", "terms", "of", "the", "drug", "master", "file.", "<tag2>", "The", "duration", "of", "foreign", "patents", "varies", "in", "accordance", "with", "the", "provisions", "of", "applicable", "local", "law,", "although", "most", "countries", "provide", "for", "patent", "terms", "of", "20", "years", "from", "the", "earliest", "asserted", "filing", "date", "and", "allow", "patent", "extensions", "similar", "to", "those", "permitted", "in", "the", "U.S.", "Patents", "may", "not", "enable", "us", "to", "preclude", "competitors", "from", "commercializing", "drugs", "in", "direct", "competition", "with", "our", "products,", "and", "consequently", "may", "not", "provide", "us", "with", "any", "meaningful", "competitive", "advantage.", "<tag3>"], "wordsA": ["By", "contract", "with", "Vista", "Biologicals", "Corporation,", "CytoDyn", "of", "New", "Mexico,", "Inc.", "had", "the", "exclusive", "right", "to", "reference", "the", "drug", "master", "file,", "that", "is,", "to", "authorize", "Vista", "Biologicals", "Corporation", "to", "manufacture", "Cytolin", "in", "accordance", "with", "the", "terms", "of", "the", "drug", "master", "file."], "wordsB": ["The", "duration", "of", "foreign", "patents", "varies", "in", "accordance", "with", "the", "provisions", "of", "applicable", "local", "law,", "although", "most", "countries", "provide", "for", "patent", "terms", "of", "20", "years", "from", "the", "earliest", "asserted", "filing", "date", "and", "allow", "patent", "extensions", "similar", "to", "those", "permitted", "in", "the", "U.S.", "Patents", "may", "not", "enable", "us", "to", "preclude", "competitors", "from", "commercializing", "drugs", "in", "direct", "competition", "with", "our", "products,", "and", "consequently", "may", "not", "provide", "us", "with", "any", "meaningful", "competitive", "advantage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p9_s2", "idA": "1175680_12_item1_p10_s4", "sentA": "In 1996, the FDA also designated our investigational new drug application for murine Cytolin as BB-IND #6845, and subsequently approved a clinical trial.", "sentB": "In connection with the Progenics Agreement, the Company assumed Progenics rights and obligations under an additional license agreement (the PDL License ) with Protein Design Labs, Inc. (now AbbVie, Inc.), pursuant to which CytoDyn is required to pay the following milestone payments and royalties: (i) $1,000,000 upon initiation of a Phase III clinical trial of a licensed product; (ii) $500,000 at filing a new drug application for PRO 140 in the U.S. or non-U.S. equivalent; (iii) $500,000 at the time of FDA approval of the first U.S. new drug application or other approval for sale by certain non-U.S. regulatory bodies; and (iv) royalties of up to seven and one-half percent (7.5%) of net sales payable to licensors or sublicensees during the period beginning on the date of the first commercial sale of PRO 140 until the later of (a) the expiration of the last to expire patent licensed and (b) 10 years following the first commercial sale of PRO 140.", "type": 1, "words": ["<tag1>", "In", "1996,", "the", "FDA", "also", "designated", "our", "investigational", "new", "drug", "application", "for", "murine", "Cytolin", "as", "BB-IND", "#6845,", "and", "subsequently", "approved", "a", "clinical", "trial.", "<tag2>", "In", "connection", "with", "the", "Progenics", "Agreement,", "the", "Company", "assumed", "Progenics", "rights", "and", "obligations", "under", "an", "additional", "license", "agreement", "(the", "PDL", "License", ")", "with", "Protein", "Design", "Labs,", "Inc.", "(now", "AbbVie,", "Inc.),", "pursuant", "to", "which", "CytoDyn", "is", "required", "to", "pay", "the", "following", "milestone", "payments", "and", "royalties:", "(i)", "$1,000,000", "upon", "initiation", "of", "a", "Phase", "III", "clinical", "trial", "of", "a", "licensed", "product;", "(ii)", "$500,000", "at", "filing", "a", "new", "drug", "application", "for", "PRO", "140", "in", "the", "U.S.", "or", "non-U.S.", "equivalent;", "(iii)", "$500,000", "at", "the", "time", "of", "FDA", "approval", "of", "the", "first", "U.S.", "new", "drug", "application", "or", "other", "approval", "for", "sale", "by", "certain", "non-U.S.", "regulatory", "bodies;", "and", "(iv)", "royalties", "of", "up", "to", "seven", "and", "one-half", "percent", "(7.5%)", "of", "net", "sales", "payable", "to", "licensors", "or", "sublicensees", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "licensed", "and", "(b)", "10", "years", "following", "the", "first", "commercial", "sale", "of", "PRO", "140.", "<tag3>"], "wordsA": ["In", "1996,", "the", "FDA", "also", "designated", "our", "investigational", "new", "drug", "application", "for", "murine", "Cytolin", "as", "BB-IND", "#6845,", "and", "subsequently", "approved", "a", "clinical", "trial."], "wordsB": ["In", "connection", "with", "the", "Progenics", "Agreement,", "the", "Company", "assumed", "Progenics", "rights", "and", "obligations", "under", "an", "additional", "license", "agreement", "(the", "PDL", "License", ")", "with", "Protein", "Design", "Labs,", "Inc.", "(now", "AbbVie,", "Inc.),", "pursuant", "to", "which", "CytoDyn", "is", "required", "to", "pay", "the", "following", "milestone", "payments", "and", "royalties:", "(i)", "$1,000,000", "upon", "initiation", "of", "a", "Phase", "III", "clinical", "trial", "of", "a", "licensed", "product;", "(ii)", "$500,000", "at", "filing", "a", "new", "drug", "application", "for", "PRO", "140", "in", "the", "U.S.", "or", "non-U.S.", "equivalent;", "(iii)", "$500,000", "at", "the", "time", "of", "FDA", "approval", "of", "the", "first", "U.S.", "new", "drug", "application", "or", "other", "approval", "for", "sale", "by", "certain", "non-U.S.", "regulatory", "bodies;", "and", "(iv)", "royalties", "of", "up", "to", "seven", "and", "one-half", "percent", "(7.5%)", "of", "net", "sales", "payable", "to", "licensors", "or", "sublicensees", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "licensed", "and", "(b)", "10", "years", "following", "the", "first", "commercial", "sale", "of", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p9_s4", "idA": "1175680_12_item1_p11_s3", "sentA": "We entered into a buy-sell agreement with Symbion to purchase the Phase Ia study data in 2004.", "sentB": "As an integral part of CytoDyn s acquisition of PRO 140, we entered into a collaboration agreement with Drexel, whereby CytoDyn will provide Drexel with the necessary quantity of PRO 140 to conduct the clinical trials and CytoDyn will have access to all clinical trial data and the right to use such data to maintain the IND (Investigational New Drug application) for PRO 140 and to support its application to the FDA.", "type": 1, "words": ["<tag1>", "We", "entered", "into", "a", "buy-sell", "agreement", "with", "Symbion", "to", "purchase", "the", "Phase", "Ia", "study", "data", "in", "2004.", "<tag2>", "As", "an", "integral", "part", "of", "CytoDyn", "s", "acquisition", "of", "PRO", "140,", "we", "entered", "into", "a", "collaboration", "agreement", "with", "Drexel,", "whereby", "CytoDyn", "will", "provide", "Drexel", "with", "the", "necessary", "quantity", "of", "PRO", "140", "to", "conduct", "the", "clinical", "trials", "and", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data", "to", "maintain", "the", "IND", "(Investigational", "New", "Drug", "application)", "for", "PRO", "140", "and", "to", "support", "its", "application", "to", "the", "FDA.", "<tag3>"], "wordsA": ["We", "entered", "into", "a", "buy-sell", "agreement", "with", "Symbion", "to", "purchase", "the", "Phase", "Ia", "study", "data", "in", "2004."], "wordsB": ["As", "an", "integral", "part", "of", "CytoDyn", "s", "acquisition", "of", "PRO", "140,", "we", "entered", "into", "a", "collaboration", "agreement", "with", "Drexel,", "whereby", "CytoDyn", "will", "provide", "Drexel", "with", "the", "necessary", "quantity", "of", "PRO", "140", "to", "conduct", "the", "clinical", "trials", "and", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data", "to", "maintain", "the", "IND", "(Investigational", "New", "Drug", "application)", "for", "PRO", "140", "and", "to", "support", "its", "application", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p9_s1", "idA": "1175680_12_item1_p12_s2", "sentA": "Some of the data was presented as an abstract and poster session, entitled Phase I Study of Anti-LFA-1 Monoclonal Antibody (Cytolin in Adults with HIV Infection) at the 9th Conference on Retroviruses and Opportunistic Infections held in Seattle, Washington on February 24-28 2002 as well as the 16th International AIDS Conference held August 2006 in Toronto, Canada.", "sentB": "The terms of the Progenics Agreement provided for an initial cash payment of $3,500,000, which was paid at closing in October 2012, as well as the following milestone payments and royalties to be paid to Progenics in the future: (i) $1,500,000 at the time of the first dosing in a U.S. Phase III trial or non-U.S. equivalent; (ii) $5,000,000 at the time of FDA approval of the first U.S. new drug application or other non-U.S. approval for the sale of PRO 140; and (iii) royalty payments of 5% of net sales during the period beginning on the date of the first commercial sale of PRO 140 until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years following the first commercial sale of PRO 140, in each case determined on a country-by-country basis.", "type": 1, "words": ["<tag1>", "Some", "of", "the", "data", "was", "presented", "as", "an", "abstract", "and", "poster", "session,", "entitled", "Phase", "I", "Study", "of", "Anti-LFA-1", "Monoclonal", "Antibody", "(Cytolin", "in", "Adults", "with", "HIV", "Infection)", "at", "the", "9th", "Conference", "on", "Retroviruses", "and", "Opportunistic", "Infections", "held", "in", "Seattle,", "Washington", "on", "February", "24-28", "2002", "as", "well", "as", "the", "16th", "International", "AIDS", "Conference", "held", "August", "2006", "in", "Toronto,", "Canada.", "<tag2>", "The", "terms", "of", "the", "Progenics", "Agreement", "provided", "for", "an", "initial", "cash", "payment", "of", "$3,500,000,", "which", "was", "paid", "at", "closing", "in", "October", "2012,", "as", "well", "as", "the", "following", "milestone", "payments", "and", "royalties", "to", "be", "paid", "to", "Progenics", "in", "the", "future:", "(i)", "$1,500,000", "at", "the", "time", "of", "the", "first", "dosing", "in", "a", "U.S.", "Phase", "III", "trial", "or", "non-U.S.", "equivalent;", "(ii)", "$5,000,000", "at", "the", "time", "of", "FDA", "approval", "of", "the", "first", "U.S.", "new", "drug", "application", "or", "other", "non-U.S.", "approval", "for", "the", "sale", "of", "PRO", "140;", "and", "(iii)", "royalty", "payments", "of", "5%", "of", "net", "sales", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "included", "in", "the", "acquired", "assets,", "and", "(b)", "10", "years", "following", "the", "first", "commercial", "sale", "of", "PRO", "140,", "in", "each", "case", "determined", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Some", "of", "the", "data", "was", "presented", "as", "an", "abstract", "and", "poster", "session,", "entitled", "Phase", "I", "Study", "of", "Anti-LFA-1", "Monoclonal", "Antibody", "(Cytolin", "in", "Adults", "with", "HIV", "Infection)", "at", "the", "9th", "Conference", "on", "Retroviruses", "and", "Opportunistic", "Infections", "held", "in", "Seattle,", "Washington", "on", "February", "24-28", "2002", "as", "well", "as", "the", "16th", "International", "AIDS", "Conference", "held", "August", "2006", "in", "Toronto,", "Canada."], "wordsB": ["The", "terms", "of", "the", "Progenics", "Agreement", "provided", "for", "an", "initial", "cash", "payment", "of", "$3,500,000,", "which", "was", "paid", "at", "closing", "in", "October", "2012,", "as", "well", "as", "the", "following", "milestone", "payments", "and", "royalties", "to", "be", "paid", "to", "Progenics", "in", "the", "future:", "(i)", "$1,500,000", "at", "the", "time", "of", "the", "first", "dosing", "in", "a", "U.S.", "Phase", "III", "trial", "or", "non-U.S.", "equivalent;", "(ii)", "$5,000,000", "at", "the", "time", "of", "FDA", "approval", "of", "the", "first", "U.S.", "new", "drug", "application", "or", "other", "non-U.S.", "approval", "for", "the", "sale", "of", "PRO", "140;", "and", "(iii)", "royalty", "payments", "of", "5%", "of", "net", "sales", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "included", "in", "the", "acquired", "assets,", "and", "(b)", "10", "years", "following", "the", "first", "commercial", "sale", "of", "PRO", "140,", "in", "each", "case", "determined", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p14_s0", "idA": "1175680_12_item1_p13_s0", "sentA": "The Company then went through a period of years where legal issues delayed the progress of this treatment.", "sentB": "A total of 113 subjects were treated for a period of up to three weeks with as much as a 324 mg dose of PRO 140 administered weekly subcutaneously and 10mg/kg intravenously.", "type": 1, "words": ["<tag1>", "The", "Company", "then", "went", "through", "a", "period", "of", "years", "where", "legal", "issues", "delayed", "the", "progress", "of", "this", "treatment.", "<tag2>", "A", "total", "of", "113", "subjects", "were", "treated", "for", "a", "period", "of", "up", "to", "three", "weeks", "with", "as", "much", "as", "a", "324", "mg", "dose", "of", "PRO", "140", "administered", "weekly", "subcutaneously", "and", "10mg/kg", "intravenously.", "<tag3>"], "wordsA": ["The", "Company", "then", "went", "through", "a", "period", "of", "years", "where", "legal", "issues", "delayed", "the", "progress", "of", "this", "treatment."], "wordsB": ["A", "total", "of", "113", "subjects", "were", "treated", "for", "a", "period", "of", "up", "to", "three", "weeks", "with", "as", "much", "as", "a", "324", "mg", "dose", "of", "PRO", "140", "administered", "weekly", "subcutaneously", "and", "10mg/kg", "intravenously."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p1_s2", "idA": "1175680_12_item1_p16_s2", "sentA": "None of the patients enrolled in the study received injections of murine Cytolin ; rather they donated blood to allow one to examine the effects of Cytolin when it was added in the test tube to their peripheral blood mononuclear cells.", "sentB": "These therapies potentially block HIV from entering into and infecting certain cells.", "type": 1, "words": ["<tag1>", "None", "of", "the", "patients", "enrolled", "in", "the", "study", "received", "injections", "of", "murine", "Cytolin", ";", "rather", "they", "donated", "blood", "to", "allow", "one", "to", "examine", "the", "effects", "of", "Cytolin", "when", "it", "was", "added", "in", "the", "test", "tube", "to", "their", "peripheral", "blood", "mononuclear", "cells.", "<tag2>", "These", "therapies", "potentially", "block", "HIV", "from", "entering", "into", "and", "infecting", "certain", "cells.", "<tag3>"], "wordsA": ["None", "of", "the", "patients", "enrolled", "in", "the", "study", "received", "injections", "of", "murine", "Cytolin", ";", "rather", "they", "donated", "blood", "to", "allow", "one", "to", "examine", "the", "effects", "of", "Cytolin", "when", "it", "was", "added", "in", "the", "test", "tube", "to", "their", "peripheral", "blood", "mononuclear", "cells."], "wordsB": ["These", "therapies", "potentially", "block", "HIV", "from", "entering", "into", "and", "infecting", "certain", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p14_s3", "idA": "1175680_12_item1_p16_s3", "sentA": "The Study design and objectives are available to view at the government s website at www.clinicaltrials.gov, ID NCT01048372.", "sentB": "With respect to subcutaneously-administered trials, no significant safety signals were observed, with only minor irritation at the injection site in some subjects.", "type": 1, "words": ["<tag1>", "The", "Study", "design", "and", "objectives", "are", "available", "to", "view", "at", "the", "government", "s", "website", "at", "www.clinicaltrials.gov,", "ID", "NCT01048372.", "<tag2>", "With", "respect", "to", "subcutaneously-administered", "trials,", "no", "significant", "safety", "signals", "were", "observed,", "with", "only", "minor", "irritation", "at", "the", "injection", "site", "in", "some", "subjects.", "<tag3>"], "wordsA": ["The", "Study", "design", "and", "objectives", "are", "available", "to", "view", "at", "the", "government", "s", "website", "at", "www.clinicaltrials.gov,", "ID", "NCT01048372."], "wordsB": ["With", "respect", "to", "subcutaneously-administered", "trials,", "no", "significant", "safety", "signals", "were", "observed,", "with", "only", "minor", "irritation", "at", "the", "injection", "site", "in", "some", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p42_s1", "idA": "1175680_12_item1_p17_s0", "sentA": "The public has online access to this federal database, which describes elements of clinical trials and their status.", "sentB": "Dr. Jacobson has received two NIH grants to fund these clinical trials.", "type": 1, "words": ["<tag1>", "The", "public", "has", "online", "access", "to", "this", "federal", "database,", "which", "describes", "elements", "of", "clinical", "trials", "and", "their", "status.", "<tag2>", "Dr.", "Jacobson", "has", "received", "two", "NIH", "grants", "to", "fund", "these", "clinical", "trials.", "<tag3>"], "wordsA": ["The", "public", "has", "online", "access", "to", "this", "federal", "database,", "which", "describes", "elements", "of", "clinical", "trials", "and", "their", "status."], "wordsB": ["Dr.", "Jacobson", "has", "received", "two", "NIH", "grants", "to", "fund", "these", "clinical", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p5_s0", "idA": "1175680_12_item1_p18_s3", "sentA": "On May 20, 2011, we entered into a fifth amendment of the Clinical Trial Agreement with The General Hospital Corporation, d/b/a/ MGH to extend the Study enabling MGH Principal Investigator Eric Rosenberg, M.D., to further explore his initial findings regarding the potential mechanism of action of murine Cytolin to treat HIV-positive adults.", "sentB": "Current collaborative research relating to PRO 140 planned for late 2013 is being conducted by Jeffrey M. Jacobson, M.D., Professor of Medicine, Microbiology and Immunology, Chief, Drexel University College of Medicine ( Drexel ), and is partially funded through two grants awarded to Drexel and Dr. Jacobson by the National Institutes of Health ( NIH ).", "type": 1, "words": ["<tag1>", "On", "May", "20,", "2011,", "we", "entered", "into", "a", "fifth", "amendment", "of", "the", "Clinical", "Trial", "Agreement", "with", "The", "General", "Hospital", "Corporation,", "d/b/a/", "MGH", "to", "extend", "the", "Study", "enabling", "MGH", "Principal", "Investigator", "Eric", "Rosenberg,", "M.D.,", "to", "further", "explore", "his", "initial", "findings", "regarding", "the", "potential", "mechanism", "of", "action", "of", "murine", "Cytolin", "to", "treat", "HIV-positive", "adults.", "<tag2>", "Current", "collaborative", "research", "relating", "to", "PRO", "140", "planned", "for", "late", "2013", "is", "being", "conducted", "by", "Jeffrey", "M.", "Jacobson,", "M.D.,", "Professor", "of", "Medicine,", "Microbiology", "and", "Immunology,", "Chief,", "Drexel", "University", "College", "of", "Medicine", "(", "Drexel", "),", "and", "is", "partially", "funded", "through", "two", "grants", "awarded", "to", "Drexel", "and", "Dr.", "Jacobson", "by", "the", "National", "Institutes", "of", "Health", "(", "NIH", ").", "<tag3>"], "wordsA": ["On", "May", "20,", "2011,", "we", "entered", "into", "a", "fifth", "amendment", "of", "the", "Clinical", "Trial", "Agreement", "with", "The", "General", "Hospital", "Corporation,", "d/b/a/", "MGH", "to", "extend", "the", "Study", "enabling", "MGH", "Principal", "Investigator", "Eric", "Rosenberg,", "M.D.,", "to", "further", "explore", "his", "initial", "findings", "regarding", "the", "potential", "mechanism", "of", "action", "of", "murine", "Cytolin", "to", "treat", "HIV-positive", "adults."], "wordsB": ["Current", "collaborative", "research", "relating", "to", "PRO", "140", "planned", "for", "late", "2013", "is", "being", "conducted", "by", "Jeffrey", "M.", "Jacobson,", "M.D.,", "Professor", "of", "Medicine,", "Microbiology", "and", "Immunology,", "Chief,", "Drexel", "University", "College", "of", "Medicine", "(", "Drexel", "),", "and", "is", "partially", "funded", "through", "two", "grants", "awarded", "to", "Drexel", "and", "Dr.", "Jacobson", "by", "the", "National", "Institutes", "of", "Health", "(", "NIH", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p4_s1", "idA": "1175680_12_item1_p18_s4", "sentA": "Under the fifth amendment, we agreed to pay MGH the remaining unpaid balance of $291,590 of the total research grant of $865,375 over the six month period beginning on May 20, 2011 and ending on November 20, 2011.", "sentB": "Progenics led, and contributed to funding of, PRO 140 development and trials through 2011.", "type": 1, "words": ["<tag1>", "Under", "the", "fifth", "amendment,", "we", "agreed", "to", "pay", "MGH", "the", "remaining", "unpaid", "balance", "of", "$291,590", "of", "the", "total", "research", "grant", "of", "$865,375", "over", "the", "six", "month", "period", "beginning", "on", "May", "20,", "2011", "and", "ending", "on", "November", "20,", "2011.", "<tag2>", "Progenics", "led,", "and", "contributed", "to", "funding", "of,", "PRO", "140", "development", "and", "trials", "through", "2011.", "<tag3>"], "wordsA": ["Under", "the", "fifth", "amendment,", "we", "agreed", "to", "pay", "MGH", "the", "remaining", "unpaid", "balance", "of", "$291,590", "of", "the", "total", "research", "grant", "of", "$865,375", "over", "the", "six", "month", "period", "beginning", "on", "May", "20,", "2011", "and", "ending", "on", "November", "20,", "2011."], "wordsB": ["Progenics", "led,", "and", "contributed", "to", "funding", "of,", "PRO", "140", "development", "and", "trials", "through", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p13_s3", "idA": "1175680_12_item1_p19_s2", "sentA": "The Company will determine if clinical trials with the humanized version of Cytolin are warranted based on these and other results from studies with the murine molecule and subsequent confirmation of activity with the humanized version of Cytolin .", "sentB": "Until the clinical trials for PRO 140 commence, we plan to devote only a modest amount of resources towards the approval or commercialization of Cytolin or CytoFeline.", "type": 1, "words": ["<tag1>", "The", "Company", "will", "determine", "if", "clinical", "trials", "with", "the", "humanized", "version", "of", "Cytolin", "are", "warranted", "based", "on", "these", "and", "other", "results", "from", "studies", "with", "the", "murine", "molecule", "and", "subsequent", "confirmation", "of", "activity", "with", "the", "humanized", "version", "of", "Cytolin", ".", "<tag2>", "Until", "the", "clinical", "trials", "for", "PRO", "140", "commence,", "we", "plan", "to", "devote", "only", "a", "modest", "amount", "of", "resources", "towards", "the", "approval", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline.", "<tag3>"], "wordsA": ["The", "Company", "will", "determine", "if", "clinical", "trials", "with", "the", "humanized", "version", "of", "Cytolin", "are", "warranted", "based", "on", "these", "and", "other", "results", "from", "studies", "with", "the", "murine", "molecule", "and", "subsequent", "confirmation", "of", "activity", "with", "the", "humanized", "version", "of", "Cytolin", "."], "wordsB": ["Until", "the", "clinical", "trials", "for", "PRO", "140", "commence,", "we", "plan", "to", "devote", "only", "a", "modest", "amount", "of", "resources", "towards", "the", "approval", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p16_s8", "idA": "1175680_12_item1_p1_s0", "sentA": "We are a development stage biotechnology company (concept company) focused on discovering and developing a class of therapeutic monoclonal antibodies to treat Human Immunodeficiency Virus ( HIV ) infection.", "sentB": "Current business plans, however, are focused on PRO 140.", "type": 1, "words": ["<tag1>", "We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection.", "<tag2>", "Current", "business", "plans,", "however,", "are", "focused", "on", "PRO", "140.", "<tag3>"], "wordsA": ["We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection."], "wordsB": ["Current", "business", "plans,", "however,", "are", "focused", "on", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p8_s3", "idA": "1175680_12_item1_p1_s0", "sentA": "We are a development stage biotechnology company (concept company) focused on discovering and developing a class of therapeutic monoclonal antibodies to treat Human Immunodeficiency Virus ( HIV ) infection.", "sentB": "Overall, we believe PRO 140 represents a distinct class of CCR5 inhibitors with unique virological and immunological properties and may provide another distinct tool to treat HIV-infected subjects developing resistance to other therapies.", "type": 1, "words": ["<tag1>", "We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection.", "<tag2>", "Overall,", "we", "believe", "PRO", "140", "represents", "a", "distinct", "class", "of", "CCR5", "inhibitors", "with", "unique", "virological", "and", "immunological", "properties", "and", "may", "provide", "another", "distinct", "tool", "to", "treat", "HIV-infected", "subjects", "developing", "resistance", "to", "other", "therapies.", "<tag3>"], "wordsA": ["We", "are", "a", "development", "stage", "biotechnology", "company", "(concept", "company)", "focused", "on", "discovering", "and", "developing", "a", "class", "of", "therapeutic", "monoclonal", "antibodies", "to", "treat", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection."], "wordsB": ["Overall,", "we", "believe", "PRO", "140", "represents", "a", "distinct", "class", "of", "CCR5", "inhibitors", "with", "unique", "virological", "and", "immunological", "properties", "and", "may", "provide", "another", "distinct", "tool", "to", "treat", "HIV-infected", "subjects", "developing", "resistance", "to", "other", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p14_s2", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "This response is similar in magnitude to that seen with any other single anti-HIV therapeutic agent.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "This", "response", "is", "similar", "in", "magnitude", "to", "that", "seen", "with", "any", "other", "single", "anti-HIV", "therapeutic", "agent.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["This", "response", "is", "similar", "in", "magnitude", "to", "that", "seen", "with", "any", "other", "single", "anti-HIV", "therapeutic", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p23_s0", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "(1) Patent term extensions and pending patent applications may extend periods of patent protection.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p23_s1", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "Additional detail regarding our patents and patent applications is available upon request.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "Additional", "detail", "regarding", "our", "patents", "and", "patent", "applications", "is", "available", "upon", "request.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["Additional", "detail", "regarding", "our", "patents", "and", "patent", "applications", "is", "available", "upon", "request."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p25_s4", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "If we cannot negotiate such a license, we might have to pursue a less desirable development route or terminate the program altogether.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "If", "we", "cannot", "negotiate", "such", "a", "license,", "we", "might", "have", "to", "pursue", "a", "less", "desirable", "development", "route", "or", "terminate", "the", "program", "altogether.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["If", "we", "cannot", "negotiate", "such", "a", "license,", "we", "might", "have", "to", "pursue", "a", "less", "desirable", "development", "route", "or", "terminate", "the", "program", "altogether."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p4_s0", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "PRO 140 was originally developed by Progenics Pharmaceuticals, Inc. ( Progenics ).", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "PRO", "140", "was", "originally", "developed", "by", "Progenics", "Pharmaceuticals,", "Inc.", "(", "Progenics", ").", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["PRO", "140", "was", "originally", "developed", "by", "Progenics", "Pharmaceuticals,", "Inc.", "(", "Progenics", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p7_s0", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "Patients with complex concomitant medical requirements.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "Patients", "with", "complex", "concomitant", "medical", "requirements.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["Patients", "with", "complex", "concomitant", "medical", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p8_s1", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "PRO 140 also appears to broadly inhibit drug-resistant CCR5-tropic HIV viruses, including those resistant to small-molecule anti-CCR5 HIV therapies.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "PRO", "140", "also", "appears", "to", "broadly", "inhibit", "drug-resistant", "CCR5-tropic", "HIV", "viruses,", "including", "those", "resistant", "to", "small-molecule", "anti-CCR5", "HIV", "therapies.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["PRO", "140", "also", "appears", "to", "broadly", "inhibit", "drug-resistant", "CCR5-tropic", "HIV", "viruses,", "including", "those", "resistant", "to", "small-molecule", "anti-CCR5", "HIV", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p9_s3", "idA": "1175680_12_item1_p20_s0", "sentA": "The Clinical Trial Agreement governs the parties rights in Study data and the results of the Study ( Study Data and Results ).", "sentB": "The PDL License also provides for an annual maintenance fee of $150,000 until royalties exceed that amount.", "type": 1, "words": ["<tag1>", "The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ").", "<tag2>", "The", "PDL", "License", "also", "provides", "for", "an", "annual", "maintenance", "fee", "of", "$150,000", "until", "royalties", "exceed", "that", "amount.", "<tag3>"], "wordsA": ["The", "Clinical", "Trial", "Agreement", "governs", "the", "parties", "rights", "in", "Study", "data", "and", "the", "results", "of", "the", "Study", "(", "Study", "Data", "and", "Results", ")."], "wordsB": ["The", "PDL", "License", "also", "provides", "for", "an", "annual", "maintenance", "fee", "of", "$150,000", "until", "royalties", "exceed", "that", "amount."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p42_s2", "idA": "1175680_12_item1_p20_s4", "sentA": "These uses are further limited by the requirements that any such use comply with applicable law (including the Health Insurance Portability and Accountability Act of 1996 ( HIPAA and that the use is permitted by the informed consent form used with subjects in connection with the Study.", "sentB": "It is critical to our business strategy and estimated capital requirements that the current clinical trials by Dr. Jacobson both be fully funded by the existing NIH grants and achieve results that enable us to proceed further along the regulatory approval process and maintain PRO 140 s status as a candidate for fast track consideration by the FDA.", "type": 1, "words": ["<tag1>", "These", "uses", "are", "further", "limited", "by", "the", "requirements", "that", "any", "such", "use", "comply", "with", "applicable", "law", "(including", "the", "Health", "Insurance", "Portability", "and", "Accountability", "Act", "of", "1996", "(", "HIPAA", "and", "that", "the", "use", "is", "permitted", "by", "the", "informed", "consent", "form", "used", "with", "subjects", "in", "connection", "with", "the", "Study.", "<tag2>", "It", "is", "critical", "to", "our", "business", "strategy", "and", "estimated", "capital", "requirements", "that", "the", "current", "clinical", "trials", "by", "Dr.", "Jacobson", "both", "be", "fully", "funded", "by", "the", "existing", "NIH", "grants", "and", "achieve", "results", "that", "enable", "us", "to", "proceed", "further", "along", "the", "regulatory", "approval", "process", "and", "maintain", "PRO", "140", "s", "status", "as", "a", "candidate", "for", "fast", "track", "consideration", "by", "the", "FDA.", "<tag3>"], "wordsA": ["These", "uses", "are", "further", "limited", "by", "the", "requirements", "that", "any", "such", "use", "comply", "with", "applicable", "law", "(including", "the", "Health", "Insurance", "Portability", "and", "Accountability", "Act", "of", "1996", "(", "HIPAA", "and", "that", "the", "use", "is", "permitted", "by", "the", "informed", "consent", "form", "used", "with", "subjects", "in", "connection", "with", "the", "Study."], "wordsB": ["It", "is", "critical", "to", "our", "business", "strategy", "and", "estimated", "capital", "requirements", "that", "the", "current", "clinical", "trials", "by", "Dr.", "Jacobson", "both", "be", "fully", "funded", "by", "the", "existing", "NIH", "grants", "and", "achieve", "results", "that", "enable", "us", "to", "proceed", "further", "along", "the", "regulatory", "approval", "process", "and", "maintain", "PRO", "140", "s", "status", "as", "a", "candidate", "for", "fast", "track", "consideration", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p24_s1", "idA": "1175680_12_item1_p21_s1", "sentA": "However, subsequent studies and analysis of the activity of Cytolin has shown that while Cytolin is highly expressed on CTLs, this antibody does not block CTLs.", "sentB": "Sufficient research and analysis was conducted to enable us to reach the conclusion that PRO 140 likely does not infringe those patent rights.", "type": 1, "words": ["<tag1>", "However,", "subsequent", "studies", "and", "analysis", "of", "the", "activity", "of", "Cytolin", "has", "shown", "that", "while", "Cytolin", "is", "highly", "expressed", "on", "CTLs,", "this", "antibody", "does", "not", "block", "CTLs.", "<tag2>", "Sufficient", "research", "and", "analysis", "was", "conducted", "to", "enable", "us", "to", "reach", "the", "conclusion", "that", "PRO", "140", "likely", "does", "not", "infringe", "those", "patent", "rights.", "<tag3>"], "wordsA": ["However,", "subsequent", "studies", "and", "analysis", "of", "the", "activity", "of", "Cytolin", "has", "shown", "that", "while", "Cytolin", "is", "highly", "expressed", "on", "CTLs,", "this", "antibody", "does", "not", "block", "CTLs."], "wordsB": ["Sufficient", "research", "and", "analysis", "was", "conducted", "to", "enable", "us", "to", "reach", "the", "conclusion", "that", "PRO", "140", "likely", "does", "not", "infringe", "those", "patent", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p3_s2", "idA": "1175680_12_item1_p22_s0", "sentA": "In addition to CTLs, murine Cytolin also recognizes and binds to dendritic cells (DCs).", "sentB": "Instead, PRO 140 binds to a precise site on CCR5 that HIV uses to enter the cell and, in doing so, inhibits the ability of HIV to infect the cell without affecting the cell s normal function.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "CTLs,", "murine", "Cytolin", "also", "recognizes", "and", "binds", "to", "dendritic", "cells", "(DCs).", "<tag2>", "Instead,", "PRO", "140", "binds", "to", "a", "precise", "site", "on", "CCR5", "that", "HIV", "uses", "to", "enter", "the", "cell", "and,", "in", "doing", "so,", "inhibits", "the", "ability", "of", "HIV", "to", "infect", "the", "cell", "without", "affecting", "the", "cell", "s", "normal", "function.", "<tag3>"], "wordsA": ["In", "addition", "to", "CTLs,", "murine", "Cytolin", "also", "recognizes", "and", "binds", "to", "dendritic", "cells", "(DCs)."], "wordsB": ["Instead,", "PRO", "140", "binds", "to", "a", "precise", "site", "on", "CCR5", "that", "HIV", "uses", "to", "enter", "the", "cell", "and,", "in", "doing", "so,", "inhibits", "the", "ability", "of", "HIV", "to", "infect", "the", "cell", "without", "affecting", "the", "cell", "s", "normal", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p44_s2", "idA": "1175680_12_item1_p23_s0", "sentA": "Acquisition of Advanced Genetic Technologies, Inc.", "sentB": "Another recent entry into the HIV treatment space is Truvada, an HIV drug produced by Gilead Sciences, Inc.", "type": 1, "words": ["<tag1>", "Acquisition", "of", "Advanced", "Genetic", "Technologies,", "Inc.", "<tag2>", "Another", "recent", "entry", "into", "the", "HIV", "treatment", "space", "is", "Truvada,", "an", "HIV", "drug", "produced", "by", "Gilead", "Sciences,", "Inc.", "<tag3>"], "wordsA": ["Acquisition", "of", "Advanced", "Genetic", "Technologies,", "Inc."], "wordsB": ["Another", "recent", "entry", "into", "the", "HIV", "treatment", "space", "is", "Truvada,", "an", "HIV", "drug", "produced", "by", "Gilead", "Sciences,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p22_s1", "idA": "1175680_12_item1_p25_s1", "sentA": "We view the formation of CVM and the exploration of CD11a-specific monoclonal antibodies to treat FIV as an effort to strategically diversify the use of monoclonal antibody expertise.", "sentB": "We generally require our employees, consultants and partners who have access to our proprietary information to sign confidentiality agreements in an effort to protect our intellectual property.", "type": 1, "words": ["<tag1>", "We", "view", "the", "formation", "of", "CVM", "and", "the", "exploration", "of", "CD11a-specific", "monoclonal", "antibodies", "to", "treat", "FIV", "as", "an", "effort", "to", "strategically", "diversify", "the", "use", "of", "monoclonal", "antibody", "expertise.", "<tag2>", "We", "generally", "require", "our", "employees,", "consultants", "and", "partners", "who", "have", "access", "to", "our", "proprietary", "information", "to", "sign", "confidentiality", "agreements", "in", "an", "effort", "to", "protect", "our", "intellectual", "property.", "<tag3>"], "wordsA": ["We", "view", "the", "formation", "of", "CVM", "and", "the", "exploration", "of", "CD11a-specific", "monoclonal", "antibodies", "to", "treat", "FIV", "as", "an", "effort", "to", "strategically", "diversify", "the", "use", "of", "monoclonal", "antibody", "expertise."], "wordsB": ["We", "generally", "require", "our", "employees,", "consultants", "and", "partners", "who", "have", "access", "to", "our", "proprietary", "information", "to", "sign", "confidentiality", "agreements", "in", "an", "effort", "to", "protect", "our", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p0_s1", "idA": "1175680_12_item1_p29_s0", "sentA": "Additionally, the Company s Australian App.", "sentB": "Unless the context otherwise requires, references in this report to CytoDyn, our, we, us, or the Company are to CytoDyn Inc. and its subsidiaries.", "type": 1, "words": ["<tag1>", "Additionally,", "the", "Company", "s", "Australian", "App.", "<tag2>", "Unless", "the", "context", "otherwise", "requires,", "references", "in", "this", "report", "to", "CytoDyn,", "our,", "we,", "us,", "or", "the", "Company", "are", "to", "CytoDyn", "Inc.", "and", "its", "subsidiaries.", "<tag3>"], "wordsA": ["Additionally,", "the", "Company", "s", "Australian", "App."], "wordsB": ["Unless", "the", "context", "otherwise", "requires,", "references", "in", "this", "report", "to", "CytoDyn,", "our,", "we,", "us,", "or", "the", "Company", "are", "to", "CytoDyn", "Inc.", "and", "its", "subsidiaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p48_s2", "idA": "1175680_12_item1_p2_s2", "sentA": "This includes issued U.S. Patent Nos. 5,424,066; 5,651,970 and 6,534,057, as well as European Patent Nos. 0690725 and 1438970.", "sentB": "Employees and Consultants We have two full-time employees, our CEO and CFO, as well as several independent consultants assisting us with preparations for our Phase IIb clinical trials of PRO 140.", "type": 1, "words": ["<tag1>", "This", "includes", "issued", "U.S.", "Patent", "Nos.", "5,424,066;", "5,651,970", "and", "6,534,057,", "as", "well", "as", "European", "Patent", "Nos.", "0690725", "and", "1438970.", "<tag2>", "Employees", "and", "Consultants", "We", "have", "two", "full-time", "employees,", "our", "CEO", "and", "CFO,", "as", "well", "as", "several", "independent", "consultants", "assisting", "us", "with", "preparations", "for", "our", "Phase", "IIb", "clinical", "trials", "of", "PRO", "140.", "<tag3>"], "wordsA": ["This", "includes", "issued", "U.S.", "Patent", "Nos.", "5,424,066;", "5,651,970", "and", "6,534,057,", "as", "well", "as", "European", "Patent", "Nos.", "0690725", "and", "1438970."], "wordsB": ["Employees", "and", "Consultants", "We", "have", "two", "full-time", "employees,", "our", "CEO", "and", "CFO,", "as", "well", "as", "several", "independent", "consultants", "assisting", "us", "with", "preparations", "for", "our", "Phase", "IIb", "clinical", "trials", "of", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p9_s0", "idA": "1175680_12_item1_p2_s2", "sentA": "This includes issued U.S. Patent Nos. 5,424,066; 5,651,970 and 6,534,057, as well as European Patent Nos. 0690725 and 1438970.", "sentB": "The Company acquired PRO 140, as well as certain other related assets, including the existing inventory of PRO 140 bulk drug substance, intellectual property, and FDA regulatory filings, pursuant to an Asset Purchase Agreement, dated as of July 25, 2012, (the Progenics Agreement ) between CytoDyn and Progenics.", "type": 1, "words": ["<tag1>", "This", "includes", "issued", "U.S.", "Patent", "Nos.", "5,424,066;", "5,651,970", "and", "6,534,057,", "as", "well", "as", "European", "Patent", "Nos.", "0690725", "and", "1438970.", "<tag2>", "The", "Company", "acquired", "PRO", "140,", "as", "well", "as", "certain", "other", "related", "assets,", "including", "the", "existing", "inventory", "of", "PRO", "140", "bulk", "drug", "substance,", "intellectual", "property,", "and", "FDA", "regulatory", "filings,", "pursuant", "to", "an", "Asset", "Purchase", "Agreement,", "dated", "as", "of", "July", "25,", "2012,", "(the", "Progenics", "Agreement", ")", "between", "CytoDyn", "and", "Progenics.", "<tag3>"], "wordsA": ["This", "includes", "issued", "U.S.", "Patent", "Nos.", "5,424,066;", "5,651,970", "and", "6,534,057,", "as", "well", "as", "European", "Patent", "Nos.", "0690725", "and", "1438970."], "wordsB": ["The", "Company", "acquired", "PRO", "140,", "as", "well", "as", "certain", "other", "related", "assets,", "including", "the", "existing", "inventory", "of", "PRO", "140", "bulk", "drug", "substance,", "intellectual", "property,", "and", "FDA", "regulatory", "filings,", "pursuant", "to", "an", "Asset", "Purchase", "Agreement,", "dated", "as", "of", "July", "25,", "2012,", "(the", "Progenics", "Agreement", ")", "between", "CytoDyn", "and", "Progenics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p25_s0", "idA": "1175680_12_item1_p34_s1", "sentA": "In February 2010, we entered into a statement of work for the development of a humanized form of Cytolin at a cost of $229,500.", "sentB": "Research, development and commercialization of a biopharmaceutical product often require choosing between alternative development and optimization routes at various stages in the development process.", "type": 1, "words": ["<tag1>", "In", "February", "2010,", "we", "entered", "into", "a", "statement", "of", "work", "for", "the", "development", "of", "a", "humanized", "form", "of", "Cytolin", "at", "a", "cost", "of", "$229,500.", "<tag2>", "Research,", "development", "and", "commercialization", "of", "a", "biopharmaceutical", "product", "often", "require", "choosing", "between", "alternative", "development", "and", "optimization", "routes", "at", "various", "stages", "in", "the", "development", "process.", "<tag3>"], "wordsA": ["In", "February", "2010,", "we", "entered", "into", "a", "statement", "of", "work", "for", "the", "development", "of", "a", "humanized", "form", "of", "Cytolin", "at", "a", "cost", "of", "$229,500."], "wordsB": ["Research,", "development", "and", "commercialization", "of", "a", "biopharmaceutical", "product", "often", "require", "choosing", "between", "alternative", "development", "and", "optimization", "routes", "at", "various", "stages", "in", "the", "development", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p10_s0", "idA": "1175680_12_item1_p36_s0", "sentA": "On September 23, 2011, the Company filed a provisional patent application (Serial No. 61/534,942) in the United States for its humanized version of Cytolin , a monoclonal antibody for the treatment of HIV infection.", "sentB": "Other Product Candidates A second product candidate, Cytolin, is also a monoclonal antibody.", "type": 1, "words": ["<tag1>", "On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin", ",", "a", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection.", "<tag2>", "Other", "Product", "Candidates", "A", "second", "product", "candidate,", "Cytolin,", "is", "also", "a", "monoclonal", "antibody.", "<tag3>"], "wordsA": ["On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin", ",", "a", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection."], "wordsB": ["Other", "Product", "Candidates", "A", "second", "product", "candidate,", "Cytolin,", "is", "also", "a", "monoclonal", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p8_s2", "idA": "1175680_12_item1_p36_s0", "sentA": "On September 23, 2011, the Company filed a provisional patent application (Serial No. 61/534,942) in the United States for its humanized version of Cytolin , a monoclonal antibody for the treatment of HIV infection.", "sentB": "It has no effect on strains of HIV that enter through the CXCR4 cell portal.", "type": 1, "words": ["<tag1>", "On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin", ",", "a", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection.", "<tag2>", "It", "has", "no", "effect", "on", "strains", "of", "HIV", "that", "enter", "through", "the", "CXCR4", "cell", "portal.", "<tag3>"], "wordsA": ["On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin", ",", "a", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection."], "wordsB": ["It", "has", "no", "effect", "on", "strains", "of", "HIV", "that", "enter", "through", "the", "CXCR4", "cell", "portal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p8_s0", "idA": "1175680_12_item1_p46_s2", "sentA": "The FDA also has the authority to revoke previously granted product approvals.", "sentB": "We believe PRO 140 has demonstrated potent, long-lived (as compared to existing treatments) antiretroviral activity and an encouraging safety profile in initial clinical testing, that PRO 140 has the potential to be the first long-acting (weekly or every other week), self-administered HIV therapy, and that PRO 140 may inhibit CCR5-tropic HIV while preserving CCR5 s natural activity.", "type": 1, "words": ["<tag1>", "The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals.", "<tag2>", "We", "believe", "PRO", "140", "has", "demonstrated", "potent,", "long-lived", "(as", "compared", "to", "existing", "treatments)", "antiretroviral", "activity", "and", "an", "encouraging", "safety", "profile", "in", "initial", "clinical", "testing,", "that", "PRO", "140", "has", "the", "potential", "to", "be", "the", "first", "long-acting", "(weekly", "or", "every", "other", "week),", "self-administered", "HIV", "therapy,", "and", "that", "PRO", "140", "may", "inhibit", "CCR5-tropic", "HIV", "while", "preserving", "CCR5", "s", "natural", "activity.", "<tag3>"], "wordsA": ["The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals."], "wordsB": ["We", "believe", "PRO", "140", "has", "demonstrated", "potent,", "long-lived", "(as", "compared", "to", "existing", "treatments)", "antiretroviral", "activity", "and", "an", "encouraging", "safety", "profile", "in", "initial", "clinical", "testing,", "that", "PRO", "140", "has", "the", "potential", "to", "be", "the", "first", "long-acting", "(weekly", "or", "every", "other", "week),", "self-administered", "HIV", "therapy,", "and", "that", "PRO", "140", "may", "inhibit", "CCR5-tropic", "HIV", "while", "preserving", "CCR5", "s", "natural", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p14_s8", "idA": "1175680_12_item1_p47_s1", "sentA": "CLIA regulates clinical laboratories by requiring that the laboratory be certified by the federal government, licensed by the state and comply with various operational, personnel and quality requirements intended to ensure that clinical laboratory test results are accurate, reliable and timely.", "sentB": "As clinical protocols are finalized for planned clinical trials expected to commence in late 2013, management, its clinical advisors, and Dr. Jacobson intend to meet with the FDA to ensure that the final clinical protocols are fully aligned with the FDA s prior guidance to Progenics, wherein the FDA designated PRO 140 as a candidate for fast track approval, and to independently confirm that such protocols are fully aligned with what is believed to be the most important clinical evaluation criteria supporting the highest commercial opportunities for PRO 140.", "type": 1, "words": ["<tag1>", "CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely.", "<tag2>", "As", "clinical", "protocols", "are", "finalized", "for", "planned", "clinical", "trials", "expected", "to", "commence", "in", "late", "2013,", "management,", "its", "clinical", "advisors,", "and", "Dr.", "Jacobson", "intend", "to", "meet", "with", "the", "FDA", "to", "ensure", "that", "the", "final", "clinical", "protocols", "are", "fully", "aligned", "with", "the", "FDA", "s", "prior", "guidance", "to", "Progenics,", "wherein", "the", "FDA", "designated", "PRO", "140", "as", "a", "candidate", "for", "fast", "track", "approval,", "and", "to", "independently", "confirm", "that", "such", "protocols", "are", "fully", "aligned", "with", "what", "is", "believed", "to", "be", "the", "most", "important", "clinical", "evaluation", "criteria", "supporting", "the", "highest", "commercial", "opportunities", "for", "PRO", "140.", "<tag3>"], "wordsA": ["CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely."], "wordsB": ["As", "clinical", "protocols", "are", "finalized", "for", "planned", "clinical", "trials", "expected", "to", "commence", "in", "late", "2013,", "management,", "its", "clinical", "advisors,", "and", "Dr.", "Jacobson", "intend", "to", "meet", "with", "the", "FDA", "to", "ensure", "that", "the", "final", "clinical", "protocols", "are", "fully", "aligned", "with", "the", "FDA", "s", "prior", "guidance", "to", "Progenics,", "wherein", "the", "FDA", "designated", "PRO", "140", "as", "a", "candidate", "for", "fast", "track", "approval,", "and", "to", "independently", "confirm", "that", "such", "protocols", "are", "fully", "aligned", "with", "what", "is", "believed", "to", "be", "the", "most", "important", "clinical", "evaluation", "criteria", "supporting", "the", "highest", "commercial", "opportunities", "for", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p25_s2", "idA": "1175680_12_item1_p48_s0", "sentA": "State Governments Most states in which we operate have regulations that parallel federal regulations.", "sentB": "There are numerous third-party patents in fields in which we work, and we may need to obtain licenses under patents of others in order to pursue a preferred development route of one or more of our product candidates.", "type": 1, "words": ["<tag1>", "State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations.", "<tag2>", "There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates.", "<tag3>"], "wordsA": ["State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations."], "wordsB": ["There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p42_s0", "idA": "1175680_12_item1_p48_s0", "sentA": "State Governments Most states in which we operate have regulations that parallel federal regulations.", "sentB": "As described above, we are currently working with Dr. Jacobson to begin two additional clinical trials of PRO 140, which we believe will satisfy requirements for Phase IIb study of the product candidate.", "type": 1, "words": ["<tag1>", "State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations.", "<tag2>", "As", "described", "above,", "we", "are", "currently", "working", "with", "Dr.", "Jacobson", "to", "begin", "two", "additional", "clinical", "trials", "of", "PRO", "140,", "which", "we", "believe", "will", "satisfy", "requirements", "for", "Phase", "IIb", "study", "of", "the", "product", "candidate.", "<tag3>"], "wordsA": ["State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations."], "wordsB": ["As", "described", "above,", "we", "are", "currently", "working", "with", "Dr.", "Jacobson", "to", "begin", "two", "additional", "clinical", "trials", "of", "PRO", "140,", "which", "we", "believe", "will", "satisfy", "requirements", "for", "Phase", "IIb", "study", "of", "the", "product", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p3_s0", "idA": "1175680_12_item1_p49_s0", "sentA": "Our research and development activities and the manufacture and marketing of our products are and will be subject to rigorous regulations relating to product safety and efficacy by numerous governmental authorities in the United States and other countries.", "sentB": "PRO 140 is an antibody and not a drug, and through preliminary, short-term trials it has demonstrated efficacy without issues relating to toxicity and autoimmune resistance.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "and", "the", "manufacture", "and", "marketing", "of", "our", "products", "are", "and", "will", "be", "subject", "to", "rigorous", "regulations", "relating", "to", "product", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries.", "<tag2>", "PRO", "140", "is", "an", "antibody", "and", "not", "a", "drug,", "and", "through", "preliminary,", "short-term", "trials", "it", "has", "demonstrated", "efficacy", "without", "issues", "relating", "to", "toxicity", "and", "autoimmune", "resistance.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "and", "the", "manufacture", "and", "marketing", "of", "our", "products", "are", "and", "will", "be", "subject", "to", "rigorous", "regulations", "relating", "to", "product", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries."], "wordsB": ["PRO", "140", "is", "an", "antibody", "and", "not", "a", "drug,", "and", "through", "preliminary,", "short-term", "trials", "it", "has", "demonstrated", "efficacy", "without", "issues", "relating", "to", "toxicity", "and", "autoimmune", "resistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p24_s0", "idA": "1175680_12_item1_p49_s1", "sentA": "Other Laws and Regulations We are subject to various laws and regulations relating to safe working conditions, clinical, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research.", "sentB": "In connection with our acquisition of rights to PRO 140, our patent counsel conducted a freedom-to-operate search that identified other patents that could relate to our proposed PRO 140 drug candidate.", "type": 1, "words": ["<tag1>", "Other", "Laws", "and", "Regulations", "We", "are", "subject", "to", "various", "laws", "and", "regulations", "relating", "to", "safe", "working", "conditions,", "clinical,", "laboratory", "and", "manufacturing", "practices,", "the", "experimental", "use", "of", "animals", "and", "the", "use", "and", "disposal", "of", "hazardous", "or", "potentially", "hazardous", "substances,", "including", "radioactive", "compounds", "and", "infectious", "disease", "agents,", "used", "in", "connection", "with", "our", "research.", "<tag2>", "In", "connection", "with", "our", "acquisition", "of", "rights", "to", "PRO", "140,", "our", "patent", "counsel", "conducted", "a", "freedom-to-operate", "search", "that", "identified", "other", "patents", "that", "could", "relate", "to", "our", "proposed", "PRO", "140", "drug", "candidate.", "<tag3>"], "wordsA": ["Other", "Laws", "and", "Regulations", "We", "are", "subject", "to", "various", "laws", "and", "regulations", "relating", "to", "safe", "working", "conditions,", "clinical,", "laboratory", "and", "manufacturing", "practices,", "the", "experimental", "use", "of", "animals", "and", "the", "use", "and", "disposal", "of", "hazardous", "or", "potentially", "hazardous", "substances,", "including", "radioactive", "compounds", "and", "infectious", "disease", "agents,", "used", "in", "connection", "with", "our", "research."], "wordsB": ["In", "connection", "with", "our", "acquisition", "of", "rights", "to", "PRO", "140,", "our", "patent", "counsel", "conducted", "a", "freedom-to-operate", "search", "that", "identified", "other", "patents", "that", "could", "relate", "to", "our", "proposed", "PRO", "140", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p21_s0", "idA": "1175680_12_item1_p50_s0", "sentA": "We are subject to a variety of federal, state and local environmental protection measures.", "sentB": "Generally, patents issued in the U.S. are effective for either (i) 20 years from the earliest asserted filing date, if the application was filed on or after June 8, 1995, or (ii) the longer of 17 years from the date of issue or 20 years from the earliest asserted filing date, if the application was filed prior to that date, subject to a five-year extension in certain instances.", "type": 1, "words": ["<tag1>", "We", "are", "subject", "to", "a", "variety", "of", "federal,", "state", "and", "local", "environmental", "protection", "measures.", "<tag2>", "Generally,", "patents", "issued", "in", "the", "U.S.", "are", "effective", "for", "either", "(i)", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "on", "or", "after", "June", "8,", "1995,", "or", "(ii)", "the", "longer", "of", "17", "years", "from", "the", "date", "of", "issue", "or", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "prior", "to", "that", "date,", "subject", "to", "a", "five-year", "extension", "in", "certain", "instances.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "a", "variety", "of", "federal,", "state", "and", "local", "environmental", "protection", "measures."], "wordsB": ["Generally,", "patents", "issued", "in", "the", "U.S.", "are", "effective", "for", "either", "(i)", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "on", "or", "after", "June", "8,", "1995,", "or", "(ii)", "the", "longer", "of", "17", "years", "from", "the", "date", "of", "issue", "or", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "prior", "to", "that", "date,", "subject", "to", "a", "five-year", "extension", "in", "certain", "instances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p40_s1", "idA": "1175680_12_item1_p50_s1", "sentA": "We believe that our operations comply in all material respects with applicable environmental laws and regulations.", "sentB": "We believe trials to be commenced in late 2013 under the direction of Dr. Jacobson at Drexel will collectively constitute a Phase IIb trial.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations.", "<tag2>", "We", "believe", "trials", "to", "be", "commenced", "in", "late", "2013", "under", "the", "direction", "of", "Dr.", "Jacobson", "at", "Drexel", "will", "collectively", "constitute", "a", "Phase", "IIb", "trial.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations."], "wordsB": ["We", "believe", "trials", "to", "be", "commenced", "in", "late", "2013", "under", "the", "direction", "of", "Dr.", "Jacobson", "at", "Drexel", "will", "collectively", "constitute", "a", "Phase", "IIb", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p24_s2", "idA": "1175680_12_item1_p50_s2", "sentA": "Our compliance with these regulations did not have during the past year and is not expected to have a material effect upon our capital expenditures, cash flows, earnings or competitive position.", "sentB": "However, we did not have an exhaustive analysis conducted as to the identified patent rights because doing so would have been more costly than appeared to be justified.", "type": 1, "words": ["<tag1>", "Our", "compliance", "with", "these", "regulations", "did", "not", "have", "during", "the", "past", "year", "and", "is", "not", "expected", "to", "have", "a", "material", "effect", "upon", "our", "capital", "expenditures,", "cash", "flows,", "earnings", "or", "competitive", "position.", "<tag2>", "However,", "we", "did", "not", "have", "an", "exhaustive", "analysis", "conducted", "as", "to", "the", "identified", "patent", "rights", "because", "doing", "so", "would", "have", "been", "more", "costly", "than", "appeared", "to", "be", "justified.", "<tag3>"], "wordsA": ["Our", "compliance", "with", "these", "regulations", "did", "not", "have", "during", "the", "past", "year", "and", "is", "not", "expected", "to", "have", "a", "material", "effect", "upon", "our", "capital", "expenditures,", "cash", "flows,", "earnings", "or", "competitive", "position."], "wordsB": ["However,", "we", "did", "not", "have", "an", "exhaustive", "analysis", "conducted", "as", "to", "the", "identified", "patent", "rights", "because", "doing", "so", "would", "have", "been", "more", "costly", "than", "appeared", "to", "be", "justified."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p44_s0", "idA": "1175680_12_item1_p51_s0", "sentA": "Registrational Clinical Trials Process Described below is the traditional registrational drug development track.", "sentB": "PRO 140 blocks a cell receptor called CCR5, which is the entry point for most strains of HIV virus.", "type": 1, "words": ["<tag1>", "Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track.", "<tag2>", "PRO", "140", "blocks", "a", "cell", "receptor", "called", "CCR5,", "which", "is", "the", "entry", "point", "for", "most", "strains", "of", "HIV", "virus.", "<tag3>"], "wordsA": ["Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track."], "wordsB": ["PRO", "140", "blocks", "a", "cell", "receptor", "called", "CCR5,", "which", "is", "the", "entry", "point", "for", "most", "strains", "of", "HIV", "virus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p44_s1", "idA": "1175680_12_item1_p51_s0", "sentA": "Registrational Clinical Trials Process Described below is the traditional registrational drug development track.", "sentB": "Pfizer s maraviroc (Selzentry ) is the only currently approved CCR5 blocking agent.", "type": 1, "words": ["<tag1>", "Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track.", "<tag2>", "Pfizer", "s", "maraviroc", "(Selzentry", ")", "is", "the", "only", "currently", "approved", "CCR5", "blocking", "agent.", "<tag3>"], "wordsA": ["Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track."], "wordsB": ["Pfizer", "s", "maraviroc", "(Selzentry", ")", "is", "the", "only", "currently", "approved", "CCR5", "blocking", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p43_s2", "idA": "1175680_12_item1_p51_s2", "sentA": "After these trials have been initiated, the Company could enter into a strategic alliance with a larger pharmaceutical company after development has progressed to a certain point.", "sentB": "Our current focus is on developing PRO 140 and, to a lesser extent, Cytolin, which are both monoclonal antibodies that have been shown to act as HIV entry inhibitors in preliminary testing.", "type": 1, "words": ["<tag1>", "After", "these", "trials", "have", "been", "initiated,", "the", "Company", "could", "enter", "into", "a", "strategic", "alliance", "with", "a", "larger", "pharmaceutical", "company", "after", "development", "has", "progressed", "to", "a", "certain", "point.", "<tag2>", "Our", "current", "focus", "is", "on", "developing", "PRO", "140", "and,", "to", "a", "lesser", "extent,", "Cytolin,", "which", "are", "both", "monoclonal", "antibodies", "that", "have", "been", "shown", "to", "act", "as", "HIV", "entry", "inhibitors", "in", "preliminary", "testing.", "<tag3>"], "wordsA": ["After", "these", "trials", "have", "been", "initiated,", "the", "Company", "could", "enter", "into", "a", "strategic", "alliance", "with", "a", "larger", "pharmaceutical", "company", "after", "development", "has", "progressed", "to", "a", "certain", "point."], "wordsB": ["Our", "current", "focus", "is", "on", "developing", "PRO", "140", "and,", "to", "a", "lesser", "extent,", "Cytolin,", "which", "are", "both", "monoclonal", "antibodies", "that", "have", "been", "shown", "to", "act", "as", "HIV", "entry", "inhibitors", "in", "preliminary", "testing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p19_s1", "idA": "1175680_12_item1_p51_s3", "sentA": "The Company is exploring all options available to determine the most cost effective implementation of the clinical trial process.", "sentB": "A clinical trial would be necessary to continue to explore Cytolin and none is currently planned.", "type": 1, "words": ["<tag1>", "The", "Company", "is", "exploring", "all", "options", "available", "to", "determine", "the", "most", "cost", "effective", "implementation", "of", "the", "clinical", "trial", "process.", "<tag2>", "A", "clinical", "trial", "would", "be", "necessary", "to", "continue", "to", "explore", "Cytolin", "and", "none", "is", "currently", "planned.", "<tag3>"], "wordsA": ["The", "Company", "is", "exploring", "all", "options", "available", "to", "determine", "the", "most", "cost", "effective", "implementation", "of", "the", "clinical", "trial", "process."], "wordsB": ["A", "clinical", "trial", "would", "be", "necessary", "to", "continue", "to", "explore", "Cytolin", "and", "none", "is", "currently", "planned."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p18_s0", "idA": "1175680_12_item1_p52_s0", "sentA": "Phase I Phase I includes the initial introduction of an investigational new drug or biologic into humans.", "sentB": "A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor.", "type": 1, "words": ["<tag1>", "Phase", "I", "Phase", "I", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans.", "<tag2>", "A", "monoclonal", "antibody", "against", "lymphocyte", "function-associated", "antigen-1", "decreases", "HIV-1", "replication", "by", "inducing", "the", "secretion", "of", "an", "antiviral", "soluble", "factor.", "<tag3>"], "wordsA": ["Phase", "I", "Phase", "I", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans."], "wordsB": ["A", "monoclonal", "antibody", "against", "lymphocyte", "function-associated", "antigen-1", "decreases", "HIV-1", "replication", "by", "inducing", "the", "secretion", "of", "an", "antiviral", "soluble", "factor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p25_s3", "idA": "1175680_12_item1_p52_s0", "sentA": "Phase I Phase I includes the initial introduction of an investigational new drug or biologic into humans.", "sentB": "The need to obtain a license would decrease the ultimate value and profitability of an affected product.", "type": 1, "words": ["<tag1>", "Phase", "I", "Phase", "I", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans.", "<tag2>", "The", "need", "to", "obtain", "a", "license", "would", "decrease", "the", "ultimate", "value", "and", "profitability", "of", "an", "affected", "product.", "<tag3>"], "wordsA": ["Phase", "I", "Phase", "I", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans."], "wordsB": ["The", "need", "to", "obtain", "a", "license", "would", "decrease", "the", "ultimate", "value", "and", "profitability", "of", "an", "affected", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p25_s1", "idA": "1175680_12_item1_p52_s1", "sentA": "These studies are closely monitored and may be conducted in patients, but are usually conducted in a small number of healthy volunteer subjects.", "sentB": "Preferred routes depend upon current and may be affected by subsequent discoveries and test results, availability of financial resources, and other factors, and cannot be identified with certainty.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "closely", "monitored", "and", "may", "be", "conducted", "in", "patients,", "but", "are", "usually", "conducted", "in", "a", "small", "number", "of", "healthy", "volunteer", "subjects.", "<tag2>", "Preferred", "routes", "depend", "upon", "current", "and", "may", "be", "affected", "by", "subsequent", "discoveries", "and", "test", "results,", "availability", "of", "financial", "resources,", "and", "other", "factors,", "and", "cannot", "be", "identified", "with", "certainty.", "<tag3>"], "wordsA": ["These", "studies", "are", "closely", "monitored", "and", "may", "be", "conducted", "in", "patients,", "but", "are", "usually", "conducted", "in", "a", "small", "number", "of", "healthy", "volunteer", "subjects."], "wordsB": ["Preferred", "routes", "depend", "upon", "current", "and", "may", "be", "affected", "by", "subsequent", "discoveries", "and", "test", "results,", "availability", "of", "financial", "resources,", "and", "other", "factors,", "and", "cannot", "be", "identified", "with", "certainty."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p40_s0", "idA": "1175680_12_item1_p52_s2", "sentA": "These studies are designed to determine the metabolic and pharmacologic actions of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.", "sentB": "Phase II is often broken into Phase IIa, which can be used to refer to pilot trials, or more limited trials evaluating exposure response in patients, and Phase IIb trials that are designed to evaluate dosing efficacy and ranges.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "designed", "to", "determine", "the", "metabolic", "and", "pharmacologic", "actions", "of", "the", "investigational", "product", "in", "humans,", "the", "side", "effects", "associated", "with", "increasing", "doses,", "and,", "if", "possible,", "to", "gain", "early", "evidence", "on", "effectiveness.", "<tag2>", "Phase", "II", "is", "often", "broken", "into", "Phase", "IIa,", "which", "can", "be", "used", "to", "refer", "to", "pilot", "trials,", "or", "more", "limited", "trials", "evaluating", "exposure", "response", "in", "patients,", "and", "Phase", "IIb", "trials", "that", "are", "designed", "to", "evaluate", "dosing", "efficacy", "and", "ranges.", "<tag3>"], "wordsA": ["These", "studies", "are", "designed", "to", "determine", "the", "metabolic", "and", "pharmacologic", "actions", "of", "the", "investigational", "product", "in", "humans,", "the", "side", "effects", "associated", "with", "increasing", "doses,", "and,", "if", "possible,", "to", "gain", "early", "evidence", "on", "effectiveness."], "wordsB": ["Phase", "II", "is", "often", "broken", "into", "Phase", "IIa,", "which", "can", "be", "used", "to", "refer", "to", "pilot", "trials,", "or", "more", "limited", "trials", "evaluating", "exposure", "response", "in", "patients,", "and", "Phase", "IIb", "trials", "that", "are", "designed", "to", "evaluate", "dosing", "efficacy", "and", "ranges."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p1_s4", "idA": "1175680_12_item1_p53_s1", "sentA": "This phase of testing also helps determine the common short-term side effects and risks associated with the drug.", "sentB": "PRO 140 We believe the PRO 140 antibody shows promise as a powerful anti-viral agent while not being a drug, which means fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.", "type": 1, "words": ["<tag1>", "This", "phase", "of", "testing", "also", "helps", "determine", "the", "common", "short-term", "side", "effects", "and", "risks", "associated", "with", "the", "drug.", "<tag2>", "PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use.", "<tag3>"], "wordsA": ["This", "phase", "of", "testing", "also", "helps", "determine", "the", "common", "short-term", "side", "effects", "and", "risks", "associated", "with", "the", "drug."], "wordsB": ["PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p24_s3", "idA": "1175680_12_item1_p56_s3", "sentA": "We cannot estimate the cost of any potential follow up study or whether any of the planned private placement offerings will be successful.", "sentB": "The validity of issued patents, patentability of claimed inventions in pending applications and applicability of any of our development programs are uncertain and subject to change, and patent rights asserted against us could adversely affect our ability to commercialize or collaborate with others on specific products.", "type": 1, "words": ["<tag1>", "We", "cannot", "estimate", "the", "cost", "of", "any", "potential", "follow", "up", "study", "or", "whether", "any", "of", "the", "planned", "private", "placement", "offerings", "will", "be", "successful.", "<tag2>", "The", "validity", "of", "issued", "patents,", "patentability", "of", "claimed", "inventions", "in", "pending", "applications", "and", "applicability", "of", "any", "of", "our", "development", "programs", "are", "uncertain", "and", "subject", "to", "change,", "and", "patent", "rights", "asserted", "against", "us", "could", "adversely", "affect", "our", "ability", "to", "commercialize", "or", "collaborate", "with", "others", "on", "specific", "products.", "<tag3>"], "wordsA": ["We", "cannot", "estimate", "the", "cost", "of", "any", "potential", "follow", "up", "study", "or", "whether", "any", "of", "the", "planned", "private", "placement", "offerings", "will", "be", "successful."], "wordsB": ["The", "validity", "of", "issued", "patents,", "patentability", "of", "claimed", "inventions", "in", "pending", "applications", "and", "applicability", "of", "any", "of", "our", "development", "programs", "are", "uncertain", "and", "subject", "to", "change,", "and", "patent", "rights", "asserted", "against", "us", "could", "adversely", "affect", "our", "ability", "to", "commercialize", "or", "collaborate", "with", "others", "on", "specific", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p44_s5", "idA": "1175680_12_item1_p57_s0", "sentA": "+ There are other factors, known and unknown, such as unexpected financial hardships, that can cause delays.", "sentB": "Nonetheless, manufacturers of current therapies, such as Pfizer and Gilead Sciences, are very large, multi-national corporations with significant resources.", "type": 1, "words": ["<tag1>", "+", "There", "are", "other", "factors,", "known", "and", "unknown,", "such", "as", "unexpected", "financial", "hardships,", "that", "can", "cause", "delays.", "<tag2>", "Nonetheless,", "manufacturers", "of", "current", "therapies,", "such", "as", "Pfizer", "and", "Gilead", "Sciences,", "are", "very", "large,", "multi-national", "corporations", "with", "significant", "resources.", "<tag3>"], "wordsA": ["+", "There", "are", "other", "factors,", "known", "and", "unknown,", "such", "as", "unexpected", "financial", "hardships,", "that", "can", "cause", "delays."], "wordsB": ["Nonetheless,", "manufacturers", "of", "current", "therapies,", "such", "as", "Pfizer", "and", "Gilead", "Sciences,", "are", "very", "large,", "multi-national", "corporations", "with", "significant", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p22_s0", "idA": "1175680_12_item1_p58_s2", "sentA": "Our potential competitors include entities that develop and produce therapeutic agents for treatment of human and animal disease.", "sentB": "may also rely on trade secrets and proprietary know-how to develop and attempt to achieve a competitive position in our product areas.", "type": 1, "words": ["<tag1>", "Our", "potential", "competitors", "include", "entities", "that", "develop", "and", "produce", "therapeutic", "agents", "for", "treatment", "of", "human", "and", "animal", "disease.", "<tag2>", "may", "also", "rely", "on", "trade", "secrets", "and", "proprietary", "know-how", "to", "develop", "and", "attempt", "to", "achieve", "a", "competitive", "position", "in", "our", "product", "areas.", "<tag3>"], "wordsA": ["Our", "potential", "competitors", "include", "entities", "that", "develop", "and", "produce", "therapeutic", "agents", "for", "treatment", "of", "human", "and", "animal", "disease."], "wordsB": ["may", "also", "rely", "on", "trade", "secrets", "and", "proprietary", "know-how", "to", "develop", "and", "attempt", "to", "achieve", "a", "competitive", "position", "in", "our", "product", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p13_s4", "idA": "1175680_12_item1_p58_s5", "sentA": "Our competitors may succeed in developing potential drugs or processes that are more effective or less costly than any that may be developed by us, or that gain regulatory approval prior to our potential drugs.", "sentB": "Product Development and Research Status of PRO 140 Phase I and IIa clinical trials of PRO 140 were completed by Dr. Jacobson of Drexel prior to our acquisition of PRO 140.", "type": 1, "words": ["<tag1>", "Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us,", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drugs.", "<tag2>", "Product", "Development", "and", "Research", "Status", "of", "PRO", "140", "Phase", "I", "and", "IIa", "clinical", "trials", "of", "PRO", "140", "were", "completed", "by", "Dr.", "Jacobson", "of", "Drexel", "prior", "to", "our", "acquisition", "of", "PRO", "140.", "<tag3>"], "wordsA": ["Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us,", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drugs."], "wordsB": ["Product", "Development", "and", "Research", "Status", "of", "PRO", "140", "Phase", "I", "and", "IIa", "clinical", "trials", "of", "PRO", "140", "were", "completed", "by", "Dr.", "Jacobson", "of", "Drexel", "prior", "to", "our", "acquisition", "of", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p44_s3", "idA": "1175680_12_item1_p60_s3", "sentA": "Any of these competitors may be more successful than us in manufacturing, marketing and distributing our potential drugs.", "sentB": "Both of these drugs must be taken daily and have significant side effects.", "type": 1, "words": ["<tag1>", "Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "our", "potential", "drugs.", "<tag2>", "Both", "of", "these", "drugs", "must", "be", "taken", "daily", "and", "have", "significant", "side", "effects.", "<tag3>"], "wordsA": ["Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "our", "potential", "drugs."], "wordsB": ["Both", "of", "these", "drugs", "must", "be", "taken", "daily", "and", "have", "significant", "side", "effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p22_s2", "idA": "1175680_12_item1_p61_s1", "sentA": "We expect that research and development expenses will increase as we seek to expand development of our current and future product pipeline.", "sentB": "Information with respect to our current patent portfolio is set forth below.", "type": 1, "words": ["<tag1>", "We", "expect", "that", "research", "and", "development", "expenses", "will", "increase", "as", "we", "seek", "to", "expand", "development", "of", "our", "current", "and", "future", "product", "pipeline.", "<tag2>", "Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below.", "<tag3>"], "wordsA": ["We", "expect", "that", "research", "and", "development", "expenses", "will", "increase", "as", "we", "seek", "to", "expand", "development", "of", "our", "current", "and", "future", "product", "pipeline."], "wordsB": ["Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_13_item1_p14_s1", "idA": "1175680_12_item1_p7_s0", "sentA": "Research History of Cytolin Compound Cytolin is part of a class of drugs called monoclonal antibodies.", "sentB": "Clinical results indicated a reduction of circulating HIV RNA an index of circulating virus of up to 2.17 logs intravenously and 1.77 logs subcutaneously (nearly a factor of a hundred) that persists for at least two weeks between injections at the 324 mg dose level.", "type": 1, "words": ["<tag1>", "Research", "History", "of", "Cytolin", "Compound", "Cytolin", "is", "part", "of", "a", "class", "of", "drugs", "called", "monoclonal", "antibodies.", "<tag2>", "Clinical", "results", "indicated", "a", "reduction", "of", "circulating", "HIV", "RNA", "an", "index", "of", "circulating", "virus", "of", "up", "to", "2.17", "logs", "intravenously", "and", "1.77", "logs", "subcutaneously", "(nearly", "a", "factor", "of", "a", "hundred)", "that", "persists", "for", "at", "least", "two", "weeks", "between", "injections", "at", "the", "324", "mg", "dose", "level.", "<tag3>"], "wordsA": ["Research", "History", "of", "Cytolin", "Compound", "Cytolin", "is", "part", "of", "a", "class", "of", "drugs", "called", "monoclonal", "antibodies."], "wordsB": ["Clinical", "results", "indicated", "a", "reduction", "of", "circulating", "HIV", "RNA", "an", "index", "of", "circulating", "virus", "of", "up", "to", "2.17", "logs", "intravenously", "and", "1.77", "logs", "subcutaneously", "(nearly", "a", "factor", "of", "a", "hundred)", "that", "persists", "for", "at", "least", "two", "weeks", "between", "injections", "at", "the", "324", "mg", "dose", "level."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p10_s4", "idA": "1175680_13_item1_p13_s3", "sentA": "Until the clinical trials for PRO 140 commence, we plan to devote only a modest amount of resources towards the approval or commercialization of Cytolin or CytoFeline.", "sentB": "Our ongoing treatment substitution study has two objectives: (1) to assess the efficacy of PRO 140 monotherapy for the maintenance of viral suppression after being used in substitution of a patient s antiretroviral therapy regimen and (2) to assess the clinical safety and tolerability parameters for PRO 140 following use in substitution of antiretroviral therapy.", "type": 1, "words": ["<tag1>", "Until", "the", "clinical", "trials", "for", "PRO", "140", "commence,", "we", "plan", "to", "devote", "only", "a", "modest", "amount", "of", "resources", "towards", "the", "approval", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline.", "<tag2>", "Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy.", "<tag3>"], "wordsA": ["Until", "the", "clinical", "trials", "for", "PRO", "140", "commence,", "we", "plan", "to", "devote", "only", "a", "modest", "amount", "of", "resources", "towards", "the", "approval", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline."], "wordsB": ["Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p10_s7", "idA": "1175680_13_item1_p14_s0", "sentA": "A total of 113 subjects were treated for a period of up to three weeks with as much as a 324 mg dose of PRO 140 administered weekly subcutaneously and 10mg/kg intravenously.", "sentB": "Total treatment duration with PRO 140 will be up to 14 weeks with one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study period and also one week of overlap at the end in subjects who did not experience virologic failure.", "type": 1, "words": ["<tag1>", "A", "total", "of", "113", "subjects", "were", "treated", "for", "a", "period", "of", "up", "to", "three", "weeks", "with", "as", "much", "as", "a", "324", "mg", "dose", "of", "PRO", "140", "administered", "weekly", "subcutaneously", "and", "10mg/kg", "intravenously.", "<tag2>", "Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure.", "<tag3>"], "wordsA": ["A", "total", "of", "113", "subjects", "were", "treated", "for", "a", "period", "of", "up", "to", "three", "weeks", "with", "as", "much", "as", "a", "324", "mg", "dose", "of", "PRO", "140", "administered", "weekly", "subcutaneously", "and", "10mg/kg", "intravenously."], "wordsB": ["Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p5_s1", "idA": "1175680_13_item1_p14_s7", "sentA": "To review these records, enter PRO 140 as the search term.", "sentB": "We have also initiated steps to explore additional therapeutic indications for PRO 140 under our own auspices, primary among which is our current clinical trial exploring PRO 140 as a short-term treatment substitution for existing drug regimens.", "type": 1, "words": ["<tag1>", "To", "review", "these", "records,", "enter", "PRO", "140", "as", "the", "search", "term.", "<tag2>", "We", "have", "also", "initiated", "steps", "to", "explore", "additional", "therapeutic", "indications", "for", "PRO", "140", "under", "our", "own", "auspices,", "primary", "among", "which", "is", "our", "current", "clinical", "trial", "exploring", "PRO", "140", "as", "a", "short-term", "treatment", "substitution", "for", "existing", "drug", "regimens.", "<tag3>"], "wordsA": ["To", "review", "these", "records,", "enter", "PRO", "140", "as", "the", "search", "term."], "wordsB": ["We", "have", "also", "initiated", "steps", "to", "explore", "additional", "therapeutic", "indications", "for", "PRO", "140", "under", "our", "own", "auspices,", "primary", "among", "which", "is", "our", "current", "clinical", "trial", "exploring", "PRO", "140", "as", "a", "short-term", "treatment", "substitution", "for", "existing", "drug", "regimens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p5_s3", "idA": "1175680_13_item1_p16_s1", "sentA": "In this study a relatively small number of physicians in the United States administered Cytolin to their HIV-infected patients over two years.", "sentB": "The estimated cost for this study is approximately $3.7 million, of which $1.0 million represents estimated direct service fees payable to Amarex.", "type": 1, "words": ["<tag1>", "In", "this", "study", "a", "relatively", "small", "number", "of", "physicians", "in", "the", "United", "States", "administered", "Cytolin", "to", "their", "HIV-infected", "patients", "over", "two", "years.", "<tag2>", "The", "estimated", "cost", "for", "this", "study", "is", "approximately", "$3.7", "million,", "of", "which", "$1.0", "million", "represents", "estimated", "direct", "service", "fees", "payable", "to", "Amarex.", "<tag3>"], "wordsA": ["In", "this", "study", "a", "relatively", "small", "number", "of", "physicians", "in", "the", "United", "States", "administered", "Cytolin", "to", "their", "HIV-infected", "patients", "over", "two", "years."], "wordsB": ["The", "estimated", "cost", "for", "this", "study", "is", "approximately", "$3.7", "million,", "of", "which", "$1.0", "million", "represents", "estimated", "direct", "service", "fees", "payable", "to", "Amarex."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p5_s5", "idA": "1175680_13_item1_p17_s7", "sentA": "The Study was completed in December 2012.", "sentB": "We paid Amarex a combined deposit of approximately $790,000 in December 2013 and have an unamortized balance of $256,800 as of May 31, 2014.", "type": 1, "words": ["<tag1>", "The", "Study", "was", "completed", "in", "December", "2012.", "<tag2>", "We", "paid", "Amarex", "a", "combined", "deposit", "of", "approximately", "$790,000", "in", "December", "2013", "and", "have", "an", "unamortized", "balance", "of", "$256,800", "as", "of", "May", "31,", "2014.", "<tag3>"], "wordsA": ["The", "Study", "was", "completed", "in", "December", "2012."], "wordsB": ["We", "paid", "Amarex", "a", "combined", "deposit", "of", "approximately", "$790,000", "in", "December", "2013", "and", "have", "an", "unamortized", "balance", "of", "$256,800", "as", "of", "May", "31,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p10_s3", "idA": "1175680_13_item1_p1_s1", "sentA": "Our lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors.", "sentB": "This Phase 2b trial is known as treatment substitution.", "type": 1, "words": ["<tag1>", "Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors.", "<tag2>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag3>"], "wordsA": ["Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors."], "wordsB": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p10_s6", "idA": "1175680_13_item1_p24_s0", "sentA": "In connection with our acquisition of rights to PRO 140, our patent counsel conducted a freedom-to-operate search that identified other patents that could relate to our proposed PRO 140 drug candidate.", "sentB": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "our", "acquisition", "of", "rights", "to", "PRO", "140,", "our", "patent", "counsel", "conducted", "a", "freedom-to-operate", "search", "that", "identified", "other", "patents", "that", "could", "relate", "to", "our", "proposed", "PRO", "140", "drug", "candidate.", "<tag2>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag3>"], "wordsA": ["In", "connection", "with", "our", "acquisition", "of", "rights", "to", "PRO", "140,", "our", "patent", "counsel", "conducted", "a", "freedom-to-operate", "search", "that", "identified", "other", "patents", "that", "could", "relate", "to", "our", "proposed", "PRO", "140", "drug", "candidate."], "wordsB": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p5_s4", "idA": "1175680_13_item1_p42_s0", "sentA": "As described above, we are currently working with Dr. Jacobson to begin two additional clinical trials of PRO 140, which we believe will satisfy requirements for Phase IIb study of the product candidate.", "sentB": "Under the terms of our agreement with Amarex, we are required to pay Amarex 30% of the unpaid balance of direct service fees upon early termination of the agreement.", "type": 1, "words": ["<tag1>", "As", "described", "above,", "we", "are", "currently", "working", "with", "Dr.", "Jacobson", "to", "begin", "two", "additional", "clinical", "trials", "of", "PRO", "140,", "which", "we", "believe", "will", "satisfy", "requirements", "for", "Phase", "IIb", "study", "of", "the", "product", "candidate.", "<tag2>", "Under", "the", "terms", "of", "our", "agreement", "with", "Amarex,", "we", "are", "required", "to", "pay", "Amarex", "30%", "of", "the", "unpaid", "balance", "of", "direct", "service", "fees", "upon", "early", "termination", "of", "the", "agreement.", "<tag3>"], "wordsA": ["As", "described", "above,", "we", "are", "currently", "working", "with", "Dr.", "Jacobson", "to", "begin", "two", "additional", "clinical", "trials", "of", "PRO", "140,", "which", "we", "believe", "will", "satisfy", "requirements", "for", "Phase", "IIb", "study", "of", "the", "product", "candidate."], "wordsB": ["Under", "the", "terms", "of", "our", "agreement", "with", "Amarex,", "we", "are", "required", "to", "pay", "Amarex", "30%", "of", "the", "unpaid", "balance", "of", "direct", "service", "fees", "upon", "early", "termination", "of", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p10_s5", "idA": "1175680_13_item1_p44_s4", "sentA": "For these reasons, we believe that our monoclonal antibody products may prove to be useful in patients that cannot tolerate existing HIV therapies.", "sentB": "The study protocol requires patients to be stable on combination antiretroviral therapy.", "type": 1, "words": ["<tag1>", "For", "these", "reasons,", "we", "believe", "that", "our", "monoclonal", "antibody", "products", "may", "prove", "to", "be", "useful", "in", "patients", "that", "cannot", "tolerate", "existing", "HIV", "therapies.", "<tag2>", "The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "combination", "antiretroviral", "therapy.", "<tag3>"], "wordsA": ["For", "these", "reasons,", "we", "believe", "that", "our", "monoclonal", "antibody", "products", "may", "prove", "to", "be", "useful", "in", "patients", "that", "cannot", "tolerate", "existing", "HIV", "therapies."], "wordsB": ["The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "combination", "antiretroviral", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_14_item1_p0_s2", "idA": "1175680_13_item1_p47_s0", "sentA": "In seeking to manufacture, distribute and market the various potential drugs we intend to develop, we face competition from established pharmaceutical companies.", "sentB": "We do not intend to incorporate any contents from our website into this annual report.", "type": 1, "words": ["<tag1>", "In", "seeking", "to", "manufacture,", "distribute", "and", "market", "the", "various", "potential", "drugs", "we", "intend", "to", "develop,", "we", "face", "competition", "from", "established", "pharmaceutical", "companies.", "<tag2>", "We", "do", "not", "intend", "to", "incorporate", "any", "contents", "from", "our", "website", "into", "this", "annual", "report.", "<tag3>"], "wordsA": ["In", "seeking", "to", "manufacture,", "distribute", "and", "market", "the", "various", "potential", "drugs", "we", "intend", "to", "develop,", "we", "face", "competition", "from", "established", "pharmaceutical", "companies."], "wordsB": ["We", "do", "not", "intend", "to", "incorporate", "any", "contents", "from", "our", "website", "into", "this", "annual", "report."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p47_s1", "idA": "1175680_14_item1_p0_s1", "sentA": "Our website can be found at www.cytodyn.com.", "sentB": "There can be no assurances, however, that we will be able to identify or hire and retain additional employees or consultants on acceptable terms in the future.", "type": 1, "words": ["<tag1>", "Our", "website", "can", "be", "found", "at", "www.cytodyn.com.", "<tag2>", "There", "can", "be", "no", "assurances,", "however,", "that", "we", "will", "be", "able", "to", "identify", "or", "hire", "and", "retain", "additional", "employees", "or", "consultants", "on", "acceptable", "terms", "in", "the", "future.", "<tag3>"], "wordsA": ["Our", "website", "can", "be", "found", "at", "www.cytodyn.com."], "wordsB": ["There", "can", "be", "no", "assurances,", "however,", "that", "we", "will", "be", "able", "to", "identify", "or", "hire", "and", "retain", "additional", "employees", "or", "consultants", "on", "acceptable", "terms", "in", "the", "future."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p40_s3", "idA": "1175680_14_item1_p10_s1", "sentA": "As such, the Company is precluded from commenting on the Drexel sponsored studies.", "sentB": "During Phase 1, sufficient information about the investigational product s pharmacokinetics and pharmacological effects are obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies.", "type": 1, "words": ["<tag1>", "As", "such,", "the", "Company", "is", "precluded", "from", "commenting", "on", "the", "Drexel", "sponsored", "studies.", "<tag2>", "During", "Phase", "1,", "sufficient", "information", "about", "the", "investigational", "product", "s", "pharmacokinetics", "and", "pharmacological", "effects", "are", "obtained", "to", "permit", "the", "design", "of", "well-controlled,", "scientifically", "valid,", "Phase", "2", "studies.", "<tag3>"], "wordsA": ["As", "such,", "the", "Company", "is", "precluded", "from", "commenting", "on", "the", "Drexel", "sponsored", "studies."], "wordsB": ["During", "Phase", "1,", "sufficient", "information", "about", "the", "investigational", "product", "s", "pharmacokinetics", "and", "pharmacological", "effects", "are", "obtained", "to", "permit", "the", "design", "of", "well-controlled,", "scientifically", "valid,", "Phase", "2", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p34_s1", "idA": "1175680_14_item1_p10_s2", "sentA": "A third clinical trial of PRO 140 commenced in May 2014 and is sponsored and funded by the Company.", "sentB": "Failure to comply with applicable regulations can result in refusal by the FDA to approve product license applications.", "type": 1, "words": ["<tag1>", "A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company.", "<tag2>", "Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications.", "<tag3>"], "wordsA": ["A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company."], "wordsB": ["Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p35_s1", "idA": "1175680_14_item1_p10_s2", "sentA": "A third clinical trial of PRO 140 commenced in May 2014 and is sponsored and funded by the Company.", "sentB": "CLIA regulates clinical laboratories by requiring that the laboratory be certified by the federal government, licensed by the state and comply with various operational, personnel and quality requirements intended to ensure that clinical laboratory test results are accurate, reliable and timely.", "type": 1, "words": ["<tag1>", "A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company.", "<tag2>", "CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely.", "<tag3>"], "wordsA": ["A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company."], "wordsB": ["CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p38_s2", "idA": "1175680_14_item1_p10_s2", "sentA": "A third clinical trial of PRO 140 commenced in May 2014 and is sponsored and funded by the Company.", "sentB": "Our compliance with these regulations did not have during the past year and is not expected to have a material effect upon our capital expenditures, cash flows, earnings or competitive position.", "type": 1, "words": ["<tag1>", "A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company.", "<tag2>", "Our", "compliance", "with", "these", "regulations", "did", "not", "have", "during", "the", "past", "year", "and", "is", "not", "expected", "to", "have", "a", "material", "effect", "upon", "our", "capital", "expenditures,", "cash", "flows,", "earnings", "or", "competitive", "position.", "<tag3>"], "wordsA": ["A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company."], "wordsB": ["Our", "compliance", "with", "these", "regulations", "did", "not", "have", "during", "the", "past", "year", "and", "is", "not", "expected", "to", "have", "a", "material", "effect", "upon", "our", "capital", "expenditures,", "cash", "flows,", "earnings", "or", "competitive", "position."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p9_s5", "idA": "1175680_14_item1_p10_s2", "sentA": "A third clinical trial of PRO 140 commenced in May 2014 and is sponsored and funded by the Company.", "sentB": "Results from these extension studies thus far indicate some patients are now reaching eight months of suppressed viral load achieved through a successful monotherapy of PRO 140.", "type": 1, "words": ["<tag1>", "A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company.", "<tag2>", "Results", "from", "these", "extension", "studies", "thus", "far", "indicate", "some", "patients", "are", "now", "reaching", "eight", "months", "of", "suppressed", "viral", "load", "achieved", "through", "a", "successful", "monotherapy", "of", "PRO", "140.", "<tag3>"], "wordsA": ["A", "third", "clinical", "trial", "of", "PRO", "140", "commenced", "in", "May", "2014", "and", "is", "sponsored", "and", "funded", "by", "the", "Company."], "wordsB": ["Results", "from", "these", "extension", "studies", "thus", "far", "indicate", "some", "patients", "are", "now", "reaching", "eight", "months", "of", "suppressed", "viral", "load", "achieved", "through", "a", "successful", "monotherapy", "of", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p12_s3", "idA": "1175680_14_item1_p10_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "CytoDyn believes its clinical trial data demonstrates that patients with either R5 exclusive virus or Dual/Mix virus have all successfully passed four weeks of monotherapy, thus there would be no need for a trofile test, if this therapy were to be used for a three to four week treatment substitution.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "CytoDyn", "believes", "its", "clinical", "trial", "data", "demonstrates", "that", "patients", "with", "either", "R5", "exclusive", "virus", "or", "Dual/Mix", "virus", "have", "all", "successfully", "passed", "four", "weeks", "of", "monotherapy,", "thus", "there", "would", "be", "no", "need", "for", "a", "trofile", "test,", "if", "this", "therapy", "were", "to", "be", "used", "for", "a", "three", "to", "four", "week", "treatment", "substitution.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["CytoDyn", "believes", "its", "clinical", "trial", "data", "demonstrates", "that", "patients", "with", "either", "R5", "exclusive", "virus", "or", "Dual/Mix", "virus", "have", "all", "successfully", "passed", "four", "weeks", "of", "monotherapy,", "thus", "there", "would", "be", "no", "need", "for", "a", "trofile", "test,", "if", "this", "therapy", "were", "to", "be", "used", "for", "a", "three", "to", "four", "week", "treatment", "substitution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p39_s1", "idA": "1175680_14_item1_p10_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "Our current business strategy is to focus primarily on the PRO 140 Phase 3 trial, seeking additional indications in Phase 3 trials, which we will sponsor and fund (subject to the availability of sufficient capital to pursue additional paths), and to continue to evaluate and leverage the clinical data from our recently completed Phase 2b treatment substitution trial.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "Our", "current", "business", "strategy", "is", "to", "focus", "primarily", "on", "the", "PRO", "140", "Phase", "3", "trial,", "seeking", "additional", "indications", "in", "Phase", "3", "trials,", "which", "we", "will", "sponsor", "and", "fund", "(subject", "to", "the", "availability", "of", "sufficient", "capital", "to", "pursue", "additional", "paths),", "and", "to", "continue", "to", "evaluate", "and", "leverage", "the", "clinical", "data", "from", "our", "recently", "completed", "Phase", "2b", "treatment", "substitution", "trial.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["Our", "current", "business", "strategy", "is", "to", "focus", "primarily", "on", "the", "PRO", "140", "Phase", "3", "trial,", "seeking", "additional", "indications", "in", "Phase", "3", "trials,", "which", "we", "will", "sponsor", "and", "fund", "(subject", "to", "the", "availability", "of", "sufficient", "capital", "to", "pursue", "additional", "paths),", "and", "to", "continue", "to", "evaluate", "and", "leverage", "the", "clinical", "data", "from", "our", "recently", "completed", "Phase", "2b", "treatment", "substitution", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s5", "idA": "1175680_14_item1_p10_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "Phase 2 is often broken into Phase 2a, which can be used to refer to pilot trials, or more limited trials evaluating exposure response in patients, and Phase 2b trials that are designed to evaluate dosing efficacy and ranges.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "Phase", "2", "is", "often", "broken", "into", "Phase", "2a,", "which", "can", "be", "used", "to", "refer", "to", "pilot", "trials,", "or", "more", "limited", "trials", "evaluating", "exposure", "response", "in", "patients,", "and", "Phase", "2b", "trials", "that", "are", "designed", "to", "evaluate", "dosing", "efficacy", "and", "ranges.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["Phase", "2", "is", "often", "broken", "into", "Phase", "2a,", "which", "can", "be", "used", "to", "refer", "to", "pilot", "trials,", "or", "more", "limited", "trials", "evaluating", "exposure", "response", "in", "patients,", "and", "Phase", "2b", "trials", "that", "are", "designed", "to", "evaluate", "dosing", "efficacy", "and", "ranges."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p12_s2", "idA": "1175680_14_item1_p10_s4", "sentA": "Our ongoing treatment substitution study has two objectives: (1) to assess the efficacy of PRO 140 monotherapy for the maintenance of viral suppression after being used in substitution of a patient s antiretroviral therapy regimen and (2) to assess the clinical safety and tolerability parameters for PRO 140 following use in substitution of antiretroviral therapy.", "sentB": "Therefore, the occurrence of a number of viral rebounds due to inaccurate trofile screening was not unexpected.", "type": 1, "words": ["<tag1>", "Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy.", "<tag2>", "Therefore,", "the", "occurrence", "of", "a", "number", "of", "viral", "rebounds", "due", "to", "inaccurate", "trofile", "screening", "was", "not", "unexpected.", "<tag3>"], "wordsA": ["Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy."], "wordsB": ["Therefore,", "the", "occurrence", "of", "a", "number", "of", "viral", "rebounds", "due", "to", "inaccurate", "trofile", "screening", "was", "not", "unexpected."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p9_s11", "idA": "1175680_14_item1_p10_s4", "sentA": "Our ongoing treatment substitution study has two objectives: (1) to assess the efficacy of PRO 140 monotherapy for the maintenance of viral suppression after being used in substitution of a patient s antiretroviral therapy regimen and (2) to assess the clinical safety and tolerability parameters for PRO 140 following use in substitution of antiretroviral therapy.", "sentB": "An independent Data Safety Monitoring Board ( DSMB ) is required to monitor the study to ensure patient safety and to assess efficacy.", "type": 1, "words": ["<tag1>", "Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy.", "<tag2>", "An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "is", "required", "to", "monitor", "the", "study", "to", "ensure", "patient", "safety", "and", "to", "assess", "efficacy.", "<tag3>"], "wordsA": ["Our", "ongoing", "treatment", "substitution", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "antiretroviral", "therapy", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "antiretroviral", "therapy."], "wordsB": ["An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "is", "required", "to", "monitor", "the", "study", "to", "ensure", "patient", "safety", "and", "to", "assess", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p7_s0", "idA": "1175680_14_item1_p10_s5", "sentA": "The study protocol requires patients to be stable on combination antiretroviral therapy.", "sentB": "Patients who choose not to start their highly active antiretroviral therapy ( HAART ) regimen immediately after being infected with HIV.", "type": 1, "words": ["<tag1>", "The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "combination", "antiretroviral", "therapy.", "<tag2>", "Patients", "who", "choose", "not", "to", "start", "their", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "regimen", "immediately", "after", "being", "infected", "with", "HIV.", "<tag3>"], "wordsA": ["The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "combination", "antiretroviral", "therapy."], "wordsB": ["Patients", "who", "choose", "not", "to", "start", "their", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "regimen", "immediately", "after", "being", "infected", "with", "HIV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p36_s1", "idA": "1175680_14_item1_p10_s6", "sentA": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "Most states conduct periodic unannounced inspections and require licensing under such state s procedures.", "type": 1, "words": ["<tag1>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "Most", "states", "conduct", "periodic", "unannounced", "inspections", "and", "require", "licensing", "under", "such", "state", "s", "procedures.", "<tag3>"], "wordsA": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["Most", "states", "conduct", "periodic", "unannounced", "inspections", "and", "require", "licensing", "under", "such", "state", "s", "procedures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p42_s0", "idA": "1175680_14_item1_p10_s6", "sentA": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "Competition The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition.", "type": 1, "words": ["<tag1>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "Competition", "The", "pharmaceutical", "and", "biotechnology", "industries", "are", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition.", "<tag3>"], "wordsA": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["Competition", "The", "pharmaceutical", "and", "biotechnology", "industries", "are", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s5", "idA": "1175680_14_item1_p10_s6", "sentA": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "Nonetheless, manufacturers of current therapies, such as Pfizer and Gilead Sciences, are very large, multi-national corporations with significant resources.", "type": 1, "words": ["<tag1>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "Nonetheless,", "manufacturers", "of", "current", "therapies,", "such", "as", "Pfizer", "and", "Gilead", "Sciences,", "are", "very", "large,", "multi-national", "corporations", "with", "significant", "resources.", "<tag3>"], "wordsA": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["Nonetheless,", "manufacturers", "of", "current", "therapies,", "such", "as", "Pfizer", "and", "Gilead", "Sciences,", "are", "very", "large,", "multi-national", "corporations", "with", "significant", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s6", "idA": "1175680_14_item1_p10_s6", "sentA": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "We expect that these companies will compete fiercely to defend and expand their market share.", "type": 1, "words": ["<tag1>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "We", "expect", "that", "these", "companies", "will", "compete", "fiercely", "to", "defend", "and", "expand", "their", "market", "share.", "<tag3>"], "wordsA": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["We", "expect", "that", "these", "companies", "will", "compete", "fiercely", "to", "defend", "and", "expand", "their", "market", "share."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s8", "idA": "1175680_14_item1_p10_s6", "sentA": "The current trial design provides that patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "These include numerous public and private academic and research organizations and pharmaceutical and biotechnology companies pursuing production of, among other things, biologics from cell cultures, genetically engineered drugs and natural and chemically synthesized drugs.", "type": 1, "words": ["<tag1>", "The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "These", "include", "numerous", "public", "and", "private", "academic", "and", "research", "organizations", "and", "pharmaceutical", "and", "biotechnology", "companies", "pursuing", "production", "of,", "among", "other", "things,", "biologics", "from", "cell", "cultures,", "genetically", "engineered", "drugs", "and", "natural", "and", "chemically", "synthesized", "drugs.", "<tag3>"], "wordsA": ["The", "current", "trial", "design", "provides", "that", "patients", "will", "be", "shifted", "from", "combination", "antiretroviral", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["These", "include", "numerous", "public", "and", "private", "academic", "and", "research", "organizations", "and", "pharmaceutical", "and", "biotechnology", "companies", "pursuing", "production", "of,", "among", "other", "things,", "biologics", "from", "cell", "cultures,", "genetically", "engineered", "drugs", "and", "natural", "and", "chemically", "synthesized", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p11_s0", "idA": "1175680_14_item1_p10_s7", "sentA": "Total treatment duration with PRO 140 will be up to 14 weeks with one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study period and also one week of overlap at the end in subjects who did not experience virologic failure.", "sentB": "14 patients, who were offered to continue in an extension study with this monotherapy, most are approaching 8 months without experiencing a virologic failure.", "type": 1, "words": ["<tag1>", "Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure.", "<tag2>", "14", "patients,", "who", "were", "offered", "to", "continue", "in", "an", "extension", "study", "with", "this", "monotherapy,", "most", "are", "approaching", "8", "months", "without", "experiencing", "a", "virologic", "failure.", "<tag3>"], "wordsA": ["Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure."], "wordsB": ["14", "patients,", "who", "were", "offered", "to", "continue", "in", "an", "extension", "study", "with", "this", "monotherapy,", "most", "are", "approaching", "8", "months", "without", "experiencing", "a", "virologic", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p25_s5", "idA": "1175680_14_item1_p10_s7", "sentA": "Total treatment duration with PRO 140 will be up to 14 weeks with one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study period and also one week of overlap at the end in subjects who did not experience virologic failure.", "sentB": "Separate from and in addition to the patent rights noted above, we expect that PRO 140 will be subject to at least a 12-year data exclusivity period measured from the first date of FDA licensure, during which period no other applications referencing PRO 140 will be approved by FDA.", "type": 1, "words": ["<tag1>", "Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure.", "<tag2>", "Separate", "from", "and", "in", "addition", "to", "the", "patent", "rights", "noted", "above,", "we", "expect", "that", "PRO", "140", "will", "be", "subject", "to", "at", "least", "a", "12-year", "data", "exclusivity", "period", "measured", "from", "the", "first", "date", "of", "FDA", "licensure,", "during", "which", "period", "no", "other", "applications", "referencing", "PRO", "140", "will", "be", "approved", "by", "FDA.", "<tag3>"], "wordsA": ["Total", "treatment", "duration", "with", "PRO", "140", "will", "be", "up", "to", "14", "weeks", "with", "one", "week", "overlap", "of", "existing", "retroviral", "regimen", "and", "PRO", "140", "at", "the", "beginning", "of", "the", "study", "period", "and", "also", "one", "week", "of", "overlap", "at", "the", "end", "in", "subjects", "who", "did", "not", "experience", "virologic", "failure."], "wordsB": ["Separate", "from", "and", "in", "addition", "to", "the", "patent", "rights", "noted", "above,", "we", "expect", "that", "PRO", "140", "will", "be", "subject", "to", "at", "least", "a", "12-year", "data", "exclusivity", "period", "measured", "from", "the", "first", "date", "of", "FDA", "licensure,", "during", "which", "period", "no", "other", "applications", "referencing", "PRO", "140", "will", "be", "approved", "by", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p46_s0", "idA": "1175680_14_item1_p10_s9", "sentA": "Other Product Candidates A second product candidate, Cytolin, is also a humanized monoclonal antibody for the treatment of HIV infection.", "sentB": "Research and Development Costs Our research and development expenses totaled approximately $15.2 million and $4.0 million for the fiscal years ended May 31, 2015 and May 31, 2014, respectively.", "type": 1, "words": ["<tag1>", "Other", "Product", "Candidates", "A", "second", "product", "candidate,", "Cytolin,", "is", "also", "a", "humanized", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection.", "<tag2>", "Research", "and", "Development", "Costs", "Our", "research", "and", "development", "expenses", "totaled", "approximately", "$15.2", "million", "and", "$4.0", "million", "for", "the", "fiscal", "years", "ended", "May", "31,", "2015", "and", "May", "31,", "2014,", "respectively.", "<tag3>"], "wordsA": ["Other", "Product", "Candidates", "A", "second", "product", "candidate,", "Cytolin,", "is", "also", "a", "humanized", "monoclonal", "antibody", "for", "the", "treatment", "of", "HIV", "infection."], "wordsB": ["Research", "and", "Development", "Costs", "Our", "research", "and", "development", "expenses", "totaled", "approximately", "$15.2", "million", "and", "$4.0", "million", "for", "the", "fiscal", "years", "ended", "May", "31,", "2015", "and", "May", "31,", "2014,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p35_s0", "idA": "1175680_14_item1_p11_s0", "sentA": "We acquired rights to Cytolin in October 2003 pursuant to an agreement with CytoDyn of New Mexico, Inc. ( CytoDyn NM ).", "sentB": "Regulation of Laboratory Operations Clinical laboratories that perform laboratory testing (except for research purposes only) on human subjects are subject to regulation under Clinical Laboratory Improvement Amendments ( CLIA ).", "type": 1, "words": ["<tag1>", "We", "acquired", "rights", "to", "Cytolin", "in", "October", "2003", "pursuant", "to", "an", "agreement", "with", "CytoDyn", "of", "New", "Mexico,", "Inc.", "(", "CytoDyn", "NM", ").", "<tag2>", "Regulation", "of", "Laboratory", "Operations", "Clinical", "laboratories", "that", "perform", "laboratory", "testing", "(except", "for", "research", "purposes", "only)", "on", "human", "subjects", "are", "subject", "to", "regulation", "under", "Clinical", "Laboratory", "Improvement", "Amendments", "(", "CLIA", ").", "<tag3>"], "wordsA": ["We", "acquired", "rights", "to", "Cytolin", "in", "October", "2003", "pursuant", "to", "an", "agreement", "with", "CytoDyn", "of", "New", "Mexico,", "Inc.", "(", "CytoDyn", "NM", ")."], "wordsB": ["Regulation", "of", "Laboratory", "Operations", "Clinical", "laboratories", "that", "perform", "laboratory", "testing", "(except", "for", "research", "purposes", "only)", "on", "human", "subjects", "are", "subject", "to", "regulation", "under", "Clinical", "Laboratory", "Improvement", "Amendments", "(", "CLIA", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p44_s0", "idA": "1175680_14_item1_p11_s1", "sentA": "As part of the transaction, we acquired the drug candidate Cytolin and were assigned rights under the patent license agreement dated July 1, 1994, between CytoDyn NM and Allen D. Allen, covering United States Patent No. 5,651,970 (which describes a method for treating HIV disease with the use of monoclonal antibodies), including the worldwide, exclusive right to develop, market and sell compounds disclosed by the patent, to practice methods taught by the patent, and to exploit specified technology related to the patent.", "sentB": "Worldwide, there are many antiviral drugs for treating HIV.", "type": 1, "words": ["<tag1>", "As", "part", "of", "the", "transaction,", "we", "acquired", "the", "drug", "candidate", "Cytolin", "and", "were", "assigned", "rights", "under", "the", "patent", "license", "agreement", "dated", "July", "1,", "1994,", "between", "CytoDyn", "NM", "and", "Allen", "D.", "Allen,", "covering", "United", "States", "Patent", "No.", "5,651,970", "(which", "describes", "a", "method", "for", "treating", "HIV", "disease", "with", "the", "use", "of", "monoclonal", "antibodies),", "including", "the", "worldwide,", "exclusive", "right", "to", "develop,", "market", "and", "sell", "compounds", "disclosed", "by", "the", "patent,", "to", "practice", "methods", "taught", "by", "the", "patent,", "and", "to", "exploit", "specified", "technology", "related", "to", "the", "patent.", "<tag2>", "Worldwide,", "there", "are", "many", "antiviral", "drugs", "for", "treating", "HIV.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "transaction,", "we", "acquired", "the", "drug", "candidate", "Cytolin", "and", "were", "assigned", "rights", "under", "the", "patent", "license", "agreement", "dated", "July", "1,", "1994,", "between", "CytoDyn", "NM", "and", "Allen", "D.", "Allen,", "covering", "United", "States", "Patent", "No.", "5,651,970", "(which", "describes", "a", "method", "for", "treating", "HIV", "disease", "with", "the", "use", "of", "monoclonal", "antibodies),", "including", "the", "worldwide,", "exclusive", "right", "to", "develop,", "market", "and", "sell", "compounds", "disclosed", "by", "the", "patent,", "to", "practice", "methods", "taught", "by", "the", "patent,", "and", "to", "exploit", "specified", "technology", "related", "to", "the", "patent."], "wordsB": ["Worldwide,", "there", "are", "many", "antiviral", "drugs", "for", "treating", "HIV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p13_s1", "idA": "1175680_14_item1_p11_s2", "sentA": "This patent is for a murine (mouse) version of the drug.", "sentB": "The Company s Phase 3 protocol provides for a 25-week study with 300 HIV patients.", "type": 1, "words": ["<tag1>", "This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug.", "<tag2>", "The", "Company", "s", "Phase", "3", "protocol", "provides", "for", "a", "25-week", "study", "with", "300", "HIV", "patients.", "<tag3>"], "wordsA": ["This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug."], "wordsB": ["The", "Company", "s", "Phase", "3", "protocol", "provides", "for", "a", "25-week", "study", "with", "300", "HIV", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p33_s1", "idA": "1175680_14_item1_p11_s2", "sentA": "This patent is for a murine (mouse) version of the drug.", "sentB": "The FDA may also enjoin and restrain certain violations of the Federal Food, Drug and Cosmetic Act, as amended, or the Public Health Service Act pertaining to certain biological products or initiate action for criminal prosecution of such violations.", "type": 1, "words": ["<tag1>", "This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug.", "<tag2>", "The", "FDA", "may", "also", "enjoin", "and", "restrain", "certain", "violations", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act,", "as", "amended,", "or", "the", "Public", "Health", "Service", "Act", "pertaining", "to", "certain", "biological", "products", "or", "initiate", "action", "for", "criminal", "prosecution", "of", "such", "violations.", "<tag3>"], "wordsA": ["This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug."], "wordsB": ["The", "FDA", "may", "also", "enjoin", "and", "restrain", "certain", "violations", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act,", "as", "amended,", "or", "the", "Public", "Health", "Service", "Act", "pertaining", "to", "certain", "biological", "products", "or", "initiate", "action", "for", "criminal", "prosecution", "of", "such", "violations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s4", "idA": "1175680_14_item1_p11_s2", "sentA": "This patent is for a murine (mouse) version of the drug.", "sentB": "In some cases, depending upon the need for a new drug, a particular drug candidate may be licensed for sale in interstate commerce after a pivotal Phase 2 trial.", "type": 1, "words": ["<tag1>", "This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug.", "<tag2>", "In", "some", "cases,", "depending", "upon", "the", "need", "for", "a", "new", "drug,", "a", "particular", "drug", "candidate", "may", "be", "licensed", "for", "sale", "in", "interstate", "commerce", "after", "a", "pivotal", "Phase", "2", "trial.", "<tag3>"], "wordsA": ["This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug."], "wordsB": ["In", "some", "cases,", "depending", "upon", "the", "need", "for", "a", "new", "drug,", "a", "particular", "drug", "candidate", "may", "be", "licensed", "for", "sale", "in", "interstate", "commerce", "after", "a", "pivotal", "Phase", "2", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p32_s0", "idA": "1175680_14_item1_p12_s0", "sentA": "On September 23, 2011, the Company filed a provisional patent application (Serial No. 61/534,942) in the United States for its humanized version of Cytolin.", "sentB": "In the United States, biological products have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling, import, export and safety reporting.", "type": 1, "words": ["<tag1>", "On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin.", "<tag2>", "In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting.", "<tag3>"], "wordsA": ["On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin."], "wordsB": ["In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p9_s12", "idA": "1175680_14_item1_p12_s0", "sentA": "On September 23, 2011, the Company filed a provisional patent application (Serial No. 61/534,942) in the United States for its humanized version of Cytolin.", "sentB": "The DSMB operates in conformance with the FDA guidelines for its independence, management and oversight.", "type": 1, "words": ["<tag1>", "On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin.", "<tag2>", "The", "DSMB", "operates", "in", "conformance", "with", "the", "FDA", "guidelines", "for", "its", "independence,", "management", "and", "oversight.", "<tag3>"], "wordsA": ["On", "September", "23,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "(Serial", "No.", "61/534,942)", "in", "the", "United", "States", "for", "its", "humanized", "version", "of", "Cytolin."], "wordsB": ["The", "DSMB", "operates", "in", "conformance", "with", "the", "FDA", "guidelines", "for", "its", "independence,", "management", "and", "oversight."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p37_s1", "idA": "1175680_14_item1_p13_s1", "sentA": "On June 17, 2011, the Company filed a provisional patent application in the United States (Serial No. 61/498,029) for the use of these antibodies, as well as selected small molecule antagonists and agonists for the treatment of FIV.", "sentB": "Other Laws and Regulations We are subject to various laws and regulations relating to safe working conditions, clinical, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research.", "type": 1, "words": ["<tag1>", "On", "June", "17,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "in", "the", "United", "States", "(Serial", "No.", "61/498,029)", "for", "the", "use", "of", "these", "antibodies,", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV.", "<tag2>", "Other", "Laws", "and", "Regulations", "We", "are", "subject", "to", "various", "laws", "and", "regulations", "relating", "to", "safe", "working", "conditions,", "clinical,", "laboratory", "and", "manufacturing", "practices,", "the", "experimental", "use", "of", "animals", "and", "the", "use", "and", "disposal", "of", "hazardous", "or", "potentially", "hazardous", "substances,", "including", "radioactive", "compounds", "and", "infectious", "disease", "agents,", "used", "in", "connection", "with", "our", "research.", "<tag3>"], "wordsA": ["On", "June", "17,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "in", "the", "United", "States", "(Serial", "No.", "61/498,029)", "for", "the", "use", "of", "these", "antibodies,", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV."], "wordsB": ["Other", "Laws", "and", "Regulations", "We", "are", "subject", "to", "various", "laws", "and", "regulations", "relating", "to", "safe", "working", "conditions,", "clinical,", "laboratory", "and", "manufacturing", "practices,", "the", "experimental", "use", "of", "animals", "and", "the", "use", "and", "disposal", "of", "hazardous", "or", "potentially", "hazardous", "substances,", "including", "radioactive", "compounds", "and", "infectious", "disease", "agents,", "used", "in", "connection", "with", "our", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s3", "idA": "1175680_14_item1_p13_s1", "sentA": "On June 17, 2011, the Company filed a provisional patent application in the United States (Serial No. 61/498,029) for the use of these antibodies, as well as selected small molecule antagonists and agonists for the treatment of FIV.", "sentB": "Both of these drugs must be taken daily and are believed to have significant side effects.", "type": 1, "words": ["<tag1>", "On", "June", "17,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "in", "the", "United", "States", "(Serial", "No.", "61/498,029)", "for", "the", "use", "of", "these", "antibodies,", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV.", "<tag2>", "Both", "of", "these", "drugs", "must", "be", "taken", "daily", "and", "are", "believed", "to", "have", "significant", "side", "effects.", "<tag3>"], "wordsA": ["On", "June", "17,", "2011,", "the", "Company", "filed", "a", "provisional", "patent", "application", "in", "the", "United", "States", "(Serial", "No.", "61/498,029)", "for", "the", "use", "of", "these", "antibodies,", "as", "well", "as", "selected", "small", "molecule", "antagonists", "and", "agonists", "for", "the", "treatment", "of", "FIV."], "wordsB": ["Both", "of", "these", "drugs", "must", "be", "taken", "daily", "and", "are", "believed", "to", "have", "significant", "side", "effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p13_s3", "idA": "1175680_14_item1_p14_s0", "sentA": "CytoFeline is the Company s proprietary product targeted to treat FIV.", "sentB": "Additionally, the Company may apply for a breakthrough designation for PRO 140, as the first self-injectable antibody for HIV therapy.", "type": 1, "words": ["<tag1>", "CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV.", "<tag2>", "Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy.", "<tag3>"], "wordsA": ["CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV."], "wordsB": ["Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p14_s1", "idA": "1175680_14_item1_p14_s0", "sentA": "CytoFeline is the Company s proprietary product targeted to treat FIV.", "sentB": "HAART is the current standard of medical care for individuals with HIV.", "type": 1, "words": ["<tag1>", "CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV.", "<tag2>", "HAART", "is", "the", "current", "standard", "of", "medical", "care", "for", "individuals", "with", "HIV.", "<tag3>"], "wordsA": ["CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV."], "wordsB": ["HAART", "is", "the", "current", "standard", "of", "medical", "care", "for", "individuals", "with", "HIV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p39_s0", "idA": "1175680_14_item1_p14_s0", "sentA": "CytoFeline is the Company s proprietary product targeted to treat FIV.", "sentB": "Registrational Clinical Trials Process Described below is the traditional registrational drug development track.", "type": 1, "words": ["<tag1>", "CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV.", "<tag2>", "Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track.", "<tag3>"], "wordsA": ["CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV."], "wordsB": ["Registrational", "Clinical", "Trials", "Process", "Described", "below", "is", "the", "traditional", "registrational", "drug", "development", "track."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s1", "idA": "1175680_14_item1_p14_s0", "sentA": "CytoFeline is the Company s proprietary product targeted to treat FIV.", "sentB": "Pfizer s maraviroc (Selzentry ) is the only currently approved CCR5 blocking agent.", "type": 1, "words": ["<tag1>", "CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV.", "<tag2>", "Pfizer", "s", "maraviroc", "(Selzentry", ")", "is", "the", "only", "currently", "approved", "CCR5", "blocking", "agent.", "<tag3>"], "wordsA": ["CytoFeline", "is", "the", "Company", "s", "proprietary", "product", "targeted", "to", "treat", "FIV."], "wordsB": ["Pfizer", "s", "maraviroc", "(Selzentry", ")", "is", "the", "only", "currently", "approved", "CCR5", "blocking", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p42_s1", "idA": "1175680_14_item1_p14_s1", "sentA": "Until the clinical trials for PRO 140 have advanced further, we do not plan to devote any resources towards the development, research, testing, approval, or commercialization of Cytolin or CytoFeline.", "sentB": "Our development efforts may compete with more established biotechnology companies that have significantly greater financial and managerial resources than we do.", "type": 1, "words": ["<tag1>", "Until", "the", "clinical", "trials", "for", "PRO", "140", "have", "advanced", "further,", "we", "do", "not", "plan", "to", "devote", "any", "resources", "towards", "the", "development,", "research,", "testing,", "approval,", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline.", "<tag2>", "Our", "development", "efforts", "may", "compete", "with", "more", "established", "biotechnology", "companies", "that", "have", "significantly", "greater", "financial", "and", "managerial", "resources", "than", "we", "do.", "<tag3>"], "wordsA": ["Until", "the", "clinical", "trials", "for", "PRO", "140", "have", "advanced", "further,", "we", "do", "not", "plan", "to", "devote", "any", "resources", "towards", "the", "development,", "research,", "testing,", "approval,", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline."], "wordsB": ["Our", "development", "efforts", "may", "compete", "with", "more", "established", "biotechnology", "companies", "that", "have", "significantly", "greater", "financial", "and", "managerial", "resources", "than", "we", "do."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s9", "idA": "1175680_14_item1_p14_s1", "sentA": "Until the clinical trials for PRO 140 have advanced further, we do not plan to devote any resources towards the development, research, testing, approval, or commercialization of Cytolin or CytoFeline.", "sentB": "All of these potential competitors have substantially greater capital resources, management expertise, research and development capabilities, manufacturing and marketing resources and experience than we do.", "type": 1, "words": ["<tag1>", "Until", "the", "clinical", "trials", "for", "PRO", "140", "have", "advanced", "further,", "we", "do", "not", "plan", "to", "devote", "any", "resources", "towards", "the", "development,", "research,", "testing,", "approval,", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline.", "<tag2>", "All", "of", "these", "potential", "competitors", "have", "substantially", "greater", "capital", "resources,", "management", "expertise,", "research", "and", "development", "capabilities,", "manufacturing", "and", "marketing", "resources", "and", "experience", "than", "we", "do.", "<tag3>"], "wordsA": ["Until", "the", "clinical", "trials", "for", "PRO", "140", "have", "advanced", "further,", "we", "do", "not", "plan", "to", "devote", "any", "resources", "towards", "the", "development,", "research,", "testing,", "approval,", "or", "commercialization", "of", "Cytolin", "or", "CytoFeline."], "wordsB": ["All", "of", "these", "potential", "competitors", "have", "substantially", "greater", "capital", "resources,", "management", "expertise,", "research", "and", "development", "capabilities,", "manufacturing", "and", "marketing", "resources", "and", "experience", "than", "we", "do."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p33_s0", "idA": "1175680_14_item1_p15_s2", "sentA": "The foregoing summary of the Progenics Agreement is qualified in its entirety by reference to the full terms of the Progenics Agreement, which is incorporated by reference as an exhibit to this report.", "sentB": "The FDA can ban certain biological products; detain or seize adulterated or misbranded biological products; order repair, replacement or refund of these products; and require notification of health professionals and others with regard to biological products that present unreasonable risks of substantial harm to the public health.", "type": 1, "words": ["<tag1>", "The", "foregoing", "summary", "of", "the", "Progenics", "Agreement", "is", "qualified", "in", "its", "entirety", "by", "reference", "to", "the", "full", "terms", "of", "the", "Progenics", "Agreement,", "which", "is", "incorporated", "by", "reference", "as", "an", "exhibit", "to", "this", "report.", "<tag2>", "The", "FDA", "can", "ban", "certain", "biological", "products;", "detain", "or", "seize", "adulterated", "or", "misbranded", "biological", "products;", "order", "repair,", "replacement", "or", "refund", "of", "these", "products;", "and", "require", "notification", "of", "health", "professionals", "and", "others", "with", "regard", "to", "biological", "products", "that", "present", "unreasonable", "risks", "of", "substantial", "harm", "to", "the", "public", "health.", "<tag3>"], "wordsA": ["The", "foregoing", "summary", "of", "the", "Progenics", "Agreement", "is", "qualified", "in", "its", "entirety", "by", "reference", "to", "the", "full", "terms", "of", "the", "Progenics", "Agreement,", "which", "is", "incorporated", "by", "reference", "as", "an", "exhibit", "to", "this", "report."], "wordsB": ["The", "FDA", "can", "ban", "certain", "biological", "products;", "detain", "or", "seize", "adulterated", "or", "misbranded", "biological", "products;", "order", "repair,", "replacement", "or", "refund", "of", "these", "products;", "and", "require", "notification", "of", "health", "professionals", "and", "others", "with", "regard", "to", "biological", "products", "that", "present", "unreasonable", "risks", "of", "substantial", "harm", "to", "the", "public", "health."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p35_s2", "idA": "1175680_14_item1_p15_s2", "sentA": "The foregoing summary of the Progenics Agreement is qualified in its entirety by reference to the full terms of the Progenics Agreement, which is incorporated by reference as an exhibit to this report.", "sentB": "State law and regulations also apply to the operation of clinical laboratories.", "type": 1, "words": ["<tag1>", "The", "foregoing", "summary", "of", "the", "Progenics", "Agreement", "is", "qualified", "in", "its", "entirety", "by", "reference", "to", "the", "full", "terms", "of", "the", "Progenics", "Agreement,", "which", "is", "incorporated", "by", "reference", "as", "an", "exhibit", "to", "this", "report.", "<tag2>", "State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories.", "<tag3>"], "wordsA": ["The", "foregoing", "summary", "of", "the", "Progenics", "Agreement", "is", "qualified", "in", "its", "entirety", "by", "reference", "to", "the", "full", "terms", "of", "the", "Progenics", "Agreement,", "which", "is", "incorporated", "by", "reference", "as", "an", "exhibit", "to", "this", "report."], "wordsB": ["State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s11", "idA": "1175680_14_item1_p16_s0", "sentA": "Payments to Progenics are in addition to payments due under a Development and License Agreement, dated April 30, 1999 (the PDL License ), between Protein Design Labs (now AbbVie Inc.) and Progenics, which was assigned to us in the PRO 140 transaction, pursuant to which we must pay additional milestone payments and royalties as follows: (i) $1,000,000 upon initiation of a Phase 3 clinical trial; (ii) $500,000 upon filing a Biologic License Application with the FDA or non-U.S. equivalent regulatory body; (iii) $500,000 upon FDA approval or approval by another non-U.S. equivalent regulatory body; and (iv) royalties of up to 7.5% of net sales for the longer of 10 years and the date of expiration of the last to expire licensed patent.", "sentB": "Phase 3 studies usually involve significantly larger groups of patients, and considerable additional expense.", "type": 1, "words": ["<tag1>", "Payments", "to", "Progenics", "are", "in", "addition", "to", "payments", "due", "under", "a", "Development", "and", "License", "Agreement,", "dated", "April", "30,", "1999", "(the", "PDL", "License", "),", "between", "Protein", "Design", "Labs", "(now", "AbbVie", "Inc.)", "and", "Progenics,", "which", "was", "assigned", "to", "us", "in", "the", "PRO", "140", "transaction,", "pursuant", "to", "which", "we", "must", "pay", "additional", "milestone", "payments", "and", "royalties", "as", "follows:", "(i)", "$1,000,000", "upon", "initiation", "of", "a", "Phase", "3", "clinical", "trial;", "(ii)", "$500,000", "upon", "filing", "a", "Biologic", "License", "Application", "with", "the", "FDA", "or", "non-U.S.", "equivalent", "regulatory", "body;", "(iii)", "$500,000", "upon", "FDA", "approval", "or", "approval", "by", "another", "non-U.S.", "equivalent", "regulatory", "body;", "and", "(iv)", "royalties", "of", "up", "to", "7.5%", "of", "net", "sales", "for", "the", "longer", "of", "10", "years", "and", "the", "date", "of", "expiration", "of", "the", "last", "to", "expire", "licensed", "patent.", "<tag2>", "Phase", "3", "studies", "usually", "involve", "significantly", "larger", "groups", "of", "patients,", "and", "considerable", "additional", "expense.", "<tag3>"], "wordsA": ["Payments", "to", "Progenics", "are", "in", "addition", "to", "payments", "due", "under", "a", "Development", "and", "License", "Agreement,", "dated", "April", "30,", "1999", "(the", "PDL", "License", "),", "between", "Protein", "Design", "Labs", "(now", "AbbVie", "Inc.)", "and", "Progenics,", "which", "was", "assigned", "to", "us", "in", "the", "PRO", "140", "transaction,", "pursuant", "to", "which", "we", "must", "pay", "additional", "milestone", "payments", "and", "royalties", "as", "follows:", "(i)", "$1,000,000", "upon", "initiation", "of", "a", "Phase", "3", "clinical", "trial;", "(ii)", "$500,000", "upon", "filing", "a", "Biologic", "License", "Application", "with", "the", "FDA", "or", "non-U.S.", "equivalent", "regulatory", "body;", "(iii)", "$500,000", "upon", "FDA", "approval", "or", "approval", "by", "another", "non-U.S.", "equivalent", "regulatory", "body;", "and", "(iv)", "royalties", "of", "up", "to", "7.5%", "of", "net", "sales", "for", "the", "longer", "of", "10", "years", "and", "the", "date", "of", "expiration", "of", "the", "last", "to", "expire", "licensed", "patent."], "wordsB": ["Phase", "3", "studies", "usually", "involve", "significantly", "larger", "groups", "of", "patients,", "and", "considerable", "additional", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p13_s2", "idA": "1175680_14_item1_p17_s1", "sentA": "CytoDyn will have access to all clinical trial data and the right to use such data.", "sentB": "The Company believes that upon successful completion of this Phase 3 study, CytoDyn will have the opportunity to seek accelerated approval for PRO 140 based on previously granted FDA fast-track candidate designation.", "type": 1, "words": ["<tag1>", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data.", "<tag2>", "The", "Company", "believes", "that", "upon", "successful", "completion", "of", "this", "Phase", "3", "study,", "CytoDyn", "will", "have", "the", "opportunity", "to", "seek", "accelerated", "approval", "for", "PRO", "140", "based", "on", "previously", "granted", "FDA", "fast-track", "candidate", "designation.", "<tag3>"], "wordsA": ["CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data."], "wordsB": ["The", "Company", "believes", "that", "upon", "successful", "completion", "of", "this", "Phase", "3", "study,", "CytoDyn", "will", "have", "the", "opportunity", "to", "seek", "accelerated", "approval", "for", "PRO", "140", "based", "on", "previously", "granted", "FDA", "fast-track", "candidate", "designation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p30_s1", "idA": "1175680_14_item1_p17_s1", "sentA": "CytoDyn will have access to all clinical trial data and the right to use such data.", "sentB": "For example, there are federal and state health care laws and regulations that apply to the operation of clinical laboratories, the business relationships between health care providers and suppliers, the privacy and security of health information and the conduct of clinical research.", "type": 1, "words": ["<tag1>", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data.", "<tag2>", "For", "example,", "there", "are", "federal", "and", "state", "health", "care", "laws", "and", "regulations", "that", "apply", "to", "the", "operation", "of", "clinical", "laboratories,", "the", "business", "relationships", "between", "health", "care", "providers", "and", "suppliers,", "the", "privacy", "and", "security", "of", "health", "information", "and", "the", "conduct", "of", "clinical", "research.", "<tag3>"], "wordsA": ["CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data."], "wordsB": ["For", "example,", "there", "are", "federal", "and", "state", "health", "care", "laws", "and", "regulations", "that", "apply", "to", "the", "operation", "of", "clinical", "laboratories,", "the", "business", "relationships", "between", "health", "care", "providers", "and", "suppliers,", "the", "privacy", "and", "security", "of", "health", "information", "and", "the", "conduct", "of", "clinical", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p34_s0", "idA": "1175680_14_item1_p17_s1", "sentA": "CytoDyn will have access to all clinical trial data and the right to use such data.", "sentB": "The lengthy process of seeking drug approvals, and the subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources.", "type": 1, "words": ["<tag1>", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data.", "<tag2>", "The", "lengthy", "process", "of", "seeking", "drug", "approvals,", "and", "the", "subsequent", "compliance", "with", "applicable", "statutes", "and", "regulations,", "require", "the", "expenditure", "of", "substantial", "resources.", "<tag3>"], "wordsA": ["CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data."], "wordsB": ["The", "lengthy", "process", "of", "seeking", "drug", "approvals,", "and", "the", "subsequent", "compliance", "with", "applicable", "statutes", "and", "regulations,", "require", "the", "expenditure", "of", "substantial", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p26_s0", "idA": "1175680_14_item1_p19_s0", "sentA": "Patents and Proprietary Technology Protection of our intellectual property rights is important to our business.", "sentB": "Patents and data exclusivity are different concepts, protect different subject matter, arise from different efforts, and have different legal effects over different time periods.", "type": 1, "words": ["<tag1>", "Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business.", "<tag2>", "Patents", "and", "data", "exclusivity", "are", "different", "concepts,", "protect", "different", "subject", "matter,", "arise", "from", "different", "efforts,", "and", "have", "different", "legal", "effects", "over", "different", "time", "periods.", "<tag3>"], "wordsA": ["Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business."], "wordsB": ["Patents", "and", "data", "exclusivity", "are", "different", "concepts,", "protect", "different", "subject", "matter,", "arise", "from", "different", "efforts,", "and", "have", "different", "legal", "effects", "over", "different", "time", "periods."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p31_s0", "idA": "1175680_14_item1_p19_s0", "sentA": "Patents and Proprietary Technology Protection of our intellectual property rights is important to our business.", "sentB": "Regulation of Products The design, testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of our products is regulated by numerous third parties, including the FDA, foreign governments, independent standards auditors and our customers.", "type": 1, "words": ["<tag1>", "Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business.", "<tag2>", "Regulation", "of", "Products", "The", "design,", "testing,", "manufacture,", "safety,", "effectiveness,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products", "is", "regulated", "by", "numerous", "third", "parties,", "including", "the", "FDA,", "foreign", "governments,", "independent", "standards", "auditors", "and", "our", "customers.", "<tag3>"], "wordsA": ["Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business."], "wordsB": ["Regulation", "of", "Products", "The", "design,", "testing,", "manufacture,", "safety,", "effectiveness,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products", "is", "regulated", "by", "numerous", "third", "parties,", "including", "the", "FDA,", "foreign", "governments,", "independent", "standards", "auditors", "and", "our", "customers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p45_s1", "idA": "1175680_14_item1_p19_s0", "sentA": "Patents and Proprietary Technology Protection of our intellectual property rights is important to our business.", "sentB": "All of our potential competitors have considerably greater financial and management resources than we possess.", "type": 1, "words": ["<tag1>", "Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business.", "<tag2>", "All", "of", "our", "potential", "competitors", "have", "considerably", "greater", "financial", "and", "management", "resources", "than", "we", "possess.", "<tag3>"], "wordsA": ["Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business."], "wordsB": ["All", "of", "our", "potential", "competitors", "have", "considerably", "greater", "financial", "and", "management", "resources", "than", "we", "possess."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p45_s2", "idA": "1175680_14_item1_p19_s0", "sentA": "Patents and Proprietary Technology Protection of our intellectual property rights is important to our business.", "sentB": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "type": 1, "words": ["<tag1>", "Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business.", "<tag2>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag3>"], "wordsA": ["Patents", "and", "Proprietary", "Technology", "Protection", "of", "our", "intellectual", "property", "rights", "is", "important", "to", "our", "business."], "wordsB": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s10", "idA": "1175680_14_item1_p19_s1", "sentA": "We may file patent applications in the U.S., Canada, and Japan, European countries that are party to the European Patent Convention and other countries on a selective basis in order to protect inventions we consider to be important to the development of our business.", "sentB": "Phase 3 studies also provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling.", "type": 1, "words": ["<tag1>", "We", "may", "file", "patent", "applications", "in", "the", "U.S.,", "Canada,", "and", "Japan,", "European", "countries", "that", "are", "party", "to", "the", "European", "Patent", "Convention", "and", "other", "countries", "on", "a", "selective", "basis", "in", "order", "to", "protect", "inventions", "we", "consider", "to", "be", "important", "to", "the", "development", "of", "our", "business.", "<tag2>", "Phase", "3", "studies", "also", "provide", "an", "adequate", "basis", "for", "extrapolating", "the", "results", "to", "the", "general", "population", "and", "transmitting", "that", "information", "in", "the", "physician", "labeling.", "<tag3>"], "wordsA": ["We", "may", "file", "patent", "applications", "in", "the", "U.S.,", "Canada,", "and", "Japan,", "European", "countries", "that", "are", "party", "to", "the", "European", "Patent", "Convention", "and", "other", "countries", "on", "a", "selective", "basis", "in", "order", "to", "protect", "inventions", "we", "consider", "to", "be", "important", "to", "the", "development", "of", "our", "business."], "wordsB": ["Phase", "3", "studies", "also", "provide", "an", "adequate", "basis", "for", "extrapolating", "the", "results", "to", "the", "general", "population", "and", "transmitting", "that", "information", "in", "the", "physician", "labeling."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p38_s0", "idA": "1175680_14_item1_p1_s1", "sentA": "Our lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors.", "sentB": "We are subject to a variety of federal, state and local environmental protection measures.", "type": 1, "words": ["<tag1>", "Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors.", "<tag2>", "We", "are", "subject", "to", "a", "variety", "of", "federal,", "state", "and", "local", "environmental", "protection", "measures.", "<tag3>"], "wordsA": ["Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors."], "wordsB": ["We", "are", "subject", "to", "a", "variety", "of", "federal,", "state", "and", "local", "environmental", "protection", "measures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p14_s2", "idA": "1175680_14_item1_p1_s4", "sentA": "PRO 140 We believe the PRO 140 antibody shows promise as a powerful anti-viral agent while not being a drug, which means fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.", "sentB": "Management believes the market size for a HAART therapy, which includes the PRO 140 antibody, along with other PRO 140 indications, could exceed a billion dollars.", "type": 1, "words": ["<tag1>", "PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use.", "<tag2>", "Management", "believes", "the", "market", "size", "for", "a", "HAART", "therapy,", "which", "includes", "the", "PRO", "140", "antibody,", "along", "with", "other", "PRO", "140", "indications,", "could", "exceed", "a", "billion", "dollars.", "<tag3>"], "wordsA": ["PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use."], "wordsB": ["Management", "believes", "the", "market", "size", "for", "a", "HAART", "therapy,", "which", "includes", "the", "PRO", "140", "antibody,", "along", "with", "other", "PRO", "140", "indications,", "could", "exceed", "a", "billion", "dollars."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p24_s1", "idA": "1175680_14_item1_p1_s4", "sentA": "PRO 140 We believe the PRO 140 antibody shows promise as a powerful anti-viral agent while not being a drug, which means fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.", "sentB": "We currently anticipate that, absent patent term extension, patent protection relating to the PRO 140 antibody itself will start to expire in 2023, certain methods of using PRO 140 will start to expire in 2026, and certain formulations comprising PRO 140 will start to expire in 2031.", "type": 1, "words": ["<tag1>", "PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use.", "<tag2>", "We", "currently", "anticipate", "that,", "absent", "patent", "term", "extension,", "patent", "protection", "relating", "to", "the", "PRO", "140", "antibody", "itself", "will", "start", "to", "expire", "in", "2023,", "certain", "methods", "of", "using", "PRO", "140", "will", "start", "to", "expire", "in", "2026,", "and", "certain", "formulations", "comprising", "PRO", "140", "will", "start", "to", "expire", "in", "2031.", "<tag3>"], "wordsA": ["PRO", "140", "We", "believe", "the", "PRO", "140", "antibody", "shows", "promise", "as", "a", "powerful", "anti-viral", "agent", "while", "not", "being", "a", "drug,", "which", "means", "fewer", "side", "effects", "and", "less", "frequent", "dosing", "requirements", "as", "compared", "to", "daily", "drug", "therapies", "currently", "in", "use."], "wordsB": ["We", "currently", "anticipate", "that,", "absent", "patent", "term", "extension,", "patent", "protection", "relating", "to", "the", "PRO", "140", "antibody", "itself", "will", "start", "to", "expire", "in", "2023,", "certain", "methods", "of", "using", "PRO", "140", "will", "start", "to", "expire", "in", "2026,", "and", "certain", "formulations", "comprising", "PRO", "140", "will", "start", "to", "expire", "in", "2031."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p12_s0", "idA": "1175680_14_item1_p20_s0", "sentA": "Generally, patents issued in the U.S. are effective for either (i) 20 years from the earliest asserted filing date, if the application was filed on or after June 8, 1995, or (ii) the longer of 17 years from the date of issue or 20 years from the earliest asserted filing date, if the application was filed prior to that date, subject to a five-year extension in certain instances.", "sentB": "As only HIV patients who have CCR5 virus exclusively can benefit from PRO 140, each patient is required to take a DNA Trofile test prior to enrollment in the study.", "type": 1, "words": ["<tag1>", "Generally,", "patents", "issued", "in", "the", "U.S.", "are", "effective", "for", "either", "(i)", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "on", "or", "after", "June", "8,", "1995,", "or", "(ii)", "the", "longer", "of", "17", "years", "from", "the", "date", "of", "issue", "or", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "prior", "to", "that", "date,", "subject", "to", "a", "five-year", "extension", "in", "certain", "instances.", "<tag2>", "As", "only", "HIV", "patients", "who", "have", "CCR5", "virus", "exclusively", "can", "benefit", "from", "PRO", "140,", "each", "patient", "is", "required", "to", "take", "a", "DNA", "Trofile", "test", "prior", "to", "enrollment", "in", "the", "study.", "<tag3>"], "wordsA": ["Generally,", "patents", "issued", "in", "the", "U.S.", "are", "effective", "for", "either", "(i)", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "on", "or", "after", "June", "8,", "1995,", "or", "(ii)", "the", "longer", "of", "17", "years", "from", "the", "date", "of", "issue", "or", "20", "years", "from", "the", "earliest", "asserted", "filing", "date,", "if", "the", "application", "was", "filed", "prior", "to", "that", "date,", "subject", "to", "a", "five-year", "extension", "in", "certain", "instances."], "wordsB": ["As", "only", "HIV", "patients", "who", "have", "CCR5", "virus", "exclusively", "can", "benefit", "from", "PRO", "140,", "each", "patient", "is", "required", "to", "take", "a", "DNA", "Trofile", "test", "prior", "to", "enrollment", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s7", "idA": "1175680_14_item1_p22_s0", "sentA": "We may also rely on trade secrets and proprietary know-how to develop and attempt to achieve a competitive position with our product candidates.", "sentB": "Our potential competitors include entities that develop and produce therapeutic agents.", "type": 1, "words": ["<tag1>", "We", "may", "also", "rely", "on", "trade", "secrets", "and", "proprietary", "know-how", "to", "develop", "and", "attempt", "to", "achieve", "a", "competitive", "position", "with", "our", "product", "candidates.", "<tag2>", "Our", "potential", "competitors", "include", "entities", "that", "develop", "and", "produce", "therapeutic", "agents.", "<tag3>"], "wordsA": ["We", "may", "also", "rely", "on", "trade", "secrets", "and", "proprietary", "know-how", "to", "develop", "and", "attempt", "to", "achieve", "a", "competitive", "position", "with", "our", "product", "candidates."], "wordsB": ["Our", "potential", "competitors", "include", "entities", "that", "develop", "and", "produce", "therapeutic", "agents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p12_s4", "idA": "1175680_14_item1_p22_s1", "sentA": "We generally require our employees, consultants and partners who have access to our proprietary information to sign confidentiality agreements in an effort to protect our intellectual property.", "sentB": "Furthermore, we believe if patients continue to remain on this monotherapy (as 14 patients are currently participating in an extension study, with some as long as eight months), then their viral load should only be tested periodically.", "type": 1, "words": ["<tag1>", "We", "generally", "require", "our", "employees,", "consultants", "and", "partners", "who", "have", "access", "to", "our", "proprietary", "information", "to", "sign", "confidentiality", "agreements", "in", "an", "effort", "to", "protect", "our", "intellectual", "property.", "<tag2>", "Furthermore,", "we", "believe", "if", "patients", "continue", "to", "remain", "on", "this", "monotherapy", "(as", "14", "patients", "are", "currently", "participating", "in", "an", "extension", "study,", "with", "some", "as", "long", "as", "eight", "months),", "then", "their", "viral", "load", "should", "only", "be", "tested", "periodically.", "<tag3>"], "wordsA": ["We", "generally", "require", "our", "employees,", "consultants", "and", "partners", "who", "have", "access", "to", "our", "proprietary", "information", "to", "sign", "confidentiality", "agreements", "in", "an", "effort", "to", "protect", "our", "intellectual", "property."], "wordsB": ["Furthermore,", "we", "believe", "if", "patients", "continue", "to", "remain", "on", "this", "monotherapy", "(as", "14", "patients", "are", "currently", "participating", "in", "an", "extension", "study,", "with", "some", "as", "long", "as", "eight", "months),", "then", "their", "viral", "load", "should", "only", "be", "tested", "periodically."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s10", "idA": "1175680_14_item1_p22_s2", "sentA": "Information with respect to our current patent portfolio is set forth below.", "sentB": "Our competitors may succeed in developing potential drugs or processes that are more effective or less costly than any that may be developed by us or that gain regulatory approval prior to our potential drug candidates.", "type": 1, "words": ["<tag1>", "Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below.", "<tag2>", "Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates.", "<tag3>"], "wordsA": ["Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below."], "wordsB": ["Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p46_s1", "idA": "1175680_14_item1_p22_s2", "sentA": "Information with respect to our current patent portfolio is set forth below.", "sentB": "We expect that research and development expenses will continue to be a significant expense as we seek to develop our current and future product pipeline.", "type": 1, "words": ["<tag1>", "Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below.", "<tag2>", "We", "expect", "that", "research", "and", "development", "expenses", "will", "continue", "to", "be", "a", "significant", "expense", "as", "we", "seek", "to", "develop", "our", "current", "and", "future", "product", "pipeline.", "<tag3>"], "wordsA": ["Information", "with", "respect", "to", "our", "current", "patent", "portfolio", "is", "set", "forth", "below."], "wordsB": ["We", "expect", "that", "research", "and", "development", "expenses", "will", "continue", "to", "be", "a", "significant", "expense", "as", "we", "seek", "to", "develop", "our", "current", "and", "future", "product", "pipeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p24_s0", "idA": "1175680_14_item1_p23_s0", "sentA": "(1) Patent term extensions and pending patent applications may extend periods of patent protection.", "sentB": "We pursue opportunities for seeking new meaningful patent protection on an ongoing basis.", "type": 1, "words": ["<tag1>", "(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection.", "<tag2>", "We", "pursue", "opportunities", "for", "seeking", "new", "meaningful", "patent", "protection", "on", "an", "ongoing", "basis.", "<tag3>"], "wordsA": ["(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection."], "wordsB": ["We", "pursue", "opportunities", "for", "seeking", "new", "meaningful", "patent", "protection", "on", "an", "ongoing", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p25_s8", "idA": "1175680_14_item1_p23_s0", "sentA": "(1) Patent term extensions and pending patent applications may extend periods of patent protection.", "sentB": "Similar data exclusivity or data protection periods of up to about 5-years or more are provided in at least Australia, Canada, Europe, Japan, and New Zealand.", "type": 1, "words": ["<tag1>", "(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection.", "<tag2>", "Similar", "data", "exclusivity", "or", "data", "protection", "periods", "of", "up", "to", "about", "5-years", "or", "more", "are", "provided", "in", "at", "least", "Australia,", "Canada,", "Europe,", "Japan,", "and", "New", "Zealand.", "<tag3>"], "wordsA": ["(1)", "Patent", "term", "extensions", "and", "pending", "patent", "applications", "may", "extend", "periods", "of", "patent", "protection."], "wordsB": ["Similar", "data", "exclusivity", "or", "data", "protection", "periods", "of", "up", "to", "about", "5-years", "or", "more", "are", "provided", "in", "at", "least", "Australia,", "Canada,", "Europe,", "Japan,", "and", "New", "Zealand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p45_s3", "idA": "1175680_14_item1_p24_s1", "sentA": "Preferred routes depend upon current and may be affected by subsequent discoveries and test results, availability of financial resources, and other factors, and cannot be identified with certainty.", "sentB": "Any of these competitors may be more successful than us in manufacturing, marketing and distributing HIV treatments.", "type": 1, "words": ["<tag1>", "Preferred", "routes", "depend", "upon", "current", "and", "may", "be", "affected", "by", "subsequent", "discoveries", "and", "test", "results,", "availability", "of", "financial", "resources,", "and", "other", "factors,", "and", "cannot", "be", "identified", "with", "certainty.", "<tag2>", "Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "HIV", "treatments.", "<tag3>"], "wordsA": ["Preferred", "routes", "depend", "upon", "current", "and", "may", "be", "affected", "by", "subsequent", "discoveries", "and", "test", "results,", "availability", "of", "financial", "resources,", "and", "other", "factors,", "and", "cannot", "be", "identified", "with", "certainty."], "wordsB": ["Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "HIV", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p36_s0", "idA": "1175680_14_item1_p24_s2", "sentA": "There are numerous third-party patents in fields in which we work, and we may need to obtain licenses under patents of others in order to pursue a preferred development route of one or more of our product candidates.", "sentB": "State Governments Most states in which we operate have regulations that parallel federal regulations.", "type": 1, "words": ["<tag1>", "There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates.", "<tag2>", "State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations.", "<tag3>"], "wordsA": ["There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates."], "wordsB": ["State", "Governments", "Most", "states", "in", "which", "we", "operate", "have", "regulations", "that", "parallel", "federal", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p15_s0", "idA": "1175680_14_item1_p2_s0", "sentA": "The PRO 140 antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.", "sentB": "CytoDyn believes that its PRO 140 antibody has compelling advantages over Maraviroc, the only other CCR5 antagonist for HIV therapy (Maraviroc is a pill taken orally twice a day.", "type": 1, "words": ["<tag1>", "The", "PRO", "140", "antibody", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors", "that", "block", "HIV", "from", "entering", "into", "and", "infecting", "certain", "cells.", "<tag2>", "CytoDyn", "believes", "that", "its", "PRO", "140", "antibody", "has", "compelling", "advantages", "over", "Maraviroc,", "the", "only", "other", "CCR5", "antagonist", "for", "HIV", "therapy", "(Maraviroc", "is", "a", "pill", "taken", "orally", "twice", "a", "day.", "<tag3>"], "wordsA": ["The", "PRO", "140", "antibody", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors", "that", "block", "HIV", "from", "entering", "into", "and", "infecting", "certain", "cells."], "wordsB": ["CytoDyn", "believes", "that", "its", "PRO", "140", "antibody", "has", "compelling", "advantages", "over", "Maraviroc,", "the", "only", "other", "CCR5", "antagonist", "for", "HIV", "therapy", "(Maraviroc", "is", "a", "pill", "taken", "orally", "twice", "a", "day."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p43_s2", "idA": "1175680_14_item1_p2_s1", "sentA": "PRO 140 blocks HIV from entering a cell by binding to a molecule called CCR5, a normal cell surface receptor protein to which HIV attaches as part of HIV s entry into a cell.", "sentB": "Another recent entry into the HIV treatment space is Truvada, an HIV drug produced by Gilead Sciences, Inc.", "type": 1, "words": ["<tag1>", "PRO", "140", "blocks", "HIV", "from", "entering", "a", "cell", "by", "binding", "to", "a", "molecule", "called", "CCR5,", "a", "normal", "cell", "surface", "receptor", "protein", "to", "which", "HIV", "attaches", "as", "part", "of", "HIV", "s", "entry", "into", "a", "cell.", "<tag2>", "Another", "recent", "entry", "into", "the", "HIV", "treatment", "space", "is", "Truvada,", "an", "HIV", "drug", "produced", "by", "Gilead", "Sciences,", "Inc.", "<tag3>"], "wordsA": ["PRO", "140", "blocks", "HIV", "from", "entering", "a", "cell", "by", "binding", "to", "a", "molecule", "called", "CCR5,", "a", "normal", "cell", "surface", "receptor", "protein", "to", "which", "HIV", "attaches", "as", "part", "of", "HIV", "s", "entry", "into", "a", "cell."], "wordsB": ["Another", "recent", "entry", "into", "the", "HIV", "treatment", "space", "is", "Truvada,", "an", "HIV", "drug", "produced", "by", "Gilead", "Sciences,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p25_s9", "idA": "1175680_14_item1_p3_s1", "sentA": "Moreover, these trials suggested that PRO 140 does not affect the normal function of the CCR5 receptor.", "sentB": "We note that data exclusivity is not an extension of patent rights, and it does not prevent the introduction of generic versions of the innovative drug during the data exclusivity period, as long as the marketing approval of the generic version does not use or rely upon the innovator s test data.", "type": 1, "words": ["<tag1>", "Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "receptor.", "<tag2>", "We", "note", "that", "data", "exclusivity", "is", "not", "an", "extension", "of", "patent", "rights,", "and", "it", "does", "not", "prevent", "the", "introduction", "of", "generic", "versions", "of", "the", "innovative", "drug", "during", "the", "data", "exclusivity", "period,", "as", "long", "as", "the", "marketing", "approval", "of", "the", "generic", "version", "does", "not", "use", "or", "rely", "upon", "the", "innovator", "s", "test", "data.", "<tag3>"], "wordsA": ["Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "receptor."], "wordsB": ["We", "note", "that", "data", "exclusivity", "is", "not", "an", "extension", "of", "patent", "rights,", "and", "it", "does", "not", "prevent", "the", "introduction", "of", "generic", "versions", "of", "the", "innovative", "drug", "during", "the", "data", "exclusivity", "period,", "as", "long", "as", "the", "marketing", "approval", "of", "the", "generic", "version", "does", "not", "use", "or", "rely", "upon", "the", "innovator", "s", "test", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p25_s7", "idA": "1175680_14_item1_p5_s6", "sentA": "In furtherance of our business strategy and subsequent to fiscal year-end 2014, the Company has entered into a manufacturing agreement with a contract manufacturing organization to initiate preparations for the potential future manufacturing of additional PRO 140.", "sentB": "Accordingly, this period of data exclusivity is expected to provide at least a 12-year term of protection against competing products shown to be biosimilar or interchangeable with PRO 140.", "type": 1, "words": ["<tag1>", "In", "furtherance", "of", "our", "business", "strategy", "and", "subsequent", "to", "fiscal", "year-end", "2014,", "the", "Company", "has", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "potential", "future", "manufacturing", "of", "additional", "PRO", "140.", "<tag2>", "Accordingly,", "this", "period", "of", "data", "exclusivity", "is", "expected", "to", "provide", "at", "least", "a", "12-year", "term", "of", "protection", "against", "competing", "products", "shown", "to", "be", "biosimilar", "or", "interchangeable", "with", "PRO", "140.", "<tag3>"], "wordsA": ["In", "furtherance", "of", "our", "business", "strategy", "and", "subsequent", "to", "fiscal", "year-end", "2014,", "the", "Company", "has", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "potential", "future", "manufacturing", "of", "additional", "PRO", "140."], "wordsB": ["Accordingly,", "this", "period", "of", "data", "exclusivity", "is", "expected", "to", "provide", "at", "least", "a", "12-year", "term", "of", "protection", "against", "competing", "products", "shown", "to", "be", "biosimilar", "or", "interchangeable", "with", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p45_s0", "idA": "1175680_14_item1_p5_s6", "sentA": "In furtherance of our business strategy and subsequent to fiscal year-end 2014, the Company has entered into a manufacturing agreement with a contract manufacturing organization to initiate preparations for the potential future manufacturing of additional PRO 140.", "sentB": "In seeking to manufacture, distribute and market the potential drugs we hope to have approved, we face competition from established pharmaceutical companies.", "type": 1, "words": ["<tag1>", "In", "furtherance", "of", "our", "business", "strategy", "and", "subsequent", "to", "fiscal", "year-end", "2014,", "the", "Company", "has", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "potential", "future", "manufacturing", "of", "additional", "PRO", "140.", "<tag2>", "In", "seeking", "to", "manufacture,", "distribute", "and", "market", "the", "potential", "drugs", "we", "hope", "to", "have", "approved,", "we", "face", "competition", "from", "established", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["In", "furtherance", "of", "our", "business", "strategy", "and", "subsequent", "to", "fiscal", "year-end", "2014,", "the", "Company", "has", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "potential", "future", "manufacturing", "of", "additional", "PRO", "140."], "wordsB": ["In", "seeking", "to", "manufacture,", "distribute", "and", "market", "the", "potential", "drugs", "we", "hope", "to", "have", "approved,", "we", "face", "competition", "from", "established", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p12_s1", "idA": "1175680_14_item1_p6_s1", "sentA": "We believe that, if PRO 140 is approved for use as an injectable by the FDA, it may nonetheless be an attractive and marketable therapeutic option (for patients with healthy CCR5), particularly in the following scenarios:", "sentB": "However, this test is not very accurate in patients with an undetectable viral load.", "type": 1, "words": ["<tag1>", "We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:", "<tag2>", "However,", "this", "test", "is", "not", "very", "accurate", "in", "patients", "with", "an", "undetectable", "viral", "load.", "<tag3>"], "wordsA": ["We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:"], "wordsB": ["However,", "this", "test", "is", "not", "very", "accurate", "in", "patients", "with", "an", "undetectable", "viral", "load."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p32_s1", "idA": "1175680_14_item1_p6_s1", "sentA": "We believe that, if PRO 140 is approved for use as an injectable by the FDA, it may nonetheless be an attractive and marketable therapeutic option (for patients with healthy CCR5), particularly in the following scenarios:", "sentB": "The exercise of broad regulatory powers by the FDA through its Center for Devices and Radiological Health and its Center for Biological Evaluation and Research continues to result in increases in the amounts of testing and documentation for FDA clearance of current and new biologic products.", "type": 1, "words": ["<tag1>", "We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:", "<tag2>", "The", "exercise", "of", "broad", "regulatory", "powers", "by", "the", "FDA", "through", "its", "Center", "for", "Devices", "and", "Radiological", "Health", "and", "its", "Center", "for", "Biological", "Evaluation", "and", "Research", "continues", "to", "result", "in", "increases", "in", "the", "amounts", "of", "testing", "and", "documentation", "for", "FDA", "clearance", "of", "current", "and", "new", "biologic", "products.", "<tag3>"], "wordsA": ["We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:"], "wordsB": ["The", "exercise", "of", "broad", "regulatory", "powers", "by", "the", "FDA", "through", "its", "Center", "for", "Devices", "and", "Radiological", "Health", "and", "its", "Center", "for", "Biological", "Evaluation", "and", "Research", "continues", "to", "result", "in", "increases", "in", "the", "amounts", "of", "testing", "and", "documentation", "for", "FDA", "clearance", "of", "current", "and", "new", "biologic", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p38_s1", "idA": "1175680_14_item1_p6_s1", "sentA": "We believe that, if PRO 140 is approved for use as an injectable by the FDA, it may nonetheless be an attractive and marketable therapeutic option (for patients with healthy CCR5), particularly in the following scenarios:", "sentB": "We believe that our operations comply in all material respects with applicable environmental laws and regulations.", "type": 1, "words": ["<tag1>", "We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:", "<tag2>", "We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["We", "believe", "that,", "if", "PRO", "140", "is", "approved", "for", "use", "as", "an", "injectable", "by", "the", "FDA,", "it", "may", "nonetheless", "be", "an", "attractive", "and", "marketable", "therapeutic", "option", "(for", "patients", "with", "healthy", "CCR5),", "particularly", "in", "the", "following", "scenarios:"], "wordsB": ["We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p34_s2", "idA": "1175680_14_item1_p8_s0", "sentA": "We believe PRO 140 has demonstrated potent (as compared to existing treatments) antiretroviral activity and an encouraging safety profile in prior clinical testing, that PRO 140 has the potential to be the first long-acting (weekly or every other week), self-administered HIV therapy, and that PRO 140 may inhibit CCR5-tropic HIV while preserving CCR5 s natural activity.", "sentB": "The FDA also has the authority to revoke previously granted product approvals.", "type": 1, "words": ["<tag1>", "We", "believe", "PRO", "140", "has", "demonstrated", "potent", "(as", "compared", "to", "existing", "treatments)", "antiretroviral", "activity", "and", "an", "encouraging", "safety", "profile", "in", "prior", "clinical", "testing,", "that", "PRO", "140", "has", "the", "potential", "to", "be", "the", "first", "long-acting", "(weekly", "or", "every", "other", "week),", "self-administered", "HIV", "therapy,", "and", "that", "PRO", "140", "may", "inhibit", "CCR5-tropic", "HIV", "while", "preserving", "CCR5", "s", "natural", "activity.", "<tag2>", "The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals.", "<tag3>"], "wordsA": ["We", "believe", "PRO", "140", "has", "demonstrated", "potent", "(as", "compared", "to", "existing", "treatments)", "antiretroviral", "activity", "and", "an", "encouraging", "safety", "profile", "in", "prior", "clinical", "testing,", "that", "PRO", "140", "has", "the", "potential", "to", "be", "the", "first", "long-acting", "(weekly", "or", "every", "other", "week),", "self-administered", "HIV", "therapy,", "and", "that", "PRO", "140", "may", "inhibit", "CCR5-tropic", "HIV", "while", "preserving", "CCR5", "s", "natural", "activity."], "wordsB": ["The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s13", "idA": "1175680_14_item1_p9_s0", "sentA": "Current Clinical Trials PRO 140 is currently being studied in three clinical trials.", "sentB": "See the discussion under the subheading PRO 140 Acquisition above.", "type": 1, "words": ["<tag1>", "Current", "Clinical", "Trials", "PRO", "140", "is", "currently", "being", "studied", "in", "three", "clinical", "trials.", "<tag2>", "See", "the", "discussion", "under", "the", "subheading", "PRO", "140", "Acquisition", "above.", "<tag3>"], "wordsA": ["Current", "Clinical", "Trials", "PRO", "140", "is", "currently", "being", "studied", "in", "three", "clinical", "trials."], "wordsB": ["See", "the", "discussion", "under", "the", "subheading", "PRO", "140", "Acquisition", "above."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_15_item1_p41_s3", "idA": "1175680_14_item1_p9_s2", "sentA": "These studies are funded directly through grants from NIH.", "sentB": "Phase 2 studies are typically well-controlled, closely monitored, and conducted in a relatively small number of patients, often involving several hundred people.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "funded", "directly", "through", "grants", "from", "NIH.", "<tag2>", "Phase", "2", "studies", "are", "typically", "well-controlled,", "closely", "monitored,", "and", "conducted", "in", "a", "relatively", "small", "number", "of", "patients,", "often", "involving", "several", "hundred", "people.", "<tag3>"], "wordsA": ["These", "studies", "are", "funded", "directly", "through", "grants", "from", "NIH."], "wordsB": ["Phase", "2", "studies", "are", "typically", "well-controlled,", "closely", "monitored,", "and", "conducted", "in", "a", "relatively", "small", "number", "of", "patients,", "often", "involving", "several", "hundred", "people."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p1_s3", "idA": "1175680_15_item1_p0_s0", "sentA": "CytoDyn Inc. is a Colorado corporation with its principal business office at 1111 Main Street, Suite 660, Vancouver, Washington 98660.", "sentB": "Unless the context otherwise requires, references in this prospectus to CytoDyn, the Company, we, our, or us are to CytoDyn Inc. and its subsidiaries.", "type": 1, "words": ["<tag1>", "CytoDyn", "Inc.", "is", "a", "Colorado", "corporation", "with", "its", "principal", "business", "office", "at", "1111", "Main", "Street,", "Suite", "660,", "Vancouver,", "Washington", "98660.", "<tag2>", "Unless", "the", "context", "otherwise", "requires,", "references", "in", "this", "prospectus", "to", "CytoDyn,", "the", "Company,", "we,", "our,", "or", "us", "are", "to", "CytoDyn", "Inc.", "and", "its", "subsidiaries.", "<tag3>"], "wordsA": ["CytoDyn", "Inc.", "is", "a", "Colorado", "corporation", "with", "its", "principal", "business", "office", "at", "1111", "Main", "Street,", "Suite", "660,", "Vancouver,", "Washington", "98660."], "wordsB": ["Unless", "the", "context", "otherwise", "requires,", "references", "in", "this", "prospectus", "to", "CytoDyn,", "the", "Company,", "we,", "our,", "or", "us", "are", "to", "CytoDyn", "Inc.", "and", "its", "subsidiaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p69_s2", "idA": "1175680_15_item1_p0_s4", "sentA": "Our lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors.", "sentB": "Each class of drugs has many drugs available in that class except the entry inhibitor (EI) class.", "type": 1, "words": ["<tag1>", "Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors.", "<tag2>", "Each", "class", "of", "drugs", "has", "many", "drugs", "available", "in", "that", "class", "except", "the", "entry", "inhibitor", "(EI)", "class.", "<tag3>"], "wordsA": ["Our", "lead", "product", "candidate,", "PRO", "140,", "belongs", "to", "a", "class", "of", "HIV", "therapies", "known", "as", "entry", "inhibitors."], "wordsB": ["Each", "class", "of", "drugs", "has", "many", "drugs", "available", "in", "that", "class", "except", "the", "entry", "inhibitor", "(EI)", "class."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p10_s0", "idA": "1175680_15_item1_p0_s6", "sentA": "Although CytoDyn intends to focus its efforts on PRO 140, we also hold certain rights in two proprietary platform technologies: Cytolin , a humanized monoclonal antibody targeting HIV with a mechanism of action which may prove to be synergistic to that of PRO 140 and other treatments, and CytoFeline , a felinized-monoclonal antibody targeting Feline Immunodeficiency Virus ( FIV ).", "sentB": "Because PRO 140 s mechanism of action (for a monoclonal antibody use in HIV) is a relatively new therapeutic approach, it provides a very useful method of suppressing the virus in treatment-experienced patients who have failed a prior HIV regimen and need new treatment options.", "type": 1, "words": ["<tag1>", "Although", "CytoDyn", "intends", "to", "focus", "its", "efforts", "on", "PRO", "140,", "we", "also", "hold", "certain", "rights", "in", "two", "proprietary", "platform", "technologies:", "Cytolin", ",", "a", "humanized", "monoclonal", "antibody", "targeting", "HIV", "with", "a", "mechanism", "of", "action", "which", "may", "prove", "to", "be", "synergistic", "to", "that", "of", "PRO", "140", "and", "other", "treatments,", "and", "CytoFeline", ",", "a", "felinized-monoclonal", "antibody", "targeting", "Feline", "Immunodeficiency", "Virus", "(", "FIV", ").", "<tag2>", "Because", "PRO", "140", "s", "mechanism", "of", "action", "(for", "a", "monoclonal", "antibody", "use", "in", "HIV)", "is", "a", "relatively", "new", "therapeutic", "approach,", "it", "provides", "a", "very", "useful", "method", "of", "suppressing", "the", "virus", "in", "treatment-experienced", "patients", "who", "have", "failed", "a", "prior", "HIV", "regimen", "and", "need", "new", "treatment", "options.", "<tag3>"], "wordsA": ["Although", "CytoDyn", "intends", "to", "focus", "its", "efforts", "on", "PRO", "140,", "we", "also", "hold", "certain", "rights", "in", "two", "proprietary", "platform", "technologies:", "Cytolin", ",", "a", "humanized", "monoclonal", "antibody", "targeting", "HIV", "with", "a", "mechanism", "of", "action", "which", "may", "prove", "to", "be", "synergistic", "to", "that", "of", "PRO", "140", "and", "other", "treatments,", "and", "CytoFeline", ",", "a", "felinized-monoclonal", "antibody", "targeting", "Feline", "Immunodeficiency", "Virus", "(", "FIV", ")."], "wordsB": ["Because", "PRO", "140", "s", "mechanism", "of", "action", "(for", "a", "monoclonal", "antibody", "use", "in", "HIV)", "is", "a", "relatively", "new", "therapeutic", "approach,", "it", "provides", "a", "very", "useful", "method", "of", "suppressing", "the", "virus", "in", "treatment-experienced", "patients", "who", "have", "failed", "a", "prior", "HIV", "regimen", "and", "need", "new", "treatment", "options."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p0_s1", "idA": "1175680_15_item1_p13_s0", "sentA": "On May 4, 2015, the Company announced that it has reached an agreement with the FDA on the Company s previously submitted Phase 3 protocol synopsis for PRO 140 and submitted the full Phase 3 protocol to the FDA.", "sentB": "Effective August 27, 2015, the Company completed a reincorporation from Colorado to Delaware.", "type": 1, "words": ["<tag1>", "On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA.", "<tag2>", "Effective", "August", "27,", "2015,", "the", "Company", "completed", "a", "reincorporation", "from", "Colorado", "to", "Delaware.", "<tag3>"], "wordsA": ["On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA."], "wordsB": ["Effective", "August", "27,", "2015,", "the", "Company", "completed", "a", "reincorporation", "from", "Colorado", "to", "Delaware."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p29_s0", "idA": "1175680_15_item1_p13_s0", "sentA": "On May 4, 2015, the Company announced that it has reached an agreement with the FDA on the Company s previously submitted Phase 3 protocol synopsis for PRO 140 and submitted the full Phase 3 protocol to the FDA.", "sentB": "Phase 2 Trial for Graft versus Host Disease In June 2015, we announced that Company-sponsored research data has expanded the potential clinical indications for PRO 140 to include certain inflammatory diseases, autoimmunity, transplantation and cancer.", "type": 1, "words": ["<tag1>", "On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA.", "<tag2>", "Phase", "2", "Trial", "for", "Graft", "versus", "Host", "Disease", "In", "June", "2015,", "we", "announced", "that", "Company-sponsored", "research", "data", "has", "expanded", "the", "potential", "clinical", "indications", "for", "PRO", "140", "to", "include", "certain", "inflammatory", "diseases,", "autoimmunity,", "transplantation", "and", "cancer.", "<tag3>"], "wordsA": ["On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA."], "wordsB": ["Phase", "2", "Trial", "for", "Graft", "versus", "Host", "Disease", "In", "June", "2015,", "we", "announced", "that", "Company-sponsored", "research", "data", "has", "expanded", "the", "potential", "clinical", "indications", "for", "PRO", "140", "to", "include", "certain", "inflammatory", "diseases,", "autoimmunity,", "transplantation", "and", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p36_s3", "idA": "1175680_15_item1_p13_s0", "sentA": "On May 4, 2015, the Company announced that it has reached an agreement with the FDA on the Company s previously submitted Phase 3 protocol synopsis for PRO 140 and submitted the full Phase 3 protocol to the FDA.", "sentB": "Using the foreign currency exchange rates at the time of payment, the Company s license fee payment approximated US$807,000.", "type": 1, "words": ["<tag1>", "On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA.", "<tag2>", "Using", "the", "foreign", "currency", "exchange", "rates", "at", "the", "time", "of", "payment,", "the", "Company", "s", "license", "fee", "payment", "approximated", "US$807,000.", "<tag3>"], "wordsA": ["On", "May", "4,", "2015,", "the", "Company", "announced", "that", "it", "has", "reached", "an", "agreement", "with", "the", "FDA", "on", "the", "Company", "s", "previously", "submitted", "Phase", "3", "protocol", "synopsis", "for", "PRO", "140", "and", "submitted", "the", "full", "Phase", "3", "protocol", "to", "the", "FDA."], "wordsB": ["Using", "the", "foreign", "currency", "exchange", "rates", "at", "the", "time", "of", "payment,", "the", "Company", "s", "license", "fee", "payment", "approximated", "US$807,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p32_s0", "idA": "1175680_15_item1_p13_s3", "sentA": "Additionally, the Company may apply for a breakthrough designation for PRO 140, as the first self-injectable antibody for HIV therapy.", "sentB": "The CCR5 receptor, the target for PRO 140, is an important mediator of GvHD, especially in the organ damage that is the usual cause of death.", "type": 1, "words": ["<tag1>", "Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy.", "<tag2>", "The", "CCR5", "receptor,", "the", "target", "for", "PRO", "140,", "is", "an", "important", "mediator", "of", "GvHD,", "especially", "in", "the", "organ", "damage", "that", "is", "the", "usual", "cause", "of", "death.", "<tag3>"], "wordsA": ["Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy."], "wordsB": ["The", "CCR5", "receptor,", "the", "target", "for", "PRO", "140,", "is", "an", "important", "mediator", "of", "GvHD,", "especially", "in", "the", "organ", "damage", "that", "is", "the", "usual", "cause", "of", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p33_s5", "idA": "1175680_15_item1_p13_s3", "sentA": "Additionally, the Company may apply for a breakthrough designation for PRO 140, as the first self-injectable antibody for HIV therapy.", "sentB": "On October 16, 2012, the Company paid to Progenics $3,500,000 in cash to close the transaction.", "type": 1, "words": ["<tag1>", "Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy.", "<tag2>", "On", "October", "16,", "2012,", "the", "Company", "paid", "to", "Progenics", "$3,500,000", "in", "cash", "to", "close", "the", "transaction.", "<tag3>"], "wordsA": ["Additionally,", "the", "Company", "may", "apply", "for", "a", "breakthrough", "designation", "for", "PRO", "140,", "as", "the", "first", "self-injectable", "antibody", "for", "HIV", "therapy."], "wordsB": ["On", "October", "16,", "2012,", "the", "Company", "paid", "to", "Progenics", "$3,500,000", "in", "cash", "to", "close", "the", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p18_s4", "idA": "1175680_15_item1_p13_s4", "sentA": "The Company announced on June 9, 2015, the FDA s approval of the Company s Phase 3 protocol for an additional indication for PRO 140 and expects to commence its first Phase 3 clinical trial in mid-2015.", "sentB": "The protocol for this trial provides for PRO 140 to be administered to HIV patients immediately upon their diagnosis of HIV and prior to waiting two weeks before receiving the results of their genotype test, which allows their physician to prescribe a specific HAART regimen.", "type": 1, "words": ["<tag1>", "The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015.", "<tag2>", "The", "protocol", "for", "this", "trial", "provides", "for", "PRO", "140", "to", "be", "administered", "to", "HIV", "patients", "immediately", "upon", "their", "diagnosis", "of", "HIV", "and", "prior", "to", "waiting", "two", "weeks", "before", "receiving", "the", "results", "of", "their", "genotype", "test,", "which", "allows", "their", "physician", "to", "prescribe", "a", "specific", "HAART", "regimen.", "<tag3>"], "wordsA": ["The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015."], "wordsB": ["The", "protocol", "for", "this", "trial", "provides", "for", "PRO", "140", "to", "be", "administered", "to", "HIV", "patients", "immediately", "upon", "their", "diagnosis", "of", "HIV", "and", "prior", "to", "waiting", "two", "weeks", "before", "receiving", "the", "results", "of", "their", "genotype", "test,", "which", "allows", "their", "physician", "to", "prescribe", "a", "specific", "HAART", "regimen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s10", "idA": "1175680_15_item1_p13_s4", "sentA": "The Company announced on June 9, 2015, the FDA s approval of the Company s Phase 3 protocol for an additional indication for PRO 140 and expects to commence its first Phase 3 clinical trial in mid-2015.", "sentB": "If and when those conditions have been met to the FDA s satisfaction, the FDA will typically issue an approval letter, which authorizes commercial marketing of the product with specific prescribing information for specific indications, and sometimes with specified post-marketing commitments.", "type": 1, "words": ["<tag1>", "The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015.", "<tag2>", "If", "and", "when", "those", "conditions", "have", "been", "met", "to", "the", "FDA", "s", "satisfaction,", "the", "FDA", "will", "typically", "issue", "an", "approval", "letter,", "which", "authorizes", "commercial", "marketing", "of", "the", "product", "with", "specific", "prescribing", "information", "for", "specific", "indications,", "and", "sometimes", "with", "specified", "post-marketing", "commitments.", "<tag3>"], "wordsA": ["The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015."], "wordsB": ["If", "and", "when", "those", "conditions", "have", "been", "met", "to", "the", "FDA", "s", "satisfaction,", "the", "FDA", "will", "typically", "issue", "an", "approval", "letter,", "which", "authorizes", "commercial", "marketing", "of", "the", "product", "with", "specific", "prescribing", "information", "for", "specific", "indications,", "and", "sometimes", "with", "specified", "post-marketing", "commitments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s7", "idA": "1175680_15_item1_p13_s4", "sentA": "The Company announced on June 9, 2015, the FDA s approval of the Company s Phase 3 protocol for an additional indication for PRO 140 and expects to commence its first Phase 3 clinical trial in mid-2015.", "sentB": "The results of the pre-clinical and clinical testing, chemistry, manufacturing and control information and proposed labeling are then submitted to the FDA in the form of either an NDA or BLA for review and potential approval to commence commercial sales.", "type": 1, "words": ["<tag1>", "The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015.", "<tag2>", "The", "results", "of", "the", "pre-clinical", "and", "clinical", "testing,", "chemistry,", "manufacturing", "and", "control", "information", "and", "proposed", "labeling", "are", "then", "submitted", "to", "the", "FDA", "in", "the", "form", "of", "either", "an", "NDA", "or", "BLA", "for", "review", "and", "potential", "approval", "to", "commence", "commercial", "sales.", "<tag3>"], "wordsA": ["The", "Company", "announced", "on", "June", "9,", "2015,", "the", "FDA", "s", "approval", "of", "the", "Company", "s", "Phase", "3", "protocol", "for", "an", "additional", "indication", "for", "PRO", "140", "and", "expects", "to", "commence", "its", "first", "Phase", "3", "clinical", "trial", "in", "mid-2015."], "wordsB": ["The", "results", "of", "the", "pre-clinical", "and", "clinical", "testing,", "chemistry,", "manufacturing", "and", "control", "information", "and", "proposed", "labeling", "are", "then", "submitted", "to", "the", "FDA", "in", "the", "form", "of", "either", "an", "NDA", "or", "BLA", "for", "review", "and", "potential", "approval", "to", "commence", "commercial", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p22_s1", "idA": "1175680_15_item1_p13_s5", "sentA": "The Company also plans to request a meeting with the FDA to discuss potential additional indications for HIV therapy following the submission of the top-line report of the recently completed Phase 2b treatment substitution study.", "sentB": "The objectives and endpoint definitions are the same for the Phase 2b extension study, as they were for the initial Phase 2b treatment substitution trial, except that patients in the extension study were trained for weekly self-injection to be administered at home, and their viral load was monitored initially on a bi-weekly basis and then on a monthly basis later in the study.", "type": 1, "words": ["<tag1>", "The", "Company", "also", "plans", "to", "request", "a", "meeting", "with", "the", "FDA", "to", "discuss", "potential", "additional", "indications", "for", "HIV", "therapy", "following", "the", "submission", "of", "the", "top-line", "report", "of", "the", "recently", "completed", "Phase", "2b", "treatment", "substitution", "study.", "<tag2>", "The", "objectives", "and", "endpoint", "definitions", "are", "the", "same", "for", "the", "Phase", "2b", "extension", "study,", "as", "they", "were", "for", "the", "initial", "Phase", "2b", "treatment", "substitution", "trial,", "except", "that", "patients", "in", "the", "extension", "study", "were", "trained", "for", "weekly", "self-injection", "to", "be", "administered", "at", "home,", "and", "their", "viral", "load", "was", "monitored", "initially", "on", "a", "bi-weekly", "basis", "and", "then", "on", "a", "monthly", "basis", "later", "in", "the", "study.", "<tag3>"], "wordsA": ["The", "Company", "also", "plans", "to", "request", "a", "meeting", "with", "the", "FDA", "to", "discuss", "potential", "additional", "indications", "for", "HIV", "therapy", "following", "the", "submission", "of", "the", "top-line", "report", "of", "the", "recently", "completed", "Phase", "2b", "treatment", "substitution", "study."], "wordsB": ["The", "objectives", "and", "endpoint", "definitions", "are", "the", "same", "for", "the", "Phase", "2b", "extension", "study,", "as", "they", "were", "for", "the", "initial", "Phase", "2b", "treatment", "substitution", "trial,", "except", "that", "patients", "in", "the", "extension", "study", "were", "trained", "for", "weekly", "self-injection", "to", "be", "administered", "at", "home,", "and", "their", "viral", "load", "was", "monitored", "initially", "on", "a", "bi-weekly", "basis", "and", "then", "on", "a", "monthly", "basis", "later", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s2", "idA": "1175680_15_item1_p13_s5", "sentA": "The Company also plans to request a meeting with the FDA to discuss potential additional indications for HIV therapy following the submission of the top-line report of the recently completed Phase 2b treatment substitution study.", "sentB": "If the FDA has comments or questions, they must be resolved to the satisfaction of the FDA before clinical trials can begin.", "type": 1, "words": ["<tag1>", "The", "Company", "also", "plans", "to", "request", "a", "meeting", "with", "the", "FDA", "to", "discuss", "potential", "additional", "indications", "for", "HIV", "therapy", "following", "the", "submission", "of", "the", "top-line", "report", "of", "the", "recently", "completed", "Phase", "2b", "treatment", "substitution", "study.", "<tag2>", "If", "the", "FDA", "has", "comments", "or", "questions,", "they", "must", "be", "resolved", "to", "the", "satisfaction", "of", "the", "FDA", "before", "clinical", "trials", "can", "begin.", "<tag3>"], "wordsA": ["The", "Company", "also", "plans", "to", "request", "a", "meeting", "with", "the", "FDA", "to", "discuss", "potential", "additional", "indications", "for", "HIV", "therapy", "following", "the", "submission", "of", "the", "top-line", "report", "of", "the", "recently", "completed", "Phase", "2b", "treatment", "substitution", "study."], "wordsB": ["If", "the", "FDA", "has", "comments", "or", "questions,", "they", "must", "be", "resolved", "to", "the", "satisfaction", "of", "the", "FDA", "before", "clinical", "trials", "can", "begin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s5", "idA": "1175680_15_item1_p14_s0", "sentA": "The Company s first Phase 3 study is designed to allow PRO 140 as a component of a HAART regimen for treatment experienced patients.", "sentB": "Our non-clinical and clinical studies must conform to the FDA s Good Laboratory Practice, or GLP, and Good Clinical Practice, or GCP, requirements, which are designed to ensure the quality and integrity of submitted data and protect the rights and well-being of study patients.", "type": 1, "words": ["<tag1>", "The", "Company", "s", "first", "Phase", "3", "study", "is", "designed", "to", "allow", "PRO", "140", "as", "a", "component", "of", "a", "HAART", "regimen", "for", "treatment", "experienced", "patients.", "<tag2>", "Our", "non-clinical", "and", "clinical", "studies", "must", "conform", "to", "the", "FDA", "s", "Good", "Laboratory", "Practice,", "or", "GLP,", "and", "Good", "Clinical", "Practice,", "or", "GCP,", "requirements,", "which", "are", "designed", "to", "ensure", "the", "quality", "and", "integrity", "of", "submitted", "data", "and", "protect", "the", "rights", "and", "well-being", "of", "study", "patients.", "<tag3>"], "wordsA": ["The", "Company", "s", "first", "Phase", "3", "study", "is", "designed", "to", "allow", "PRO", "140", "as", "a", "component", "of", "a", "HAART", "regimen", "for", "treatment", "experienced", "patients."], "wordsB": ["Our", "non-clinical", "and", "clinical", "studies", "must", "conform", "to", "the", "FDA", "s", "Good", "Laboratory", "Practice,", "or", "GLP,", "and", "Good", "Clinical", "Practice,", "or", "GCP,", "requirements,", "which", "are", "designed", "to", "ensure", "the", "quality", "and", "integrity", "of", "submitted", "data", "and", "protect", "the", "rights", "and", "well-being", "of", "study", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p69_s5", "idA": "1175680_15_item1_p15_s0", "sentA": "CytoDyn believes that its PRO 140 antibody has compelling advantages over Maraviroc, the only other CCR5 antagonist for HIV therapy (Maraviroc is a pill taken orally twice a day.", "sentB": "The only other monoclonal antibody in clinical development for HIV that we are aware of is TMB-335 referred to as ibalizumab being developed by TiaMed Biologics.", "type": 1, "words": ["<tag1>", "CytoDyn", "believes", "that", "its", "PRO", "140", "antibody", "has", "compelling", "advantages", "over", "Maraviroc,", "the", "only", "other", "CCR5", "antagonist", "for", "HIV", "therapy", "(Maraviroc", "is", "a", "pill", "taken", "orally", "twice", "a", "day.", "<tag2>", "The", "only", "other", "monoclonal", "antibody", "in", "clinical", "development", "for", "HIV", "that", "we", "are", "aware", "of", "is", "TMB-335", "referred", "to", "as", "ibalizumab", "being", "developed", "by", "TiaMed", "Biologics.", "<tag3>"], "wordsA": ["CytoDyn", "believes", "that", "its", "PRO", "140", "antibody", "has", "compelling", "advantages", "over", "Maraviroc,", "the", "only", "other", "CCR5", "antagonist", "for", "HIV", "therapy", "(Maraviroc", "is", "a", "pill", "taken", "orally", "twice", "a", "day."], "wordsB": ["The", "only", "other", "monoclonal", "antibody", "in", "clinical", "development", "for", "HIV", "that", "we", "are", "aware", "of", "is", "TMB-335", "referred", "to", "as", "ibalizumab", "being", "developed", "by", "TiaMed", "Biologics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p36_s4", "idA": "1175680_15_item1_p15_s1", "sentA": "PRO 140 is currently being tested as a once-a-week subcutaneous injection of 350mg dose).", "sentB": "Future annual license fees and royalty rate will vary depending on whether we manufacture PRO 140 ourselves, utilize the third-party licensor as a contract manufacturer, or utilize an independent party as a contract manufacturer.", "type": 1, "words": ["<tag1>", "PRO", "140", "is", "currently", "being", "tested", "as", "a", "once-a-week", "subcutaneous", "injection", "of", "350mg", "dose).", "<tag2>", "Future", "annual", "license", "fees", "and", "royalty", "rate", "will", "vary", "depending", "on", "whether", "we", "manufacture", "PRO", "140", "ourselves,", "utilize", "the", "third-party", "licensor", "as", "a", "contract", "manufacturer,", "or", "utilize", "an", "independent", "party", "as", "a", "contract", "manufacturer.", "<tag3>"], "wordsA": ["PRO", "140", "is", "currently", "being", "tested", "as", "a", "once-a-week", "subcutaneous", "injection", "of", "350mg", "dose)."], "wordsB": ["Future", "annual", "license", "fees", "and", "royalty", "rate", "will", "vary", "depending", "on", "whether", "we", "manufacture", "PRO", "140", "ourselves,", "utilize", "the", "third-party", "licensor", "as", "a", "contract", "manufacturer,", "or", "utilize", "an", "independent", "party", "as", "a", "contract", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p36_s6", "idA": "1175680_15_item1_p15_s1", "sentA": "PRO 140 is currently being tested as a once-a-week subcutaneous injection of 350mg dose).", "sentB": "However, we currently use an independent party as a contract manufacturer.", "type": 1, "words": ["<tag1>", "PRO", "140", "is", "currently", "being", "tested", "as", "a", "once-a-week", "subcutaneous", "injection", "of", "350mg", "dose).", "<tag2>", "However,", "we", "currently", "use", "an", "independent", "party", "as", "a", "contract", "manufacturer.", "<tag3>"], "wordsA": ["PRO", "140", "is", "currently", "being", "tested", "as", "a", "once-a-week", "subcutaneous", "injection", "of", "350mg", "dose)."], "wordsB": ["However,", "we", "currently", "use", "an", "independent", "party", "as", "a", "contract", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p69_s7", "idA": "1175680_15_item1_p16_s2", "sentA": "This patent is for a murine (mouse) version of the drug.", "sentB": "However, CD4 is the T-cell receptor for recognizing targets of the immune response and critical for immunologic responses.", "type": 1, "words": ["<tag1>", "This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug.", "<tag2>", "However,", "CD4", "is", "the", "T-cell", "receptor", "for", "recognizing", "targets", "of", "the", "immune", "response", "and", "critical", "for", "immunologic", "responses.", "<tag3>"], "wordsA": ["This", "patent", "is", "for", "a", "murine", "(mouse)", "version", "of", "the", "drug."], "wordsB": ["However,", "CD4", "is", "the", "T-cell", "receptor", "for", "recognizing", "targets", "of", "the", "immune", "response", "and", "critical", "for", "immunologic", "responses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p36_s1", "idA": "1175680_15_item1_p17_s2", "sentA": "We now refer to Cytolin as the humanized version of the old Cytolin, which was the murine monoclonal antibody.", "sentB": "The Lonza Agreement required payment of 600,000 (approximately US$915,000) by December 15, 2015, which was timely paid.", "type": 1, "words": ["<tag1>", "We", "now", "refer", "to", "Cytolin", "as", "the", "humanized", "version", "of", "the", "old", "Cytolin,", "which", "was", "the", "murine", "monoclonal", "antibody.", "<tag2>", "The", "Lonza", "Agreement", "required", "payment", "of", "600,000", "(approximately", "US$915,000)", "by", "December", "15,", "2015,", "which", "was", "timely", "paid.", "<tag3>"], "wordsA": ["We", "now", "refer", "to", "Cytolin", "as", "the", "humanized", "version", "of", "the", "old", "Cytolin,", "which", "was", "the", "murine", "monoclonal", "antibody."], "wordsB": ["The", "Lonza", "Agreement", "required", "payment", "of", "600,000", "(approximately", "US$915,000)", "by", "December", "15,", "2015,", "which", "was", "timely", "paid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p72_s3", "idA": "1175680_15_item1_p18_s3", "sentA": "This international patent application has since entered European regional and U.S. and Canadian national stage examinations.", "sentB": "We have developed and validated a current good manufacturing practice ( cGMP ) process to manufacture PRO 140, through a single contract manufacturer, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.", "type": 1, "words": ["<tag1>", "This", "international", "patent", "application", "has", "since", "entered", "European", "regional", "and", "U.S.", "and", "Canadian", "national", "stage", "examinations.", "<tag2>", "We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc.", "<tag3>"], "wordsA": ["This", "international", "patent", "application", "has", "since", "entered", "European", "regional", "and", "U.S.", "and", "Canadian", "national", "stage", "examinations."], "wordsB": ["We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p54_s4", "idA": "1175680_15_item1_p20_s0", "sentA": "PRO 140 Acquisition We acquired PRO 140, as well as certain other related assets, including the existing inventory of PRO 140 bulk drug substance, intellectual property, and FDA regulatory filings, pursuant to an Asset Purchase Agreement, dated as of July 25, 2012 (the Progenics Agreement ), between CytoDyn and Progenics.", "sentB": "Newly discovered or developed safety or efficacy data may require changes to an approved product s approved labeling, including the addition of new warnings and contraindications, the imposition of additional mandatory post-market studies or clinical trials, or the imposition of or revisions to a REMS program, including distribution and/or use restrictions.", "type": 1, "words": ["<tag1>", "PRO", "140", "Acquisition", "We", "acquired", "PRO", "140,", "as", "well", "as", "certain", "other", "related", "assets,", "including", "the", "existing", "inventory", "of", "PRO", "140", "bulk", "drug", "substance,", "intellectual", "property,", "and", "FDA", "regulatory", "filings,", "pursuant", "to", "an", "Asset", "Purchase", "Agreement,", "dated", "as", "of", "July", "25,", "2012", "(the", "Progenics", "Agreement", "),", "between", "CytoDyn", "and", "Progenics.", "<tag2>", "Newly", "discovered", "or", "developed", "safety", "or", "efficacy", "data", "may", "require", "changes", "to", "an", "approved", "product", "s", "approved", "labeling,", "including", "the", "addition", "of", "new", "warnings", "and", "contraindications,", "the", "imposition", "of", "additional", "mandatory", "post-market", "studies", "or", "clinical", "trials,", "or", "the", "imposition", "of", "or", "revisions", "to", "a", "REMS", "program,", "including", "distribution", "and/or", "use", "restrictions.", "<tag3>"], "wordsA": ["PRO", "140", "Acquisition", "We", "acquired", "PRO", "140,", "as", "well", "as", "certain", "other", "related", "assets,", "including", "the", "existing", "inventory", "of", "PRO", "140", "bulk", "drug", "substance,", "intellectual", "property,", "and", "FDA", "regulatory", "filings,", "pursuant", "to", "an", "Asset", "Purchase", "Agreement,", "dated", "as", "of", "July", "25,", "2012", "(the", "Progenics", "Agreement", "),", "between", "CytoDyn", "and", "Progenics."], "wordsB": ["Newly", "discovered", "or", "developed", "safety", "or", "efficacy", "data", "may", "require", "changes", "to", "an", "approved", "product", "s", "approved", "labeling,", "including", "the", "addition", "of", "new", "warnings", "and", "contraindications,", "the", "imposition", "of", "additional", "mandatory", "post-market", "studies", "or", "clinical", "trials,", "or", "the", "imposition", "of", "or", "revisions", "to", "a", "REMS", "program,", "including", "distribution", "and/or", "use", "restrictions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p33_s8", "idA": "1175680_15_item1_p20_s1", "sentA": "The terms of the Progenics Agreement provided for an initial cash payment of $3,500,000, which was paid at closing in October 2012, as well as the following milestone payments and royalties to be paid to Progenics in the future: (i) $1,500,000 at the time of the first dosing in a U.S. Phase 3 trial or non-US equivalent; (ii) $5,000,000 at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of PRO 140; and (iii) royalty payments of 5% of net sales during the period beginning on the date of the first commercial sale of PRO 140 until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years following the first commercialization sale of PRO 140, in each case determined on a country-by-country basis.", "sentB": "To the extent that such milestone payments and royalties are not timely made, under the terms of the Progenics Purchase Agreement, Progenics has certain repurchase rights relating to the assets sold to the Company thereunder.", "type": 1, "words": ["<tag1>", "The", "terms", "of", "the", "Progenics", "Agreement", "provided", "for", "an", "initial", "cash", "payment", "of", "$3,500,000,", "which", "was", "paid", "at", "closing", "in", "October", "2012,", "as", "well", "as", "the", "following", "milestone", "payments", "and", "royalties", "to", "be", "paid", "to", "Progenics", "in", "the", "future:", "(i)", "$1,500,000", "at", "the", "time", "of", "the", "first", "dosing", "in", "a", "U.S.", "Phase", "3", "trial", "or", "non-US", "equivalent;", "(ii)", "$5,000,000", "at", "the", "time", "of", "the", "first", "U.S.", "new", "drug", "application", "approval", "by", "the", "FDA", "or", "other", "non-U.S.", "approval", "for", "the", "sale", "of", "PRO", "140;", "and", "(iii)", "royalty", "payments", "of", "5%", "of", "net", "sales", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "included", "in", "the", "acquired", "assets,", "and", "(b)", "10", "years", "following", "the", "first", "commercialization", "sale", "of", "PRO", "140,", "in", "each", "case", "determined", "on", "a", "country-by-country", "basis.", "<tag2>", "To", "the", "extent", "that", "such", "milestone", "payments", "and", "royalties", "are", "not", "timely", "made,", "under", "the", "terms", "of", "the", "Progenics", "Purchase", "Agreement,", "Progenics", "has", "certain", "repurchase", "rights", "relating", "to", "the", "assets", "sold", "to", "the", "Company", "thereunder.", "<tag3>"], "wordsA": ["The", "terms", "of", "the", "Progenics", "Agreement", "provided", "for", "an", "initial", "cash", "payment", "of", "$3,500,000,", "which", "was", "paid", "at", "closing", "in", "October", "2012,", "as", "well", "as", "the", "following", "milestone", "payments", "and", "royalties", "to", "be", "paid", "to", "Progenics", "in", "the", "future:", "(i)", "$1,500,000", "at", "the", "time", "of", "the", "first", "dosing", "in", "a", "U.S.", "Phase", "3", "trial", "or", "non-US", "equivalent;", "(ii)", "$5,000,000", "at", "the", "time", "of", "the", "first", "U.S.", "new", "drug", "application", "approval", "by", "the", "FDA", "or", "other", "non-U.S.", "approval", "for", "the", "sale", "of", "PRO", "140;", "and", "(iii)", "royalty", "payments", "of", "5%", "of", "net", "sales", "during", "the", "period", "beginning", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "PRO", "140", "until", "the", "later", "of", "(a)", "the", "expiration", "of", "the", "last", "to", "expire", "patent", "included", "in", "the", "acquired", "assets,", "and", "(b)", "10", "years", "following", "the", "first", "commercialization", "sale", "of", "PRO", "140,", "in", "each", "case", "determined", "on", "a", "country-by-country", "basis."], "wordsB": ["To", "the", "extent", "that", "such", "milestone", "payments", "and", "royalties", "are", "not", "timely", "made,", "under", "the", "terms", "of", "the", "Progenics", "Purchase", "Agreement,", "Progenics", "has", "certain", "repurchase", "rights", "relating", "to", "the", "assets", "sold", "to", "the", "Company", "thereunder."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p21_s3", "idA": "1175680_15_item1_p20_s4", "sentA": "As of the date of this filing, management has reasonably estimated the likelihood of paying the first milestone payments, as probable, and accordingly, as of May 31, 2015, the Company has accrued $2,500,000 for the initial milestone associated with the first dosing in a Phase 3 trial.", "sentB": "The success of this initial monotherapy trial served as the foundation for the ongoing extension study described below.", "type": 1, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "filing,", "management", "has", "reasonably", "estimated", "the", "likelihood", "of", "paying", "the", "first", "milestone", "payments,", "as", "probable,", "and", "accordingly,", "as", "of", "May", "31,", "2015,", "the", "Company", "has", "accrued", "$2,500,000", "for", "the", "initial", "milestone", "associated", "with", "the", "first", "dosing", "in", "a", "Phase", "3", "trial.", "<tag2>", "The", "success", "of", "this", "initial", "monotherapy", "trial", "served", "as", "the", "foundation", "for", "the", "ongoing", "extension", "study", "described", "below.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "filing,", "management", "has", "reasonably", "estimated", "the", "likelihood", "of", "paying", "the", "first", "milestone", "payments,", "as", "probable,", "and", "accordingly,", "as", "of", "May", "31,", "2015,", "the", "Company", "has", "accrued", "$2,500,000", "for", "the", "initial", "milestone", "associated", "with", "the", "first", "dosing", "in", "a", "Phase", "3", "trial."], "wordsB": ["The", "success", "of", "this", "initial", "monotherapy", "trial", "served", "as", "the", "foundation", "for", "the", "ongoing", "extension", "study", "described", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p54_s1", "idA": "1175680_15_item1_p21_s1", "sentA": "CytoDyn will have access to all clinical trial data and the right to use such data.", "sentB": "We use and plan to continue to use third-party manufacturers to produce our products in clinical and commercial quantities.", "type": 1, "words": ["<tag1>", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data.", "<tag2>", "We", "use", "and", "plan", "to", "continue", "to", "use", "third-party", "manufacturers", "to", "produce", "our", "products", "in", "clinical", "and", "commercial", "quantities.", "<tag3>"], "wordsA": ["CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data."], "wordsB": ["We", "use", "and", "plan", "to", "continue", "to", "use", "third-party", "manufacturers", "to", "produce", "our", "products", "in", "clinical", "and", "commercial", "quantities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p72_s2", "idA": "1175680_15_item1_p21_s1", "sentA": "CytoDyn will have access to all clinical trial data and the right to use such data.", "sentB": "We continue to explore alternative manufacturing sources, in order to ensure that we have access to sufficient manufacturing capacity in order to meet potential demand for PRO 140 in a cost-efficient manner.", "type": 1, "words": ["<tag1>", "CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data.", "<tag2>", "We", "continue", "to", "explore", "alternative", "manufacturing", "sources,", "in", "order", "to", "ensure", "that", "we", "have", "access", "to", "sufficient", "manufacturing", "capacity", "in", "order", "to", "meet", "potential", "demand", "for", "PRO", "140", "in", "a", "cost-efficient", "manner.", "<tag3>"], "wordsA": ["CytoDyn", "will", "have", "access", "to", "all", "clinical", "trial", "data", "and", "the", "right", "to", "use", "such", "data."], "wordsB": ["We", "continue", "to", "explore", "alternative", "manufacturing", "sources,", "in", "order", "to", "ensure", "that", "we", "have", "access", "to", "sufficient", "manufacturing", "capacity", "in", "order", "to", "meet", "potential", "demand", "for", "PRO", "140", "in", "a", "cost-efficient", "manner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p0_s0", "idA": "1175680_15_item1_p25_s2", "sentA": "See related risk factors under the heading Risk Factors above.", "sentB": "CytoDyn Inc. (the Company ) was originally incorporated under the laws of Colorado on May 2, 2002 under the name RexRay Corporation (its previous name).", "type": 1, "words": ["<tag1>", "See", "related", "risk", "factors", "under", "the", "heading", "Risk", "Factors", "above.", "<tag2>", "CytoDyn", "Inc.", "(the", "Company", ")", "was", "originally", "incorporated", "under", "the", "laws", "of", "Colorado", "on", "May", "2,", "2002", "under", "the", "name", "RexRay", "Corporation", "(its", "previous", "name).", "<tag3>"], "wordsA": ["See", "related", "risk", "factors", "under", "the", "heading", "Risk", "Factors", "above."], "wordsB": ["CytoDyn", "Inc.", "(the", "Company", ")", "was", "originally", "incorporated", "under", "the", "laws", "of", "Colorado", "on", "May", "2,", "2002", "under", "the", "name", "RexRay", "Corporation", "(its", "previous", "name)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p55_s0", "idA": "1175680_15_item1_p25_s5", "sentA": "Separate from and in addition to the patent rights noted above, we expect that PRO 140 will be subject to at least a 12-year data exclusivity period measured from the first date of FDA licensure, during which period no other applications referencing PRO 140 will be approved by FDA.", "sentB": "Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements, including requirements for adverse event reporting and submission of periodic reports to the FDA, recordkeeping, product sampling and distribution, and, as discussed above, may be subject to mandatory post-market study and REMS requirements.", "type": 1, "words": ["<tag1>", "Separate", "from", "and", "in", "addition", "to", "the", "patent", "rights", "noted", "above,", "we", "expect", "that", "PRO", "140", "will", "be", "subject", "to", "at", "least", "a", "12-year", "data", "exclusivity", "period", "measured", "from", "the", "first", "date", "of", "FDA", "licensure,", "during", "which", "period", "no", "other", "applications", "referencing", "PRO", "140", "will", "be", "approved", "by", "FDA.", "<tag2>", "Once", "an", "NDA", "or", "BLA", "is", "approved,", "a", "product", "will", "be", "subject", "to", "certain", "post-approval", "requirements,", "including", "requirements", "for", "adverse", "event", "reporting", "and", "submission", "of", "periodic", "reports", "to", "the", "FDA,", "recordkeeping,", "product", "sampling", "and", "distribution,", "and,", "as", "discussed", "above,", "may", "be", "subject", "to", "mandatory", "post-market", "study", "and", "REMS", "requirements.", "<tag3>"], "wordsA": ["Separate", "from", "and", "in", "addition", "to", "the", "patent", "rights", "noted", "above,", "we", "expect", "that", "PRO", "140", "will", "be", "subject", "to", "at", "least", "a", "12-year", "data", "exclusivity", "period", "measured", "from", "the", "first", "date", "of", "FDA", "licensure,", "during", "which", "period", "no", "other", "applications", "referencing", "PRO", "140", "will", "be", "approved", "by", "FDA."], "wordsB": ["Once", "an", "NDA", "or", "BLA", "is", "approved,", "a", "product", "will", "be", "subject", "to", "certain", "post-approval", "requirements,", "including", "requirements", "for", "adverse", "event", "reporting", "and", "submission", "of", "periodic", "reports", "to", "the", "FDA,", "recordkeeping,", "product", "sampling", "and", "distribution,", "and,", "as", "discussed", "above,", "may", "be", "subject", "to", "mandatory", "post-market", "study", "and", "REMS", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p25_s3", "idA": "1175680_15_item1_p29_s2", "sentA": "There are numerous third-party patents in fields in which we work, and we may need to obtain licenses under patents of others in order to pursue a preferred development route of one or more of our product candidates.", "sentB": "Subjects will have one or more fully active, approved drugs available for construction of a viable alternative option.", "type": 1, "words": ["<tag1>", "There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates.", "<tag2>", "Subjects", "will", "have", "one", "or", "more", "fully", "active,", "approved", "drugs", "available", "for", "construction", "of", "a", "viable", "alternative", "option.", "<tag3>"], "wordsA": ["There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates."], "wordsB": ["Subjects", "will", "have", "one", "or", "more", "fully", "active,", "approved", "drugs", "available", "for", "construction", "of", "a", "viable", "alternative", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s9", "idA": "1175680_15_item1_p29_s2", "sentA": "There are numerous third-party patents in fields in which we work, and we may need to obtain licenses under patents of others in order to pursue a preferred development route of one or more of our product candidates.", "sentB": "A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of an NDA or BLA and may require additional testing.", "type": 1, "words": ["<tag1>", "There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates.", "<tag2>", "A", "complete", "response", "letter", "generally", "contains", "a", "statement", "of", "specific", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "an", "NDA", "or", "BLA", "and", "may", "require", "additional", "testing.", "<tag3>"], "wordsA": ["There", "are", "numerous", "third-party", "patents", "in", "fields", "in", "which", "we", "work,", "and", "we", "may", "need", "to", "obtain", "licenses", "under", "patents", "of", "others", "in", "order", "to", "pursue", "a", "preferred", "development", "route", "of", "one", "or", "more", "of", "our", "product", "candidates."], "wordsB": ["A", "complete", "response", "letter", "generally", "contains", "a", "statement", "of", "specific", "conditions", "that", "must", "be", "met", "in", "order", "to", "secure", "final", "approval", "of", "an", "NDA", "or", "BLA", "and", "may", "require", "additional", "testing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p16_s3", "idA": "1175680_15_item1_p2_s1", "sentA": "Moreover, these trials suggested that PRO 140 does not affect the normal function of the CCR5 co-receptor for HIV.", "sentB": "The first subject to have successfully completed this trial has transitioned into a FDA-cleared compassionate use protocol, so as to continue on PRO 140 therapy at the request of the treating physician.", "type": 1, "words": ["<tag1>", "Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "co-receptor", "for", "HIV.", "<tag2>", "The", "first", "subject", "to", "have", "successfully", "completed", "this", "trial", "has", "transitioned", "into", "a", "FDA-cleared", "compassionate", "use", "protocol,", "so", "as", "to", "continue", "on", "PRO", "140", "therapy", "at", "the", "request", "of", "the", "treating", "physician.", "<tag3>"], "wordsA": ["Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "co-receptor", "for", "HIV."], "wordsB": ["The", "first", "subject", "to", "have", "successfully", "completed", "this", "trial", "has", "transitioned", "into", "a", "FDA-cleared", "compassionate", "use", "protocol,", "so", "as", "to", "continue", "on", "PRO", "140", "therapy", "at", "the", "request", "of", "the", "treating", "physician."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p18_s7", "idA": "1175680_15_item1_p2_s1", "sentA": "Moreover, these trials suggested that PRO 140 does not affect the normal function of the CCR5 co-receptor for HIV.", "sentB": "We are continuing to explore opportunities for clinical applications for PRO 140 involving the CCR5 receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases and cancer.", "type": 1, "words": ["<tag1>", "Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "co-receptor", "for", "HIV.", "<tag2>", "We", "are", "continuing", "to", "explore", "opportunities", "for", "clinical", "applications", "for", "PRO", "140", "involving", "the", "CCR5", "receptor,", "other", "than", "HIV-related", "treatments,", "such", "as", "inflammatory", "conditions,", "autoimmune", "diseases", "and", "cancer.", "<tag3>"], "wordsA": ["Moreover,", "these", "trials", "suggested", "that", "PRO", "140", "does", "not", "affect", "the", "normal", "function", "of", "the", "CCR5", "co-receptor", "for", "HIV."], "wordsB": ["We", "are", "continuing", "to", "explore", "opportunities", "for", "clinical", "applications", "for", "PRO", "140", "involving", "the", "CCR5", "receptor,", "other", "than", "HIV-related", "treatments,", "such", "as", "inflammatory", "conditions,", "autoimmune", "diseases", "and", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p49_s4", "idA": "1175680_15_item1_p32_s0", "sentA": "In the United States, biological products have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling, import, export and safety reporting.", "sentB": "In the United States, the process for obtaining FDA approval for products like PRO140 typically includes pre-clinical studies, the filing of an Investigational New Drug application, or IND, human clinical trials and filing and approval of either a New Drug Application, or NDA, for chemical pharmaceutical products, or a BLA (biologics license application) for biological pharmaceutical products, such as PRO 140.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting.", "<tag2>", "In", "the", "United", "States,", "the", "process", "for", "obtaining", "FDA", "approval", "for", "products", "like", "PRO140", "typically", "includes", "pre-clinical", "studies,", "the", "filing", "of", "an", "Investigational", "New", "Drug", "application,", "or", "IND,", "human", "clinical", "trials", "and", "filing", "and", "approval", "of", "either", "a", "New", "Drug", "Application,", "or", "NDA,", "for", "chemical", "pharmaceutical", "products,", "or", "a", "BLA", "(biologics", "license", "application)", "for", "biological", "pharmaceutical", "products,", "such", "as", "PRO", "140.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting."], "wordsB": ["In", "the", "United", "States,", "the", "process", "for", "obtaining", "FDA", "approval", "for", "products", "like", "PRO140", "typically", "includes", "pre-clinical", "studies,", "the", "filing", "of", "an", "Investigational", "New", "Drug", "application,", "or", "IND,", "human", "clinical", "trials", "and", "filing", "and", "approval", "of", "either", "a", "New", "Drug", "Application,", "or", "NDA,", "for", "chemical", "pharmaceutical", "products,", "or", "a", "BLA", "(biologics", "license", "application)", "for", "biological", "pharmaceutical", "products,", "such", "as", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p53_s0", "idA": "1175680_15_item1_p34_s1", "sentA": "Failure to comply with applicable regulations can result in refusal by the FDA to approve product license applications.", "sentB": "The European Union has established a unified centralized filing and approval system administered by the Committee for Medicinal Products for Human Use designed to reduce the administrative burden of processing applications for pharmaceutical products derived from new technologies.", "type": 1, "words": ["<tag1>", "Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications.", "<tag2>", "The", "European", "Union", "has", "established", "a", "unified", "centralized", "filing", "and", "approval", "system", "administered", "by", "the", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "designed", "to", "reduce", "the", "administrative", "burden", "of", "processing", "applications", "for", "pharmaceutical", "products", "derived", "from", "new", "technologies.", "<tag3>"], "wordsA": ["Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications."], "wordsB": ["The", "European", "Union", "has", "established", "a", "unified", "centralized", "filing", "and", "approval", "system", "administered", "by", "the", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "designed", "to", "reduce", "the", "administrative", "burden", "of", "processing", "applications", "for", "pharmaceutical", "products", "derived", "from", "new", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p54_s3", "idA": "1175680_15_item1_p34_s1", "sentA": "Failure to comply with applicable regulations can result in refusal by the FDA to approve product license applications.", "sentB": "In addition, discovery of problems with a product, including new safety risks, or the failure to comply with requirements may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary or FDA-initiated action that could delay further marketing.", "type": 1, "words": ["<tag1>", "Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications.", "<tag2>", "In", "addition,", "discovery", "of", "problems", "with", "a", "product,", "including", "new", "safety", "risks,", "or", "the", "failure", "to", "comply", "with", "requirements", "may", "result", "in", "restrictions", "on", "a", "product,", "manufacturer", "or", "holder", "of", "an", "approved", "NDA", "or", "BLA,", "including", "withdrawal", "or", "recall", "of", "the", "product", "from", "the", "market", "or", "other", "voluntary", "or", "FDA-initiated", "action", "that", "could", "delay", "further", "marketing.", "<tag3>"], "wordsA": ["Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications."], "wordsB": ["In", "addition,", "discovery", "of", "problems", "with", "a", "product,", "including", "new", "safety", "risks,", "or", "the", "failure", "to", "comply", "with", "requirements", "may", "result", "in", "restrictions", "on", "a", "product,", "manufacturer", "or", "holder", "of", "an", "approved", "NDA", "or", "BLA,", "including", "withdrawal", "or", "recall", "of", "the", "product", "from", "the", "market", "or", "other", "voluntary", "or", "FDA-initiated", "action", "that", "could", "delay", "further", "marketing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p51_s1", "idA": "1175680_15_item1_p35_s2", "sentA": "State law and regulations also apply to the operation of clinical laboratories.", "sentB": "In complying with cGMPs, we must expend time, money and effort in the areas of training, production and quality control within our own organization and at our contract manufacturing laboratories.", "type": 1, "words": ["<tag1>", "State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories.", "<tag2>", "In", "complying", "with", "cGMPs,", "we", "must", "expend", "time,", "money", "and", "effort", "in", "the", "areas", "of", "training,", "production", "and", "quality", "control", "within", "our", "own", "organization", "and", "at", "our", "contract", "manufacturing", "laboratories.", "<tag3>"], "wordsA": ["State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories."], "wordsB": ["In", "complying", "with", "cGMPs,", "we", "must", "expend", "time,", "money", "and", "effort", "in", "the", "areas", "of", "training,", "production", "and", "quality", "control", "within", "our", "own", "organization", "and", "at", "our", "contract", "manufacturing", "laboratories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p69_s8", "idA": "1175680_15_item1_p38_s1", "sentA": "We believe that our operations comply in all material respects with applicable environmental laws and regulations.", "sentB": "We believe that targeting CD4 will interfere with immune function to an undesirable extent and if developed further will vastly limit the potential of ibalizumab as an effective anti-HIV therapy.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations.", "<tag2>", "We", "believe", "that", "targeting", "CD4", "will", "interfere", "with", "immune", "function", "to", "an", "undesirable", "extent", "and", "if", "developed", "further", "will", "vastly", "limit", "the", "potential", "of", "ibalizumab", "as", "an", "effective", "anti-HIV", "therapy.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "operations", "comply", "in", "all", "material", "respects", "with", "applicable", "environmental", "laws", "and", "regulations."], "wordsB": ["We", "believe", "that", "targeting", "CD4", "will", "interfere", "with", "immune", "function", "to", "an", "undesirable", "extent", "and", "if", "developed", "further", "will", "vastly", "limit", "the", "potential", "of", "ibalizumab", "as", "an", "effective", "anti-HIV", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p16_s1", "idA": "1175680_15_item1_p40_s1", "sentA": "These studies are closely monitored and may be conducted in patients, but are usually conducted in a small number of healthy volunteer subjects.", "sentB": "The initial 25-week trial protocol included a requirement for 300 subjects.", "type": 1, "words": ["<tag1>", "These", "studies", "are", "closely", "monitored", "and", "may", "be", "conducted", "in", "patients,", "but", "are", "usually", "conducted", "in", "a", "small", "number", "of", "healthy", "volunteer", "subjects.", "<tag2>", "The", "initial", "25-week", "trial", "protocol", "included", "a", "requirement", "for", "300", "subjects.", "<tag3>"], "wordsA": ["These", "studies", "are", "closely", "monitored", "and", "may", "be", "conducted", "in", "patients,", "but", "are", "usually", "conducted", "in", "a", "small", "number", "of", "healthy", "volunteer", "subjects."], "wordsB": ["The", "initial", "25-week", "trial", "protocol", "included", "a", "requirement", "for", "300", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p51_s4", "idA": "1175680_15_item1_p41_s0", "sentA": "Phase 1 studies of PRO 140 have been conducted and completed by or on behalf of Progenics by Dr. Jacobson and others prior to our acquisition of PRO 140.", "sentB": "We also face similar inspections coordinated by the EMEA by inspectors from particular E.U. member countries that conduct inspections on behalf of the European Union and from other foreign regulatory authorities.", "type": 1, "words": ["<tag1>", "Phase", "1", "studies", "of", "PRO", "140", "have", "been", "conducted", "and", "completed", "by", "or", "on", "behalf", "of", "Progenics", "by", "Dr.", "Jacobson", "and", "others", "prior", "to", "our", "acquisition", "of", "PRO", "140.", "<tag2>", "We", "also", "face", "similar", "inspections", "coordinated", "by", "the", "EMEA", "by", "inspectors", "from", "particular", "E.U.", "member", "countries", "that", "conduct", "inspections", "on", "behalf", "of", "the", "European", "Union", "and", "from", "other", "foreign", "regulatory", "authorities.", "<tag3>"], "wordsA": ["Phase", "1", "studies", "of", "PRO", "140", "have", "been", "conducted", "and", "completed", "by", "or", "on", "behalf", "of", "Progenics", "by", "Dr.", "Jacobson", "and", "others", "prior", "to", "our", "acquisition", "of", "PRO", "140."], "wordsB": ["We", "also", "face", "similar", "inspections", "coordinated", "by", "the", "EMEA", "by", "inspectors", "from", "particular", "E.U.", "member", "countries", "that", "conduct", "inspections", "on", "behalf", "of", "the", "European", "Union", "and", "from", "other", "foreign", "regulatory", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p54_s0", "idA": "1175680_15_item1_p41_s1", "sentA": "Phase 2 Phase 2 includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular indication or indications in patients with the disease or condition.", "sentB": "In addition to obtaining regulatory approval of products, it is generally necessary to obtain regulatory approval of the facility in which the product will be manufactured.", "type": 1, "words": ["<tag1>", "Phase", "2", "Phase", "2", "includes", "the", "early", "controlled", "clinical", "studies", "conducted", "to", "obtain", "some", "preliminary", "data", "on", "the", "effectiveness", "of", "the", "drug", "for", "a", "particular", "indication", "or", "indications", "in", "patients", "with", "the", "disease", "or", "condition.", "<tag2>", "In", "addition", "to", "obtaining", "regulatory", "approval", "of", "products,", "it", "is", "generally", "necessary", "to", "obtain", "regulatory", "approval", "of", "the", "facility", "in", "which", "the", "product", "will", "be", "manufactured.", "<tag3>"], "wordsA": ["Phase", "2", "Phase", "2", "includes", "the", "early", "controlled", "clinical", "studies", "conducted", "to", "obtain", "some", "preliminary", "data", "on", "the", "effectiveness", "of", "the", "drug", "for", "a", "particular", "indication", "or", "indications", "in", "patients", "with", "the", "disease", "or", "condition."], "wordsB": ["In", "addition", "to", "obtaining", "regulatory", "approval", "of", "products,", "it", "is", "generally", "necessary", "to", "obtain", "regulatory", "approval", "of", "the", "facility", "in", "which", "the", "product", "will", "be", "manufactured."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s1", "idA": "1175680_15_item1_p41_s10", "sentA": "Phase 3 studies also provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling.", "sentB": "Once a sponsor submits an IND, the sponsor must wait 30 calendar days before initiating any clinical trials, during which time the FDA has an opportunity to review the IND and raise concerns or questions relating to the proposed clinical trials outlined in the IND.", "type": 1, "words": ["<tag1>", "Phase", "3", "studies", "also", "provide", "an", "adequate", "basis", "for", "extrapolating", "the", "results", "to", "the", "general", "population", "and", "transmitting", "that", "information", "in", "the", "physician", "labeling.", "<tag2>", "Once", "a", "sponsor", "submits", "an", "IND,", "the", "sponsor", "must", "wait", "30", "calendar", "days", "before", "initiating", "any", "clinical", "trials,", "during", "which", "time", "the", "FDA", "has", "an", "opportunity", "to", "review", "the", "IND", "and", "raise", "concerns", "or", "questions", "relating", "to", "the", "proposed", "clinical", "trials", "outlined", "in", "the", "IND.", "<tag3>"], "wordsA": ["Phase", "3", "studies", "also", "provide", "an", "adequate", "basis", "for", "extrapolating", "the", "results", "to", "the", "general", "population", "and", "transmitting", "that", "information", "in", "the", "physician", "labeling."], "wordsB": ["Once", "a", "sponsor", "submits", "an", "IND,", "the", "sponsor", "must", "wait", "30", "calendar", "days", "before", "initiating", "any", "clinical", "trials,", "during", "which", "time", "the", "FDA", "has", "an", "opportunity", "to", "review", "the", "IND", "and", "raise", "concerns", "or", "questions", "relating", "to", "the", "proposed", "clinical", "trials", "outlined", "in", "the", "IND."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p17_s3", "idA": "1175680_15_item1_p41_s12", "sentA": "We are required to pay significant fees to third parties upon the first patient dosing in a Phase 3 trial of PRO 140.", "sentB": "Enrollment of first patient is anticipated to occur within the next quarter.", "type": 1, "words": ["<tag1>", "We", "are", "required", "to", "pay", "significant", "fees", "to", "third", "parties", "upon", "the", "first", "patient", "dosing", "in", "a", "Phase", "3", "trial", "of", "PRO", "140.", "<tag2>", "Enrollment", "of", "first", "patient", "is", "anticipated", "to", "occur", "within", "the", "next", "quarter.", "<tag3>"], "wordsA": ["We", "are", "required", "to", "pay", "significant", "fees", "to", "third", "parties", "upon", "the", "first", "patient", "dosing", "in", "a", "Phase", "3", "trial", "of", "PRO", "140."], "wordsB": ["Enrollment", "of", "first", "patient", "is", "anticipated", "to", "occur", "within", "the", "next", "quarter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p32_s3", "idA": "1175680_15_item1_p41_s12", "sentA": "We are required to pay significant fees to third parties upon the first patient dosing in a Phase 3 trial of PRO 140.", "sentB": "In December 2015, we received clearance from the FDA to conduct a Phase 2 trial to evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) undergoing allogeneic stem-cell transplantation.", "type": 1, "words": ["<tag1>", "We", "are", "required", "to", "pay", "significant", "fees", "to", "third", "parties", "upon", "the", "first", "patient", "dosing", "in", "a", "Phase", "3", "trial", "of", "PRO", "140.", "<tag2>", "In", "December", "2015,", "we", "received", "clearance", "from", "the", "FDA", "to", "conduct", "a", "Phase", "2", "trial", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "PRO", "140", "for", "prophylaxis", "of", "acute", "GvHD", "in", "patients", "with", "acute", "myeloid", "leukemia", "(", "AML", ")", "or", "myelodysplastic", "syndromes", "(", "MDS", ")", "undergoing", "allogeneic", "stem-cell", "transplantation.", "<tag3>"], "wordsA": ["We", "are", "required", "to", "pay", "significant", "fees", "to", "third", "parties", "upon", "the", "first", "patient", "dosing", "in", "a", "Phase", "3", "trial", "of", "PRO", "140."], "wordsB": ["In", "December", "2015,", "we", "received", "clearance", "from", "the", "FDA", "to", "conduct", "a", "Phase", "2", "trial", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "PRO", "140", "for", "prophylaxis", "of", "acute", "GvHD", "in", "patients", "with", "acute", "myeloid", "leukemia", "(", "AML", ")", "or", "myelodysplastic", "syndromes", "(", "MDS", ")", "undergoing", "allogeneic", "stem-cell", "transplantation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p69_s0", "idA": "1175680_15_item1_p41_s3", "sentA": "Phase 2 studies are typically well-controlled, closely monitored, and conducted in a relatively small number of patients, often involving several hundred people.", "sentB": "To construct a HAART regimen, three drugs from two classes of drugs are typically needed.", "type": 1, "words": ["<tag1>", "Phase", "2", "studies", "are", "typically", "well-controlled,", "closely", "monitored,", "and", "conducted", "in", "a", "relatively", "small", "number", "of", "patients,", "often", "involving", "several", "hundred", "people.", "<tag2>", "To", "construct", "a", "HAART", "regimen,", "three", "drugs", "from", "two", "classes", "of", "drugs", "are", "typically", "needed.", "<tag3>"], "wordsA": ["Phase", "2", "studies", "are", "typically", "well-controlled,", "closely", "monitored,", "and", "conducted", "in", "a", "relatively", "small", "number", "of", "patients,", "often", "involving", "several", "hundred", "people."], "wordsB": ["To", "construct", "a", "HAART", "regimen,", "three", "drugs", "from", "two", "classes", "of", "drugs", "are", "typically", "needed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p28_s0", "idA": "1175680_15_item1_p42_s2", "sentA": "Advancing PRO 140 is our highest priority.", "sentB": "A Phase 3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects with CCR5-tropic HIV-1 infection.", "type": 1, "words": ["<tag1>", "Advancing", "PRO", "140", "is", "our", "highest", "priority.", "<tag2>", "A", "Phase", "3,", "Multicenter", "Study", "to", "Assess", "the", "Treatment", "Strategy", "of", "Using", "PRO", "140", "SC", "as", "Long-Acting", "Single-Agent", "Maintenance", "Therapy", "for", "48", "Weeks", "in", "Virologically", "Suppressed", "Subjects", "with", "CCR5-tropic", "HIV-1", "infection.", "<tag3>"], "wordsA": ["Advancing", "PRO", "140", "is", "our", "highest", "priority."], "wordsB": ["A", "Phase", "3,", "Multicenter", "Study", "to", "Assess", "the", "Treatment", "Strategy", "of", "Using", "PRO", "140", "SC", "as", "Long-Acting", "Single-Agent", "Maintenance", "Therapy", "for", "48", "Weeks", "in", "Virologically", "Suppressed", "Subjects", "with", "CCR5-tropic", "HIV-1", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p25_s1", "idA": "1175680_15_item1_p43_s0", "sentA": "PRO 140 blocks a cell receptor called CCR5, which is the entry point for most strains of HIV virus.", "sentB": "The study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus with documented genotypic or phenotypic resistance to antiretroviral drugs within one or more drug classes, which is a second-line therapy, with additional conditions to include patients who have demonstrated evidence of HIV replication despite ongoing antiretroviral therapy and have limited treatment options.", "type": 1, "words": ["<tag1>", "PRO", "140", "blocks", "a", "cell", "receptor", "called", "CCR5,", "which", "is", "the", "entry", "point", "for", "most", "strains", "of", "HIV", "virus.", "<tag2>", "The", "study", "population", "includes", "treatment-experienced", "HIV-infected", "patients", "with", "CCR5-tropic", "virus", "with", "documented", "genotypic", "or", "phenotypic", "resistance", "to", "antiretroviral", "drugs", "within", "one", "or", "more", "drug", "classes,", "which", "is", "a", "second-line", "therapy,", "with", "additional", "conditions", "to", "include", "patients", "who", "have", "demonstrated", "evidence", "of", "HIV", "replication", "despite", "ongoing", "antiretroviral", "therapy", "and", "have", "limited", "treatment", "options.", "<tag3>"], "wordsA": ["PRO", "140", "blocks", "a", "cell", "receptor", "called", "CCR5,", "which", "is", "the", "entry", "point", "for", "most", "strains", "of", "HIV", "virus."], "wordsB": ["The", "study", "population", "includes", "treatment-experienced", "HIV-infected", "patients", "with", "CCR5-tropic", "virus", "with", "documented", "genotypic", "or", "phenotypic", "resistance", "to", "antiretroviral", "drugs", "within", "one", "or", "more", "drug", "classes,", "which", "is", "a", "second-line", "therapy,", "with", "additional", "conditions", "to", "include", "patients", "who", "have", "demonstrated", "evidence", "of", "HIV", "replication", "despite", "ongoing", "antiretroviral", "therapy", "and", "have", "limited", "treatment", "options."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p25_s2", "idA": "1175680_15_item1_p43_s10", "sentA": "Our competitors may succeed in developing potential drugs or processes that are more effective or less costly than any that may be developed by us or that gain regulatory approval prior to our potential drug candidates.", "sentB": "The treatment options may be limited as a result of drug antiretroviral class cross-resistance, documented treatment intolerance, potential for hypersensitivity to one or more antiretroviral drugs, or potential drug interactions with treatment for co-morbid conditions.", "type": 1, "words": ["<tag1>", "Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates.", "<tag2>", "The", "treatment", "options", "may", "be", "limited", "as", "a", "result", "of", "drug", "antiretroviral", "class", "cross-resistance,", "documented", "treatment", "intolerance,", "potential", "for", "hypersensitivity", "to", "one", "or", "more", "antiretroviral", "drugs,", "or", "potential", "drug", "interactions", "with", "treatment", "for", "co-morbid", "conditions.", "<tag3>"], "wordsA": ["Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates."], "wordsB": ["The", "treatment", "options", "may", "be", "limited", "as", "a", "result", "of", "drug", "antiretroviral", "class", "cross-resistance,", "documented", "treatment", "intolerance,", "potential", "for", "hypersensitivity", "to", "one", "or", "more", "antiretroviral", "drugs,", "or", "potential", "drug", "interactions", "with", "treatment", "for", "co-morbid", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p55_s1", "idA": "1175680_15_item1_p43_s10", "sentA": "Our competitors may succeed in developing potential drugs or processes that are more effective or less costly than any that may be developed by us or that gain regulatory approval prior to our potential drug candidates.", "sentB": "In addition, the FDA strictly regulates the promotional claims that may be made about prescription drug products and biologics.", "type": 1, "words": ["<tag1>", "Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates.", "<tag2>", "In", "addition,", "the", "FDA", "strictly", "regulates", "the", "promotional", "claims", "that", "may", "be", "made", "about", "prescription", "drug", "products", "and", "biologics.", "<tag3>"], "wordsA": ["Our", "competitors", "may", "succeed", "in", "developing", "potential", "drugs", "or", "processes", "that", "are", "more", "effective", "or", "less", "costly", "than", "any", "that", "may", "be", "developed", "by", "us", "or", "that", "gain", "regulatory", "approval", "prior", "to", "our", "potential", "drug", "candidates."], "wordsB": ["In", "addition,", "the", "FDA", "strictly", "regulates", "the", "promotional", "claims", "that", "may", "be", "made", "about", "prescription", "drug", "products", "and", "biologics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p54_s2", "idA": "1175680_15_item1_p45_s1", "sentA": "All of our potential competitors have considerably greater financial and management resources than we possess.", "sentB": "Future FDA inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct.", "type": 1, "words": ["<tag1>", "All", "of", "our", "potential", "competitors", "have", "considerably", "greater", "financial", "and", "management", "resources", "than", "we", "possess.", "<tag2>", "Future", "FDA", "inspections", "may", "identify", "compliance", "issues", "at", "the", "facilities", "of", "our", "contract", "manufacturers", "that", "may", "disrupt", "production", "or", "distribution,", "or", "require", "substantial", "resources", "to", "correct.", "<tag3>"], "wordsA": ["All", "of", "our", "potential", "competitors", "have", "considerably", "greater", "financial", "and", "management", "resources", "than", "we", "possess."], "wordsB": ["Future", "FDA", "inspections", "may", "identify", "compliance", "issues", "at", "the", "facilities", "of", "our", "contract", "manufacturers", "that", "may", "disrupt", "production", "or", "distribution,", "or", "require", "substantial", "resources", "to", "correct."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p17_s2", "idA": "1175680_15_item1_p45_s2", "sentA": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "sentB": "The secondary endpoint is the number of weeks a patient is off of their ART regimen.", "type": 1, "words": ["<tag1>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag2>", "The", "secondary", "endpoint", "is", "the", "number", "of", "weeks", "a", "patient", "is", "off", "of", "their", "ART", "regimen.", "<tag3>"], "wordsA": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "wordsB": ["The", "secondary", "endpoint", "is", "the", "number", "of", "weeks", "a", "patient", "is", "off", "of", "their", "ART", "regimen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p24_s1", "idA": "1175680_15_item1_p45_s2", "sentA": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "sentB": "The FDA recently reduced the number of required subjects in this trial from 300 to 150.", "type": 1, "words": ["<tag1>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag2>", "The", "FDA", "recently", "reduced", "the", "number", "of", "required", "subjects", "in", "this", "trial", "from", "300", "to", "150.", "<tag3>"], "wordsA": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "wordsB": ["The", "FDA", "recently", "reduced", "the", "number", "of", "required", "subjects", "in", "this", "trial", "from", "300", "to", "150."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p27_s2", "idA": "1175680_15_item1_p45_s2", "sentA": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "sentB": "The secondary endpoint is the number of weeks a patient is off of their ART regimen.", "type": 1, "words": ["<tag1>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag2>", "The", "secondary", "endpoint", "is", "the", "number", "of", "weeks", "a", "patient", "is", "off", "of", "their", "ART", "regimen.", "<tag3>"], "wordsA": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "wordsB": ["The", "secondary", "endpoint", "is", "the", "number", "of", "weeks", "a", "patient", "is", "off", "of", "their", "ART", "regimen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p49_s3", "idA": "1175680_15_item1_p45_s2", "sentA": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "sentB": "Pharmaceutical products such as PRO140 may not be commercially marketed without prior approval from the FDA and comparable agencies in foreign countries.", "type": 1, "words": ["<tag1>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag2>", "Pharmaceutical", "products", "such", "as", "PRO140", "may", "not", "be", "commercially", "marketed", "without", "prior", "approval", "from", "the", "FDA", "and", "comparable", "agencies", "in", "foreign", "countries.", "<tag3>"], "wordsA": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "wordsB": ["Pharmaceutical", "products", "such", "as", "PRO140", "may", "not", "be", "commercially", "marketed", "without", "prior", "approval", "from", "the", "FDA", "and", "comparable", "agencies", "in", "foreign", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p50_s11", "idA": "1175680_15_item1_p45_s2", "sentA": "We also expect that the number of our competitors and potential competitors will increase as more potential drugs receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies.", "sentB": "Any approval required from the FDA might not be obtained on a timely basis, if at all.", "type": 1, "words": ["<tag1>", "We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies.", "<tag2>", "Any", "approval", "required", "from", "the", "FDA", "might", "not", "be", "obtained", "on", "a", "timely", "basis,", "if", "at", "all.", "<tag3>"], "wordsA": ["We", "also", "expect", "that", "the", "number", "of", "our", "competitors", "and", "potential", "competitors", "will", "increase", "as", "more", "potential", "drugs", "receive", "commercial", "marketing", "approvals", "from", "the", "FDA", "or", "analogous", "foreign", "regulatory", "agencies."], "wordsB": ["Any", "approval", "required", "from", "the", "FDA", "might", "not", "be", "obtained", "on", "a", "timely", "basis,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p23_s3", "idA": "1175680_15_item1_p45_s3", "sentA": "Any of these competitors may be more successful than us in manufacturing, marketing and distributing HIV treatments.", "sentB": "Three patients discontinued the extension protocol due to either violating protocol design or missing weekly treatments.", "type": 1, "words": ["<tag1>", "Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "HIV", "treatments.", "<tag2>", "Three", "patients", "discontinued", "the", "extension", "protocol", "due", "to", "either", "violating", "protocol", "design", "or", "missing", "weekly", "treatments.", "<tag3>"], "wordsA": ["Any", "of", "these", "competitors", "may", "be", "more", "successful", "than", "us", "in", "manufacturing,", "marketing", "and", "distributing", "HIV", "treatments."], "wordsB": ["Three", "patients", "discontinued", "the", "extension", "protocol", "due", "to", "either", "violating", "protocol", "design", "or", "missing", "weekly", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p30_s1", "idA": "1175680_15_item1_p46_s1", "sentA": "We expect that research and development expenses will continue to be a significant expense as we seek to develop our current and future product pipeline.", "sentB": "The receptor is activated by a chemokine mediator called CCL5, which has been shown to be a central figure in many inflammatory disease processes.", "type": 1, "words": ["<tag1>", "We", "expect", "that", "research", "and", "development", "expenses", "will", "continue", "to", "be", "a", "significant", "expense", "as", "we", "seek", "to", "develop", "our", "current", "and", "future", "product", "pipeline.", "<tag2>", "The", "receptor", "is", "activated", "by", "a", "chemokine", "mediator", "called", "CCL5,", "which", "has", "been", "shown", "to", "be", "a", "central", "figure", "in", "many", "inflammatory", "disease", "processes.", "<tag3>"], "wordsA": ["We", "expect", "that", "research", "and", "development", "expenses", "will", "continue", "to", "be", "a", "significant", "expense", "as", "we", "seek", "to", "develop", "our", "current", "and", "future", "product", "pipeline."], "wordsB": ["The", "receptor", "is", "activated", "by", "a", "chemokine", "mediator", "called", "CCL5,", "which", "has", "been", "shown", "to", "be", "a", "central", "figure", "in", "many", "inflammatory", "disease", "processes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p36_s0", "idA": "1175680_15_item1_p5_s1", "sentA": "In furtherance of our business strategy, in mid-2014 we entered into a manufacturing agreement with a contract manufacturing organization to initiate preparations for the future manufacturing of additional PRO 140.", "sentB": "Effective July 29, 2015, the Company entered into a License Agreement (the Lonza Agreement ) with Lonza Sales AG ( Lonza ) covering Lonza s system know-how technology with respect to CytoDyn s use of proprietary cell lines to manufacture new PRO 140 material.", "type": 1, "words": ["<tag1>", "In", "furtherance", "of", "our", "business", "strategy,", "in", "mid-2014", "we", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "future", "manufacturing", "of", "additional", "PRO", "140.", "<tag2>", "Effective", "July", "29,", "2015,", "the", "Company", "entered", "into", "a", "License", "Agreement", "(the", "Lonza", "Agreement", ")", "with", "Lonza", "Sales", "AG", "(", "Lonza", ")", "covering", "Lonza", "s", "system", "know-how", "technology", "with", "respect", "to", "CytoDyn", "s", "use", "of", "proprietary", "cell", "lines", "to", "manufacture", "new", "PRO", "140", "material.", "<tag3>"], "wordsA": ["In", "furtherance", "of", "our", "business", "strategy,", "in", "mid-2014", "we", "entered", "into", "a", "manufacturing", "agreement", "with", "a", "contract", "manufacturing", "organization", "to", "initiate", "preparations", "for", "the", "future", "manufacturing", "of", "additional", "PRO", "140."], "wordsB": ["Effective", "July", "29,", "2015,", "the", "Company", "entered", "into", "a", "License", "Agreement", "(the", "Lonza", "Agreement", ")", "with", "Lonza", "Sales", "AG", "(", "Lonza", ")", "covering", "Lonza", "s", "system", "know-how", "technology", "with", "respect", "to", "CytoDyn", "s", "use", "of", "proprietary", "cell", "lines", "to", "manufacture", "new", "PRO", "140", "material."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p12_s5", "idA": "1175680_15_item1_p7_s4", "sentA": "Overall, we believe PRO 140 represents a distinct class of CCR5 inhibitors with unique virological and immunological properties and may provide another distinct tool to treat HIV-infected subjects.", "sentB": "Based on the preliminary results of such studies, we believe that a PRO 140 treatment option could address the unmet medical need for therapy options for certain HIV-infected patients with uncontrolled viral load, despite conventional HAART treatments.", "type": 1, "words": ["<tag1>", "Overall,", "we", "believe", "PRO", "140", "represents", "a", "distinct", "class", "of", "CCR5", "inhibitors", "with", "unique", "virological", "and", "immunological", "properties", "and", "may", "provide", "another", "distinct", "tool", "to", "treat", "HIV-infected", "subjects.", "<tag2>", "Based", "on", "the", "preliminary", "results", "of", "such", "studies,", "we", "believe", "that", "a", "PRO", "140", "treatment", "option", "could", "address", "the", "unmet", "medical", "need", "for", "therapy", "options", "for", "certain", "HIV-infected", "patients", "with", "uncontrolled", "viral", "load,", "despite", "conventional", "HAART", "treatments.", "<tag3>"], "wordsA": ["Overall,", "we", "believe", "PRO", "140", "represents", "a", "distinct", "class", "of", "CCR5", "inhibitors", "with", "unique", "virological", "and", "immunological", "properties", "and", "may", "provide", "another", "distinct", "tool", "to", "treat", "HIV-infected", "subjects."], "wordsB": ["Based", "on", "the", "preliminary", "results", "of", "such", "studies,", "we", "believe", "that", "a", "PRO", "140", "treatment", "option", "could", "address", "the", "unmet", "medical", "need", "for", "therapy", "options", "for", "certain", "HIV-infected", "patients", "with", "uncontrolled", "viral", "load,", "despite", "conventional", "HAART", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p9_s1", "idA": "1175680_15_item1_p8_s0", "sentA": "Current Clinical Trials PRO 140 is currently being studied in two clinical trials.", "sentB": "In addition, there were no dose-limiting toxicities or patterns of drug-related toxicities observed during these trials.", "type": 1, "words": ["<tag1>", "Current", "Clinical", "Trials", "PRO", "140", "is", "currently", "being", "studied", "in", "two", "clinical", "trials.", "<tag2>", "In", "addition,", "there", "were", "no", "dose-limiting", "toxicities", "or", "patterns", "of", "drug-related", "toxicities", "observed", "during", "these", "trials.", "<tag3>"], "wordsA": ["Current", "Clinical", "Trials", "PRO", "140", "is", "currently", "being", "studied", "in", "two", "clinical", "trials."], "wordsB": ["In", "addition,", "there", "were", "no", "dose-limiting", "toxicities", "or", "patterns", "of", "drug-related", "toxicities", "observed", "during", "these", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p18_s10", "idA": "1175680_15_item1_p9_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "An extension study of this trial is currently ongoing, as described in greater detail below.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "An", "extension", "study", "of", "this", "trial", "is", "currently", "ongoing,", "as", "described", "in", "greater", "detail", "below.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["An", "extension", "study", "of", "this", "trial", "is", "currently", "ongoing,", "as", "described", "in", "greater", "detail", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p23_s0", "idA": "1175680_15_item1_p9_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "For the Phase 2b extension study, 19 subjects were screened for participation and 16 were allowed to enter.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "For", "the", "Phase", "2b", "extension", "study,", "19", "subjects", "were", "screened", "for", "participation", "and", "16", "were", "allowed", "to", "enter.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["For", "the", "Phase", "2b", "extension", "study,", "19", "subjects", "were", "screened", "for", "participation", "and", "16", "were", "allowed", "to", "enter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p23_s4", "idA": "1175680_15_item1_p9_s3", "sentA": "This Phase 2b trial is known as treatment substitution.", "sentB": "The trial is ongoing and as a result, we are only able to discuss the clinical findings to date.", "type": 1, "words": ["<tag1>", "This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution.", "<tag2>", "The", "trial", "is", "ongoing", "and", "as", "a", "result,", "we", "are", "only", "able", "to", "discuss", "the", "clinical", "findings", "to", "date.", "<tag3>"], "wordsA": ["This", "Phase", "2b", "trial", "is", "known", "as", "treatment", "substitution."], "wordsB": ["The", "trial", "is", "ongoing", "and", "as", "a", "result,", "we", "are", "only", "able", "to", "discuss", "the", "clinical", "findings", "to", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p33_s2", "idA": "1175680_15_item1_p9_s6", "sentA": "Our ongoing treatment substitution extension study has two objectives: (1) to assess the efficacy of PRO 140 monotherapy for the maintenance of viral suppression after being used in substitution of a patient s HAART regimen and (2) to assess the clinical safety and tolerability parameters for PRO 140 following use in substitution of HAART.", "sentB": "Study participants will be monitored for one year following initiation of HAART.", "type": 1, "words": ["<tag1>", "Our", "ongoing", "treatment", "substitution", "extension", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "HAART", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "HAART.", "<tag2>", "Study", "participants", "will", "be", "monitored", "for", "one", "year", "following", "initiation", "of", "HAART.", "<tag3>"], "wordsA": ["Our", "ongoing", "treatment", "substitution", "extension", "study", "has", "two", "objectives:", "(1)", "to", "assess", "the", "efficacy", "of", "PRO", "140", "monotherapy", "for", "the", "maintenance", "of", "viral", "suppression", "after", "being", "used", "in", "substitution", "of", "a", "patient", "s", "HAART", "regimen", "and", "(2)", "to", "assess", "the", "clinical", "safety", "and", "tolerability", "parameters", "for", "PRO", "140", "following", "use", "in", "substitution", "of", "HAART."], "wordsB": ["Study", "participants", "will", "be", "monitored", "for", "one", "year", "following", "initiation", "of", "HAART."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p30_s2", "idA": "1175680_15_item1_p9_s7", "sentA": "The study protocol requires patients to be stable on HAART with an undetectable viral load.", "sentB": "Blocking the interaction of CCL5 with the receptor CCR5 is believed to be of therapeutic benefit.", "type": 1, "words": ["<tag1>", "The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "HAART", "with", "an", "undetectable", "viral", "load.", "<tag2>", "Blocking", "the", "interaction", "of", "CCL5", "with", "the", "receptor", "CCR5", "is", "believed", "to", "be", "of", "therapeutic", "benefit.", "<tag3>"], "wordsA": ["The", "study", "protocol", "requires", "patients", "to", "be", "stable", "on", "HAART", "with", "an", "undetectable", "viral", "load."], "wordsB": ["Blocking", "the", "interaction", "of", "CCL5", "with", "the", "receptor", "CCR5", "is", "believed", "to", "be", "of", "therapeutic", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_16_item1_p32_s9", "idA": "1175680_15_item1_p9_s8", "sentA": "The trial design provided that patients will be shifted from HAART regimen to PRO 140 monotherapy for 12 weeks.", "sentB": "All eligible and consenting participants will be randomized in a 1:1 ratio to one of two treatment arms:", "type": 1, "words": ["<tag1>", "The", "trial", "design", "provided", "that", "patients", "will", "be", "shifted", "from", "HAART", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks.", "<tag2>", "All", "eligible", "and", "consenting", "participants", "will", "be", "randomized", "in", "a", "1:1", "ratio", "to", "one", "of", "two", "treatment", "arms:", "<tag3>"], "wordsA": ["The", "trial", "design", "provided", "that", "patients", "will", "be", "shifted", "from", "HAART", "regimen", "to", "PRO", "140", "monotherapy", "for", "12", "weeks."], "wordsB": ["All", "eligible", "and", "consenting", "participants", "will", "be", "randomized", "in", "a", "1:1", "ratio", "to", "one", "of", "two", "treatment", "arms:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p37_s1", "idA": "1175680_16_item1_p28_s1", "sentA": "This study is a multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry.", "sentB": "These chemokines are specific for CCR5 and cause the migration of T-cells to these sites promoting further inflammation.", "type": 1, "words": ["<tag1>", "This", "study", "is", "a", "multi-center", "study", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "and", "tolerability", "of", "the", "strategy", "of", "shifting", "clinically", "stable", "patients", "receiving", "suppressive", "combination", "antiretroviral", "therapy", "to", "PRO", "140", "monotherapy", "and", "maintaining", "viral", "suppression", "for", "48", "weeks", "following", "study", "entry.", "<tag2>", "These", "chemokines", "are", "specific", "for", "CCR5", "and", "cause", "the", "migration", "of", "T-cells", "to", "these", "sites", "promoting", "further", "inflammation.", "<tag3>"], "wordsA": ["This", "study", "is", "a", "multi-center", "study", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "and", "tolerability", "of", "the", "strategy", "of", "shifting", "clinically", "stable", "patients", "receiving", "suppressive", "combination", "antiretroviral", "therapy", "to", "PRO", "140", "monotherapy", "and", "maintaining", "viral", "suppression", "for", "48", "weeks", "following", "study", "entry."], "wordsB": ["These", "chemokines", "are", "specific", "for", "CCR5", "and", "cause", "the", "migration", "of", "T-cells", "to", "these", "sites", "promoting", "further", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p18_s1", "idA": "1175680_16_item1_p36_s6", "sentA": "However, we currently use an independent party as a contract manufacturer.", "sentB": "Also, patients who had other infections before they were declared virologic failure are not categorized as a failure.", "type": 1, "words": ["<tag1>", "However,", "we", "currently", "use", "an", "independent", "party", "as", "a", "contract", "manufacturer.", "<tag2>", "Also,", "patients", "who", "had", "other", "infections", "before", "they", "were", "declared", "virologic", "failure", "are", "not", "categorized", "as", "a", "failure.", "<tag3>"], "wordsA": ["However,", "we", "currently", "use", "an", "independent", "party", "as", "a", "contract", "manufacturer."], "wordsB": ["Also,", "patients", "who", "had", "other", "infections", "before", "they", "were", "declared", "virologic", "failure", "are", "not", "categorized", "as", "a", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p14_s0", "idA": "1175680_16_item1_p37_s3", "sentA": "A U.S. patent, to be selected by the Company upon receipt of FDA regulatory approval, may be subject to up to a five-year patent term extension in certain instances.", "sentB": "The first patients were enrolled in December 2016, and we expect enrollment to be completed by the end of calendar 2017.", "type": 1, "words": ["<tag1>", "A", "U.S.", "patent,", "to", "be", "selected", "by", "the", "Company", "upon", "receipt", "of", "FDA", "regulatory", "approval,", "may", "be", "subject", "to", "up", "to", "a", "five-year", "patent", "term", "extension", "in", "certain", "instances.", "<tag2>", "The", "first", "patients", "were", "enrolled", "in", "December", "2016,", "and", "we", "expect", "enrollment", "to", "be", "completed", "by", "the", "end", "of", "calendar", "2017.", "<tag3>"], "wordsA": ["A", "U.S.", "patent,", "to", "be", "selected", "by", "the", "Company", "upon", "receipt", "of", "FDA", "regulatory", "approval,", "may", "be", "subject", "to", "up", "to", "a", "five-year", "patent", "term", "extension", "in", "certain", "instances."], "wordsB": ["The", "first", "patients", "were", "enrolled", "in", "December", "2016,", "and", "we", "expect", "enrollment", "to", "be", "completed", "by", "the", "end", "of", "calendar", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p54_s10", "idA": "1175680_16_item1_p37_s4", "sentA": "While the duration of foreign patents varies in accordance with the provisions of applicable local law, most countries provide for a patent term of 20 years measured from the application filing date and some may also allow for patent term extension to compensate for regulatory approval delay.", "sentB": "Unless an exemption applies, a substantial user fee must accompany the application.", "type": 1, "words": ["<tag1>", "While", "the", "duration", "of", "foreign", "patents", "varies", "in", "accordance", "with", "the", "provisions", "of", "applicable", "local", "law,", "most", "countries", "provide", "for", "a", "patent", "term", "of", "20", "years", "measured", "from", "the", "application", "filing", "date", "and", "some", "may", "also", "allow", "for", "patent", "term", "extension", "to", "compensate", "for", "regulatory", "approval", "delay.", "<tag2>", "Unless", "an", "exemption", "applies,", "a", "substantial", "user", "fee", "must", "accompany", "the", "application.", "<tag3>"], "wordsA": ["While", "the", "duration", "of", "foreign", "patents", "varies", "in", "accordance", "with", "the", "provisions", "of", "applicable", "local", "law,", "most", "countries", "provide", "for", "a", "patent", "term", "of", "20", "years", "measured", "from", "the", "application", "filing", "date", "and", "some", "may", "also", "allow", "for", "patent", "term", "extension", "to", "compensate", "for", "regulatory", "approval", "delay."], "wordsB": ["Unless", "an", "exemption", "applies,", "a", "substantial", "user", "fee", "must", "accompany", "the", "application."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p61_s1", "idA": "1175680_16_item1_p47_s0", "sentA": "In the United States, biological products have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling, import, export and safety reporting.", "sentB": "In addition, our relationships with doctors and other healthcare professionals are regulated by the DOJ, the OIG and other law enforcement and regulatory agencies under the federal Anti-Kickback Statute, the False Claims Act, the Sunshine Act, and similar and related federal and state laws.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting.", "<tag2>", "In", "addition,", "our", "relationships", "with", "doctors", "and", "other", "healthcare", "professionals", "are", "regulated", "by", "the", "DOJ,", "the", "OIG", "and", "other", "law", "enforcement", "and", "regulatory", "agencies", "under", "the", "federal", "Anti-Kickback", "Statute,", "the", "False", "Claims", "Act,", "the", "Sunshine", "Act,", "and", "similar", "and", "related", "federal", "and", "state", "laws.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "biological", "products", "have", "long", "been", "subject", "to", "regulation", "by", "various", "federal", "and", "state", "agencies,", "primarily", "as", "to", "product", "safety,", "efficacy,", "manufacturing,", "advertising,", "labeling,", "import,", "export", "and", "safety", "reporting."], "wordsB": ["In", "addition,", "our", "relationships", "with", "doctors", "and", "other", "healthcare", "professionals", "are", "regulated", "by", "the", "DOJ,", "the", "OIG", "and", "other", "law", "enforcement", "and", "regulatory", "agencies", "under", "the", "federal", "Anti-Kickback", "Statute,", "the", "False", "Claims", "Act,", "the", "Sunshine", "Act,", "and", "similar", "and", "related", "federal", "and", "state", "laws."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p38_s1", "idA": "1175680_16_item1_p49_s3", "sentA": "Pharmaceutical products such as PRO140 may not be commercially marketed without prior approval from the FDA and comparable agencies in foreign countries.", "sentB": "Some disease processes that could benefit from CCR5 blockade include new reactions to cancer, transplantation rejection, autoimmunity and chronic inflammation such as rheumatoid arthritis and psoriasis.", "type": 1, "words": ["<tag1>", "Pharmaceutical", "products", "such", "as", "PRO140", "may", "not", "be", "commercially", "marketed", "without", "prior", "approval", "from", "the", "FDA", "and", "comparable", "agencies", "in", "foreign", "countries.", "<tag2>", "Some", "disease", "processes", "that", "could", "benefit", "from", "CCR5", "blockade", "include", "new", "reactions", "to", "cancer,", "transplantation", "rejection,", "autoimmunity", "and", "chronic", "inflammation", "such", "as", "rheumatoid", "arthritis", "and", "psoriasis.", "<tag3>"], "wordsA": ["Pharmaceutical", "products", "such", "as", "PRO140", "may", "not", "be", "commercially", "marketed", "without", "prior", "approval", "from", "the", "FDA", "and", "comparable", "agencies", "in", "foreign", "countries."], "wordsB": ["Some", "disease", "processes", "that", "could", "benefit", "from", "CCR5", "blockade", "include", "new", "reactions", "to", "cancer,", "transplantation", "rejection,", "autoimmunity", "and", "chronic", "inflammation", "such", "as", "rheumatoid", "arthritis", "and", "psoriasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p36_s1", "idA": "1175680_16_item1_p57_s1", "sentA": "State law and regulations also apply to the operation of clinical laboratories.", "sentB": "Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.", "type": 1, "words": ["<tag1>", "State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories.", "<tag2>", "Chemokines", "are", "the", "key", "orchestrators", "of", "leukocyte", "trafficking", "by", "attracting", "immune", "cells", "to", "the", "sites", "of", "inflammation.", "<tag3>"], "wordsA": ["State", "law", "and", "regulations", "also", "apply", "to", "the", "operation", "of", "clinical", "laboratories."], "wordsB": ["Chemokines", "are", "the", "key", "orchestrators", "of", "leukocyte", "trafficking", "by", "attracting", "immune", "cells", "to", "the", "sites", "of", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p37_s0", "idA": "1175680_16_item1_p63_s0", "sentA": "Phase 1 Phase 1 includes the initial introduction of an investigational new drug or biologic into humans.", "sentB": "At the site of an inflammatory reaction, chemokines are released.", "type": 1, "words": ["<tag1>", "Phase", "1", "Phase", "1", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans.", "<tag2>", "At", "the", "site", "of", "an", "inflammatory", "reaction,", "chemokines", "are", "released.", "<tag3>"], "wordsA": ["Phase", "1", "Phase", "1", "includes", "the", "initial", "introduction", "of", "an", "investigational", "new", "drug", "or", "biologic", "into", "humans."], "wordsB": ["At", "the", "site", "of", "an", "inflammatory", "reaction,", "chemokines", "are", "released."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p41_s3", "idA": "1175680_16_item1_p64_s0", "sentA": "Phase 1 studies of PRO 140 have been conducted and completed by or on behalf of Progenics by Dr. Jacobson and others prior to our acquisition of PRO 140.", "sentB": "Our animal studies in GvHD have been submitted for publication in peer-reviewed journals.", "type": 1, "words": ["<tag1>", "Phase", "1", "studies", "of", "PRO", "140", "have", "been", "conducted", "and", "completed", "by", "or", "on", "behalf", "of", "Progenics", "by", "Dr.", "Jacobson", "and", "others", "prior", "to", "our", "acquisition", "of", "PRO", "140.", "<tag2>", "Our", "animal", "studies", "in", "GvHD", "have", "been", "submitted", "for", "publication", "in", "peer-reviewed", "journals.", "<tag3>"], "wordsA": ["Phase", "1", "studies", "of", "PRO", "140", "have", "been", "conducted", "and", "completed", "by", "or", "on", "behalf", "of", "Progenics", "by", "Dr.", "Jacobson", "and", "others", "prior", "to", "our", "acquisition", "of", "PRO", "140."], "wordsB": ["Our", "animal", "studies", "in", "GvHD", "have", "been", "submitted", "for", "publication", "in", "peer-reviewed", "journals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p76_s3", "idA": "1175680_16_item1_p72_s3", "sentA": "We have developed and validated a current good manufacturing practice ( cGMP ) process to manufacture PRO 140, through a single contract manufacturer, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.", "sentB": "We have engaged a contract manufacturing organization ( CMO ) to initiate the scale-up to commercial batch quantities of product, and develop the necessary controls and specifications to manufacture product on a consistent and reproducible manner.", "type": 1, "words": ["<tag1>", "We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc.", "<tag2>", "We", "have", "engaged", "a", "contract", "manufacturing", "organization", "(", "CMO", ")", "to", "initiate", "the", "scale-up", "to", "commercial", "batch", "quantities", "of", "product,", "and", "develop", "the", "necessary", "controls", "and", "specifications", "to", "manufacture", "product", "on", "a", "consistent", "and", "reproducible", "manner.", "<tag3>"], "wordsA": ["We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc."], "wordsB": ["We", "have", "engaged", "a", "contract", "manufacturing", "organization", "(", "CMO", ")", "to", "initiate", "the", "scale-up", "to", "commercial", "batch", "quantities", "of", "product,", "and", "develop", "the", "necessary", "controls", "and", "specifications", "to", "manufacture", "product", "on", "a", "consistent", "and", "reproducible", "manner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_17_item1_p76_s4", "idA": "1175680_16_item1_p72_s3", "sentA": "We have developed and validated a current good manufacturing practice ( cGMP ) process to manufacture PRO 140, through a single contract manufacturer, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.", "sentB": "We have also contracted with a suitable CMO who will fill, label, and package product into the final commercial package for commercial sale.", "type": 1, "words": ["<tag1>", "We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc.", "<tag2>", "We", "have", "also", "contracted", "with", "a", "suitable", "CMO", "who", "will", "fill,", "label,", "and", "package", "product", "into", "the", "final", "commercial", "package", "for", "commercial", "sale.", "<tag3>"], "wordsA": ["We", "have", "developed", "and", "validated", "a", "current", "good", "manufacturing", "practice", "(", "cGMP", ")", "process", "to", "manufacture", "PRO", "140,", "through", "a", "single", "contract", "manufacturer,", "FUJIFILM", "Diosynth", "Biotechnologies", "U.S.A.,", "Inc."], "wordsB": ["We", "have", "also", "contracted", "with", "a", "suitable", "CMO", "who", "will", "fill,", "label,", "and", "package", "product", "into", "the", "final", "commercial", "package", "for", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p13_s2", "idA": "1175680_17_item1_p12_s1", "sentA": "Patient enrollment is expected to be completed in July 2017 and we will announce whether the trial has achieved its primary endpoint as soon as that determination is available.", "sentB": "In late February 2018, the Company reported that it had enrolled 52 patients and the trial s primary endpoint was achieved with a p-value of 0.0032.", "type": 1, "words": ["<tag1>", "Patient", "enrollment", "is", "expected", "to", "be", "completed", "in", "July", "2017", "and", "we", "will", "announce", "whether", "the", "trial", "has", "achieved", "its", "primary", "endpoint", "as", "soon", "as", "that", "determination", "is", "available.", "<tag2>", "In", "late", "February", "2018,", "the", "Company", "reported", "that", "it", "had", "enrolled", "52", "patients", "and", "the", "trial", "s", "primary", "endpoint", "was", "achieved", "with", "a", "p-value", "of", "0.0032.", "<tag3>"], "wordsA": ["Patient", "enrollment", "is", "expected", "to", "be", "completed", "in", "July", "2017", "and", "we", "will", "announce", "whether", "the", "trial", "has", "achieved", "its", "primary", "endpoint", "as", "soon", "as", "that", "determination", "is", "available."], "wordsB": ["In", "late", "February", "2018,", "the", "Company", "reported", "that", "it", "had", "enrolled", "52", "patients", "and", "the", "trial", "s", "primary", "endpoint", "was", "achieved", "with", "a", "p-value", "of", "0.0032."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p17_s4", "idA": "1175680_17_item1_p12_s1", "sentA": "Patient enrollment is expected to be completed in July 2017 and we will announce whether the trial has achieved its primary endpoint as soon as that determination is available.", "sentB": "In late February 2018, the Company reported that it had enrolled 52 patients and the trial s primary endpoint was achieved with a p-value of 0.0032.", "type": 1, "words": ["<tag1>", "Patient", "enrollment", "is", "expected", "to", "be", "completed", "in", "July", "2017", "and", "we", "will", "announce", "whether", "the", "trial", "has", "achieved", "its", "primary", "endpoint", "as", "soon", "as", "that", "determination", "is", "available.", "<tag2>", "In", "late", "February", "2018,", "the", "Company", "reported", "that", "it", "had", "enrolled", "52", "patients", "and", "the", "trial", "s", "primary", "endpoint", "was", "achieved", "with", "a", "p-value", "of", "0.0032.", "<tag3>"], "wordsA": ["Patient", "enrollment", "is", "expected", "to", "be", "completed", "in", "July", "2017", "and", "we", "will", "announce", "whether", "the", "trial", "has", "achieved", "its", "primary", "endpoint", "as", "soon", "as", "that", "determination", "is", "available."], "wordsB": ["In", "late", "February", "2018,", "the", "Company", "reported", "that", "it", "had", "enrolled", "52", "patients", "and", "the", "trial", "s", "primary", "endpoint", "was", "achieved", "with", "a", "p-value", "of", "0.0032."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p0_s7", "idA": "1175680_17_item1_p16_s2", "sentA": "An extension study of this trial is currently ongoing, as described in greater detail below.", "sentB": "Further, a copy of this Annual Report on Form 10-K is located at the SEC s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549.", "type": 1, "words": ["<tag1>", "An", "extension", "study", "of", "this", "trial", "is", "currently", "ongoing,", "as", "described", "in", "greater", "detail", "below.", "<tag2>", "Further,", "a", "copy", "of", "this", "Annual", "Report", "on", "Form", "10-K", "is", "located", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549.", "<tag3>"], "wordsA": ["An", "extension", "study", "of", "this", "trial", "is", "currently", "ongoing,", "as", "described", "in", "greater", "detail", "below."], "wordsB": ["Further,", "a", "copy", "of", "this", "Annual", "Report", "on", "Form", "10-K", "is", "located", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p13_s1", "idA": "1175680_17_item1_p17_s7", "sentA": "DSMB s management and oversight of the trial was successfully completed in January 2015.", "sentB": "This trial was a double blind placebo controlled trial.", "type": 1, "words": ["<tag1>", "DSMB", "s", "management", "and", "oversight", "of", "the", "trial", "was", "successfully", "completed", "in", "January", "2015.", "<tag2>", "This", "trial", "was", "a", "double", "blind", "placebo", "controlled", "trial.", "<tag3>"], "wordsA": ["DSMB", "s", "management", "and", "oversight", "of", "the", "trial", "was", "successfully", "completed", "in", "January", "2015."], "wordsB": ["This", "trial", "was", "a", "double", "blind", "placebo", "controlled", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p17_s3", "idA": "1175680_17_item1_p17_s7", "sentA": "DSMB s management and oversight of the trial was successfully completed in January 2015.", "sentB": "This trial was a double blind, placebo controlled trial.", "type": 1, "words": ["<tag1>", "DSMB", "s", "management", "and", "oversight", "of", "the", "trial", "was", "successfully", "completed", "in", "January", "2015.", "<tag2>", "This", "trial", "was", "a", "double", "blind,", "placebo", "controlled", "trial.", "<tag3>"], "wordsA": ["DSMB", "s", "management", "and", "oversight", "of", "the", "trial", "was", "successfully", "completed", "in", "January", "2015."], "wordsB": ["This", "trial", "was", "a", "double", "blind,", "placebo", "controlled", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p0_s5", "idA": "1175680_17_item1_p33_s0", "sentA": "The CCR5 receptor, the target for PRO 140, is an important mediator of GvHD, especially in the organ damage that is the usual cause of death.", "sentB": "The SEC also maintains a website that contains our SEC filings.", "type": 1, "words": ["<tag1>", "The", "CCR5", "receptor,", "the", "target", "for", "PRO", "140,", "is", "an", "important", "mediator", "of", "GvHD,", "especially", "in", "the", "organ", "damage", "that", "is", "the", "usual", "cause", "of", "death.", "<tag2>", "The", "SEC", "also", "maintains", "a", "website", "that", "contains", "our", "SEC", "filings.", "<tag3>"], "wordsA": ["The", "CCR5", "receptor,", "the", "target", "for", "PRO", "140,", "is", "an", "important", "mediator", "of", "GvHD,", "especially", "in", "the", "organ", "damage", "that", "is", "the", "usual", "cause", "of", "death."], "wordsB": ["The", "SEC", "also", "maintains", "a", "website", "that", "contains", "our", "SEC", "filings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p17_s6", "idA": "1175680_17_item1_p33_s4", "sentA": "The trial is a 100-day study with 60 patients.", "sentB": "Following the achievement of primary endpoint, the trial is continuing to enroll under an open label for safety analysis.", "type": 1, "words": ["<tag1>", "The", "trial", "is", "a", "100-day", "study", "with", "60", "patients.", "<tag2>", "Following", "the", "achievement", "of", "primary", "endpoint,", "the", "trial", "is", "continuing", "to", "enroll", "under", "an", "open", "label", "for", "safety", "analysis.", "<tag3>"], "wordsA": ["The", "trial", "is", "a", "100-day", "study", "with", "60", "patients."], "wordsB": ["Following", "the", "achievement", "of", "primary", "endpoint,", "the", "trial", "is", "continuing", "to", "enroll", "under", "an", "open", "label", "for", "safety", "analysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p0_s4", "idA": "1175680_17_item1_p34_s0", "sentA": "In late December 2015, we announced that we had filed with the FDA for designation of PRO 140 as an orphan drug, in connection with our GvHD Phase 2 trial and our request remains open at this time.", "sentB": "We will make available on our website, free of charge, the proxy statements and reports on Forms 8-K, 10-K, and 10-Q that we file with the United States Securities and Exchange Commission ( SEC ) as soon as reasonably practicable, after such material is electronically filed with or furnished to, the SEC.", "type": 1, "words": ["<tag1>", "In", "late", "December", "2015,", "we", "announced", "that", "we", "had", "filed", "with", "the", "FDA", "for", "designation", "of", "PRO", "140", "as", "an", "orphan", "drug,", "in", "connection", "with", "our", "GvHD", "Phase", "2", "trial", "and", "our", "request", "remains", "open", "at", "this", "time.", "<tag2>", "We", "will", "make", "available", "on", "our", "website,", "free", "of", "charge,", "the", "proxy", "statements", "and", "reports", "on", "Forms", "8-K,", "10-K,", "and", "10-Q", "that", "we", "file", "with", "the", "United", "States", "Securities", "and", "Exchange", "Commission", "(", "SEC", ")", "as", "soon", "as", "reasonably", "practicable,", "after", "such", "material", "is", "electronically", "filed", "with", "or", "furnished", "to,", "the", "SEC.", "<tag3>"], "wordsA": ["In", "late", "December", "2015,", "we", "announced", "that", "we", "had", "filed", "with", "the", "FDA", "for", "designation", "of", "PRO", "140", "as", "an", "orphan", "drug,", "in", "connection", "with", "our", "GvHD", "Phase", "2", "trial", "and", "our", "request", "remains", "open", "at", "this", "time."], "wordsB": ["We", "will", "make", "available", "on", "our", "website,", "free", "of", "charge,", "the", "proxy", "statements", "and", "reports", "on", "Forms", "8-K,", "10-K,", "and", "10-Q", "that", "we", "file", "with", "the", "United", "States", "Securities", "and", "Exchange", "Commission", "(", "SEC", ")", "as", "soon", "as", "reasonably", "practicable,", "after", "such", "material", "is", "electronically", "filed", "with", "or", "furnished", "to,", "the", "SEC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p20_s5", "idA": "1175680_17_item1_p35_s2", "sentA": "This opens the potential for multiple pipeline opportunities for PRO 140.", "sentB": "The amendments included switching the pre-treatment conditioning regimen from aggressive myeloablative ( MA ) conditioning to a reduced intensity conditioning ( RIC ), and switching from a blinded one-for-one randomized placebo-controlled design to an open-label design under which all enrollees receive PRO 140.", "type": 1, "words": ["<tag1>", "This", "opens", "the", "potential", "for", "multiple", "pipeline", "opportunities", "for", "PRO", "140.", "<tag2>", "The", "amendments", "included", "switching", "the", "pre-treatment", "conditioning", "regimen", "from", "aggressive", "myeloablative", "(", "MA", ")", "conditioning", "to", "a", "reduced", "intensity", "conditioning", "(", "RIC", "),", "and", "switching", "from", "a", "blinded", "one-for-one", "randomized", "placebo-controlled", "design", "to", "an", "open-label", "design", "under", "which", "all", "enrollees", "receive", "PRO", "140.", "<tag3>"], "wordsA": ["This", "opens", "the", "potential", "for", "multiple", "pipeline", "opportunities", "for", "PRO", "140."], "wordsB": ["The", "amendments", "included", "switching", "the", "pre-treatment", "conditioning", "regimen", "from", "aggressive", "myeloablative", "(", "MA", ")", "conditioning", "to", "a", "reduced", "intensity", "conditioning", "(", "RIC", "),", "and", "switching", "from", "a", "blinded", "one-for-one", "randomized", "placebo-controlled", "design", "to", "an", "open-label", "design", "under", "which", "all", "enrollees", "receive", "PRO", "140."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p27_s4", "idA": "1175680_17_item1_p41_s3", "sentA": "Our animal studies in GvHD have been submitted for publication in peer-reviewed journals.", "sentB": "Our pre-clinical study in GvHD has been published in the peer-reviewed journal Biology of Blood and Marrow Transplantation .", "type": 1, "words": ["<tag1>", "Our", "animal", "studies", "in", "GvHD", "have", "been", "submitted", "for", "publication", "in", "peer-reviewed", "journals.", "<tag2>", "Our", "pre-clinical", "study", "in", "GvHD", "has", "been", "published", "in", "the", "peer-reviewed", "journal", "Biology", "of", "Blood", "and", "Marrow", "Transplantation", ".", "<tag3>"], "wordsA": ["Our", "animal", "studies", "in", "GvHD", "have", "been", "submitted", "for", "publication", "in", "peer-reviewed", "journals."], "wordsB": ["Our", "pre-clinical", "study", "in", "GvHD", "has", "been", "published", "in", "the", "peer-reviewed", "journal", "Biology", "of", "Blood", "and", "Marrow", "Transplantation", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p10_s2", "idA": "1175680_17_item1_p42_s14", "sentA": "In connection with this license agreement, we became the primary obligor of an additional 600,000, which was accrued in the first quarter of the fiscal year ended May 31, 2016 and was timely paid by June 30, 2016.", "sentB": "In connection with this expansion, we signed a non-binding letter of intent regarding a proposed acquisition of intellectual property and other assets of ProstaGene LLC ( ProstaGene ), a privately held company focused on prostate cancer diagnostics and therapeutics aimed at blocking cancer metastasis by blocking CCR5.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "this", "license", "agreement,", "we", "became", "the", "primary", "obligor", "of", "an", "additional", "600,000,", "which", "was", "accrued", "in", "the", "first", "quarter", "of", "the", "fiscal", "year", "ended", "May", "31,", "2016", "and", "was", "timely", "paid", "by", "June", "30,", "2016.", "<tag2>", "In", "connection", "with", "this", "expansion,", "we", "signed", "a", "non-binding", "letter", "of", "intent", "regarding", "a", "proposed", "acquisition", "of", "intellectual", "property", "and", "other", "assets", "of", "ProstaGene", "LLC", "(", "ProstaGene", "),", "a", "privately", "held", "company", "focused", "on", "prostate", "cancer", "diagnostics", "and", "therapeutics", "aimed", "at", "blocking", "cancer", "metastasis", "by", "blocking", "CCR5.", "<tag3>"], "wordsA": ["In", "connection", "with", "this", "license", "agreement,", "we", "became", "the", "primary", "obligor", "of", "an", "additional", "600,000,", "which", "was", "accrued", "in", "the", "first", "quarter", "of", "the", "fiscal", "year", "ended", "May", "31,", "2016", "and", "was", "timely", "paid", "by", "June", "30,", "2016."], "wordsB": ["In", "connection", "with", "this", "expansion,", "we", "signed", "a", "non-binding", "letter", "of", "intent", "regarding", "a", "proposed", "acquisition", "of", "intellectual", "property", "and", "other", "assets", "of", "ProstaGene", "LLC", "(", "ProstaGene", "),", "a", "privately", "held", "company", "focused", "on", "prostate", "cancer", "diagnostics", "and", "therapeutics", "aimed", "at", "blocking", "cancer", "metastasis", "by", "blocking", "CCR5."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p19_s3", "idA": "1175680_17_item1_p42_s19", "sentA": "If that arrangement continues, the annual license fee of 300,000 would continue to apply, as well as a royalty of 1.0% of the net selling price upon commercialization of PRO 140 (excluding value added taxes and similar amounts).", "sentB": "We are currently exploring a high-dose arm with a 50% increase in dosage (525mg), as well as a 700mg dose, within the trial s protocol in order to evaluate an increased response rate of all patients.", "type": 1, "words": ["<tag1>", "If", "that", "arrangement", "continues,", "the", "annual", "license", "fee", "of", "300,000", "would", "continue", "to", "apply,", "as", "well", "as", "a", "royalty", "of", "1.0%", "of", "the", "net", "selling", "price", "upon", "commercialization", "of", "PRO", "140", "(excluding", "value", "added", "taxes", "and", "similar", "amounts).", "<tag2>", "We", "are", "currently", "exploring", "a", "high-dose", "arm", "with", "a", "50%", "increase", "in", "dosage", "(525mg),", "as", "well", "as", "a", "700mg", "dose,", "within", "the", "trial", "s", "protocol", "in", "order", "to", "evaluate", "an", "increased", "response", "rate", "of", "all", "patients.", "<tag3>"], "wordsA": ["If", "that", "arrangement", "continues,", "the", "annual", "license", "fee", "of", "300,000", "would", "continue", "to", "apply,", "as", "well", "as", "a", "royalty", "of", "1.0%", "of", "the", "net", "selling", "price", "upon", "commercialization", "of", "PRO", "140", "(excluding", "value", "added", "taxes", "and", "similar", "amounts)."], "wordsB": ["We", "are", "currently", "exploring", "a", "high-dose", "arm", "with", "a", "50%", "increase", "in", "dosage", "(525mg),", "as", "well", "as", "a", "700mg", "dose,", "within", "the", "trial", "s", "protocol", "in", "order", "to", "evaluate", "an", "increased", "response", "rate", "of", "all", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p47_s1", "idA": "1175680_17_item1_p53_s1", "sentA": "Failure to comply with applicable regulations can result in refusal by the FDA to approve product license applications.", "sentB": "CLIA regulates clinical laboratories by requiring that the laboratory be certified by the federal government, licensed by the state and comply with various operational, personnel and quality requirements intended to ensure that clinical laboratory test results are accurate, reliable and timely.", "type": 1, "words": ["<tag1>", "Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications.", "<tag2>", "CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely.", "<tag3>"], "wordsA": ["Failure", "to", "comply", "with", "applicable", "regulations", "can", "result", "in", "refusal", "by", "the", "FDA", "to", "approve", "product", "license", "applications."], "wordsB": ["CLIA", "regulates", "clinical", "laboratories", "by", "requiring", "that", "the", "laboratory", "be", "certified", "by", "the", "federal", "government,", "licensed", "by", "the", "state", "and", "comply", "with", "various", "operational,", "personnel", "and", "quality", "requirements", "intended", "to", "ensure", "that", "clinical", "laboratory", "test", "results", "are", "accurate,", "reliable", "and", "timely."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p10_s6", "idA": "1175680_17_item1_p53_s2", "sentA": "The FDA also has the authority to revoke previously granted product approvals.", "sentB": "The transaction is subject to completion of due diligence review, customary definitive documentation, deal structure and requisite corporate and regulatory approvals.", "type": 1, "words": ["<tag1>", "The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals.", "<tag2>", "The", "transaction", "is", "subject", "to", "completion", "of", "due", "diligence", "review,", "customary", "definitive", "documentation,", "deal", "structure", "and", "requisite", "corporate", "and", "regulatory", "approvals.", "<tag3>"], "wordsA": ["The", "FDA", "also", "has", "the", "authority", "to", "revoke", "previously", "granted", "product", "approvals."], "wordsB": ["The", "transaction", "is", "subject", "to", "completion", "of", "due", "diligence", "review,", "customary", "definitive", "documentation,", "deal", "structure", "and", "requisite", "corporate", "and", "regulatory", "approvals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p10_s4", "idA": "1175680_17_item1_p54_s1", "sentA": "The results of pre-clinical testing, which include laboratory evaluation of product chemistry and formulation, animal studies to assess the potential safety and efficacy of the product and its formulations, details concerning the drug manufacturing process and its controls, and proposed clinical trial protocols and other information must be submitted to the FDA as part of an IND that must be reviewed and become effective before clinical testing can begin.", "sentB": "As part of the proposed transaction with ProstaGene, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., the Chief Executive Officer of ProstaGene and President of the Pennsylvania Cancer and Regenerative Medicine Research Center, will join as our Chief Medical Officer.", "type": 1, "words": ["<tag1>", "The", "results", "of", "pre-clinical", "testing,", "which", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "formulation,", "animal", "studies", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "formulations,", "details", "concerning", "the", "drug", "manufacturing", "process", "and", "its", "controls,", "and", "proposed", "clinical", "trial", "protocols", "and", "other", "information", "must", "be", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "that", "must", "be", "reviewed", "and", "become", "effective", "before", "clinical", "testing", "can", "begin.", "<tag2>", "As", "part", "of", "the", "proposed", "transaction", "with", "ProstaGene,", "Richard", "G.", "Pestell,", "M.D.,", "Ph.D.,", "M.B.A.,", "F.A.C.P.,", "F.R.A.C.P.,", "the", "Chief", "Executive", "Officer", "of", "ProstaGene", "and", "President", "of", "the", "Pennsylvania", "Cancer", "and", "Regenerative", "Medicine", "Research", "Center,", "will", "join", "as", "our", "Chief", "Medical", "Officer.", "<tag3>"], "wordsA": ["The", "results", "of", "pre-clinical", "testing,", "which", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "formulation,", "animal", "studies", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "formulations,", "details", "concerning", "the", "drug", "manufacturing", "process", "and", "its", "controls,", "and", "proposed", "clinical", "trial", "protocols", "and", "other", "information", "must", "be", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "that", "must", "be", "reviewed", "and", "become", "effective", "before", "clinical", "testing", "can", "begin."], "wordsB": ["As", "part", "of", "the", "proposed", "transaction", "with", "ProstaGene,", "Richard", "G.", "Pestell,", "M.D.,", "Ph.D.,", "M.B.A.,", "F.A.C.P.,", "F.R.A.C.P.,", "the", "Chief", "Executive", "Officer", "of", "ProstaGene", "and", "President", "of", "the", "Pennsylvania", "Cancer", "and", "Regenerative", "Medicine", "Research", "Center,", "will", "join", "as", "our", "Chief", "Medical", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p15_s5", "idA": "1175680_17_item1_p55_s0", "sentA": "In responding to an NDA or BLA, the FDA may grant marketing approval, request additional information in a complete response letter, or deny the approval if it determines that the NDA or BLA does not provide an adequate basis for approval.", "sentB": "The Company believes that the higher dose will result in a higher response rate, which is supported by preliminary data.", "type": 1, "words": ["<tag1>", "In", "responding", "to", "an", "NDA", "or", "BLA,", "the", "FDA", "may", "grant", "marketing", "approval,", "request", "additional", "information", "in", "a", "complete", "response", "letter,", "or", "deny", "the", "approval", "if", "it", "determines", "that", "the", "NDA", "or", "BLA", "does", "not", "provide", "an", "adequate", "basis", "for", "approval.", "<tag2>", "The", "Company", "believes", "that", "the", "higher", "dose", "will", "result", "in", "a", "higher", "response", "rate,", "which", "is", "supported", "by", "preliminary", "data.", "<tag3>"], "wordsA": ["In", "responding", "to", "an", "NDA", "or", "BLA,", "the", "FDA", "may", "grant", "marketing", "approval,", "request", "additional", "information", "in", "a", "complete", "response", "letter,", "or", "deny", "the", "approval", "if", "it", "determines", "that", "the", "NDA", "or", "BLA", "does", "not", "provide", "an", "adequate", "basis", "for", "approval."], "wordsB": ["The", "Company", "believes", "that", "the", "higher", "dose", "will", "result", "in", "a", "higher", "response", "rate,", "which", "is", "supported", "by", "preliminary", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p20_s7", "idA": "1175680_17_item1_p61_s1", "sentA": "In addition, our relationships with doctors and other healthcare professionals are regulated by the DOJ, the OIG and other law enforcement and regulatory agencies under the federal Anti-Kickback Statute, the False Claims Act, the Sunshine Act, and similar and related federal and state laws.", "sentB": "The next review of data by the IDMC will occur following enrollment of 10 patients under the amended protocol after each patient has been dosed for 30 days.", "type": 1, "words": ["<tag1>", "In", "addition,", "our", "relationships", "with", "doctors", "and", "other", "healthcare", "professionals", "are", "regulated", "by", "the", "DOJ,", "the", "OIG", "and", "other", "law", "enforcement", "and", "regulatory", "agencies", "under", "the", "federal", "Anti-Kickback", "Statute,", "the", "False", "Claims", "Act,", "the", "Sunshine", "Act,", "and", "similar", "and", "related", "federal", "and", "state", "laws.", "<tag2>", "The", "next", "review", "of", "data", "by", "the", "IDMC", "will", "occur", "following", "enrollment", "of", "10", "patients", "under", "the", "amended", "protocol", "after", "each", "patient", "has", "been", "dosed", "for", "30", "days.", "<tag3>"], "wordsA": ["In", "addition,", "our", "relationships", "with", "doctors", "and", "other", "healthcare", "professionals", "are", "regulated", "by", "the", "DOJ,", "the", "OIG", "and", "other", "law", "enforcement", "and", "regulatory", "agencies", "under", "the", "federal", "Anti-Kickback", "Statute,", "the", "False", "Claims", "Act,", "the", "Sunshine", "Act,", "and", "similar", "and", "related", "federal", "and", "state", "laws."], "wordsB": ["The", "next", "review", "of", "data", "by", "the", "IDMC", "will", "occur", "following", "enrollment", "of", "10", "patients", "under", "the", "amended", "protocol", "after", "each", "patient", "has", "been", "dosed", "for", "30", "days."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1175680_18_item1_p16_s4", "idA": "1175680_17_item1_p76_s6", "sentA": "GMP material will be produced, as needed, to support clinical trials for all therapeutic indications and until commercial product is approved by the FDA.", "sentB": "We will require a significant amount of additional capital to complete the foregoing clinical trials for HIV and to prepare and file our BLA submission.", "type": 1, "words": ["<tag1>", "GMP", "material", "will", "be", "produced,", "as", "needed,", "to", "support", "clinical", "trials", "for", "all", "therapeutic", "indications", "and", "until", "commercial", "product", "is", "approved", "by", "the", "FDA.", "<tag2>", "We", "will", "require", "a", "significant", "amount", "of", "additional", "capital", "to", "complete", "the", "foregoing", "clinical", "trials", "for", "HIV", "and", "to", "prepare", "and", "file", "our", "BLA", "submission.", "<tag3>"], "wordsA": ["GMP", "material", "will", "be", "produced,", "as", "needed,", "to", "support", "clinical", "trials", "for", "all", "therapeutic", "indications", "and", "until", "commercial", "product", "is", "approved", "by", "the", "FDA."], "wordsB": ["We", "will", "require", "a", "significant", "amount", "of", "additional", "capital", "to", "complete", "the", "foregoing", "clinical", "trials", "for", "HIV", "and", "to", "prepare", "and", "file", "our", "BLA", "submission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
